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The pivotal role parkin plays in maintaining dopaminergic neuronal survival is  
underscored by our current recognition that parkin dysfunction represents not only a 
predominant cause of familial parkinsonism but also a formal risk factor for the more 
common, sporadic form of Parkinson’s disease (PD). However, how parkin becomes 
dysfunctional was not well understood. In this study, I found that mutations in parkin do 
not typically impair its catalytic competency but instead frequently alter the protein 
solubility and concomitantly promote its intracellular aggregation. Related to this, I also 
found that a wide variety of PD-linked stressors, including dopamine (DA), induce parkin 
solubility alterations and promote its aggregation within the cell, thereby suggesting a 
mechanism for parkin dysfunction in the pathogenesis of idiopathic PD. More recently, I 
demonstrated that select parkin mutations could exert dominant effects over the wild-type 
protein in vivo, thus supporting emerging evidence suggesting that heterozygous parkin 
mutations may be pathogenic. Taken together, these findings contribute significantly to 
our understanding of the contributors to parkin dysfunction and provide important sights 
into the pathogenesis of PD. 





Parkinson’s disease (PD) is a relentlessly progressive neurodegenerative disorder that 
crosses geographical, racial and social boundaries affecting 1-2% of the elderly 
population worldwide. Currently, PD represents the second most common 
neurodegenerative disorder after Alzheimer’s disease. Most cases of PD occur in sporadic 
manner. Since the first description of PD by Dr. James Parkinson in 1817, numerous 
attempts have been made to understand the etiology of this most common 
neurodegenerative movement disorder. However, the precise mechanism underlying PD 
pathogenesis remains uncertain, and consequently, current treatment options provide 
symptomatic relief rather than cure. Following the "landmark" discovery in 1997 of a rare 
mutation in the alpha-synuclein gene as a direct cause of PD in several families, 
numerous other genes were identified in familial PD cases, including parkin, ubiquitin C-
terminal hydrolase (UCH-L1), DJ-1, PTEN-induced putative kinase 1 (PINK-1), leucine-
rich repeat kinase 2 (LRRK2), and most recently, ATP13A2, a P-type ATPase gene 
(Moore et al., 2005; Ravina, et al., 2006). During the past decade, the functional 
characterization of these genes has provided tremendous insight into the nature of 
neurodegeneration of PD. The new understanding holds promise to uncover the secrets of 
the pathogenic mechanisms governing the selective neurodegeneration of PD, information 
of which will potentially open new avenues to the next revolution in PD disease therapy. 
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1.2 Parkinson’s Disease (PD) 
Clinically, the characteristic primary symptoms of PD include tremors, rigidity, 
slowness in movements (bradykinesia), postural instability, and difficulty in walking 
(called parkinsonian gait). Although PD is largely a movement disorder, several non-
motor problems associated with cognition and autonomic functions are frequently also 
encountered in advanced PD cases (Alexander, et al., 2004). Pathologically, PD can be 
described as the clinical entity related to a significant loss of neuromelanin-containing 
dopaminergic neurons in a region of the midbrain known as substantia nigra pars 
compacta (SNpc), with consequent loss of dopaminergic innervations to the caudate and 
putamen. Together, the SN and the caudate-putamen (also known as the dorsal striatum) 
constitute the nigro-striatal dopaminergic system. Consistent with PD-associated non-
motor problems, other areas of the brain are often also affected in the PD brain. These 
include the locus coeruleus, dorsal motor nucleus of the vagus and olfactory regions 
(Braak, et al. 2000). 
Classically, surviving neurons in the SNpc contain intracellular inclusions that are 
typified by an eosinophilic core surrounded by a clear halo, called Lewy bodies (LB). LB 
contains accumulations of normal neurofilaments, ubiquitin, α-synuclein, and a variety of 
other biochemical markers. However, little is known about the mechanism of LB 
formation and its role in selective dopaminergic neuronal vulnerability and dysfunction in 
PD. Whether LB represents a cause, consequence or epiphenomenon in PD remains a 
hotly debated issue.  
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1.3 Dopaminergic neurons and the nigro-striatal system 
Dopaminergic neurons, which produce the neurontransmitter dopamine (DA), are an 
anatomically and functionally heterogeneous group of cells localised in the diencephalon, 
mesencephalon and the olfactory bulb of the brain (Chinta, et al., 2005). The majority of 
dopaminergic neurons (90%) are found in the ventral part of the mesencephalon, which 
gives rise to several nominal systems. Probably the best known mesencephalic 
dopaminergic system is the nigrostriatal system, which originates in the SNpc and 
extends its fibres into the dorsal striatum. This system is essential for voluntary 
movement control and coordination and is impaired in PD patients. 
The striatum is the major recipient of motor inputs via excitatory glutamergic 
projections from the precentral motor areas of the cerebral cortex. However, it cannot act 
on the information it receives without concurrent activity in the dopaminergic 
nigrostriatal pathway. The striatal-putamen neurons project into the globus pallidus and 
SN. The medial globus pallidus (GPi) and the recticular zone of the SN (SNr), which 
receives neuronal projections from the putamen, represent the output stations. These 
structures send inhibitory γ-aminobutyric acid (GABA)-containing projections to the 
motor thalamus, which in turn projects back to the cortical motor areas via excitatory 
glutamergic projections (Fig. 1.1).  
The input (putamen) and output (GPi and SNr) stations are connected by two 
pathways (Fig. 1.1A):  
1. Direct Pathway: Consisting of a single limb from putamen to GPi and SNr (via 
GABAergic connections)  
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2. Indirect Pathway: Consisting of 3 limbs, A) From putamen to lateral globus 
pallidus (GPe) (via GABAergic connections); B) From GPe to subthalamic nucleus 














Fig. 1.1. The nigro-striatal system. Simplified summary of the nigro-striatal circuit in (A) 
normal and (B) Parkinson’s disease individuals. Excitatory and inhibitory neuronal activities 
are represented by black and grey lines respectively. Dashed lines represent degenerated SNpc 
dopaminergic neurons. 
 
The arrangement of the inhibitory GABAergic and the excitatory glutamergic 
neurons is such that stimulation of the direct pathway facilitates the thalamocortical 
activity while stimulation of the indirect pathway inhibits it. DA activates the direct 
pathway via the putaminal D1 receptors and inhibits the indirect pathway via D2 receptor. 
In so doing, DA serves to regulate the activity of these two functionally opposing systems 
and facilitates the flow of impulse through the motor circuits. In the absence of the 
modulatory effects of striatal DA, as in the case of PD patients, the activity of the direct 
pathway will decrease while that of the indirect pathway will increase. The end result is 
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an increased inhibitory drive of the excessively active GABAergic GPi/SNr neurons on 
the thalamocortical activity, leading to profound inhibition of cortically initiated 
movement, thus giving rise to hypokinesia seen in PD patients (Fig. 1.1B).  
Notwithstanding the important contribution of other neural systems to associated 
functional abnormalities, the impairment of the nigrostriatal system as a result of SNpc 
dopaminergic neurodegeneration is still justifiably the principal cause of motoric 
aberrations in patients with PD. 
 
1.4 Therapies for the PD patients 
1.4.1 Pharmacological Therapies 
      It was not until the late 1950s, following the discovery of dopamine as a 
neurotransmitter in the mammalian brain by Arvid Carlsson, that deficiency in striatal 
dopamine levels was recognized to be responsible for the major symptoms of PD. The 
understanding of this subsequently led to the development of effective pharmacological 
therapeutic strategy of the replacement of brain DA through pharmacological means for 
the PD patient. However, DA itself cannot cross the blood brain barrier (BBB) which 
negates its utility as an orally or intravenously administered medicine. On the other hand, 
the precursor of DA, levodopa or L-DOPA (L-Dihyroxyphenylalanine) readily crosses the 
BBB and is converted to DA in the brain, primarily in the striatal dopaminergic terminals, 
by the action of L-DOPA decarboxylase (also known as aromatic amino acid 
decarboxylase, AADC). In 1967, George Cotzias first developed an adequate dose 
regimen that propelled L-DOPA treatment to become the gold standard for the treatment 
Introduction    6 
of PD (Cotzias, et al., 1967).  To this day, L-DOPA remains the most effective drug in 
providing symptomatic relief for the PD patient.  
Subsequent advances in therapy included combining levodopa with a peripheral 
decarboxylase inhibitor, such as carbidopa or benserazide (Rinne, et al). This combination 
significantly reduced the side effects associated with levodopa therapy and its loss by 
decarboxylation in the gut and liver (and other peripheral tissues) through oral 
administration, which allowed a greater proportion of levodopa to enter the brain. 
Catechol-O-methyltransferase (COMT) is another ubiquitous enzyme that metabolises L-
DOPA. Similarly, catechol-O-methyltransferase (COMT) inhibitors, such as entacapone, 
can prolong the half-life of levodopa and dopamine and hence enhance the effect of a 
given levodopa dose. COMT is currently also being used as an adjunctive therapy to the 
standard combination for some PD patients. In addition to increasing the level of 
dopamine precursors, the focus of therapeutic design was also on limiting the breakdown 
of endogenous dopamine. The monoamine oxidase type B (MAO-B) inhibitor selegiline 
works in this fashion and provides symptomatic benefit (Chrisp, et al., 1991). 
Current trend favours using dopamine agonists as early therapy. DA agonists, such as 
bromocriptine, can directly stimulate postsynaptic dopamine receptors, thus bypassing 
dopamine synthesis completely (Calne, et al., 1974; Cotzias, et al., 1967). The use of DA 
agonists may delay the initiation of L-DOPA treatment, and hence postpone motor 
complications due to long-term therapy with L-DOPA. The spectrum of DA agonists 
available includes ergot-derived drugs such as bromocriptine, cabergoline, lisuride and 
pergolide. Newer forms of non-ergot synthetic DA agonists such as piribedil, 
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pramipexole and ropinirole are aggressively being marketed (Korczyn, et al., 2004). 
Despite these landmark advances in symptomatic PD therapy, the ability of these 
treatments to facilitate an acceptable quality of life for the patient wanes with time. This 
is due to the development of motor complications including wearing-off (the return of PD 
symptoms too soon after a given levodopa dose), the presence of involuntary abnormal 
movements (dyskinesias and dystonia), and the emergence of treatment-resistant 
symptoms such as gait impairment, cognitive decline, autonomic dysfunction, and 
medication-induced psychosis. 
 
1.4.2 Surgical Options 
When patients with advanced PD have difficulties with their medications due to the 
presence of L-DOPA-associated motor fluctuations and dyskinesias, surgical treatment is 
often considered as a treatment option. Surgical modalities for PD have improved 
tremendously following a better understanding of the motor circuitry affected by the loss 
of striatal dopamine.  
Surgical procedures used in the early 1930s are rather destructive, which involved 
resection of motor-associated regions of the brain including the primary motor cortex, 
caudate and pallidum that often resulted in a high incidence of morbidity and mortality. 
Since the late 1980s, “stereotactic lesional surgery” techniques have helped to reduce the 
risk of the operation, providing surgeons with more precision. Thalamotomy refers to the 
lesioning of the ventral intermediate nucleus of the thalamus, which is responsible for the 
tremors in PD. Pallidotomy involves destruction of part of the globus pallidus (GPi), 
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which is responsible for the stiffness, slow movements and tremors seen in Parkinson's 
disease.  
Current surgical approaches to PD such as bilateral pallidal deep brain stimulation 
(DBS) and bilateral subthalamic deep brain stimulation substantially alleviate L-DOPA-
induced dyskinesias (Walter, et al., 2004). DBS is the most recent advance in brain 
surgery for PD. It involves placing an electrode deep in the brain to the same positions 
targeted in pallidotomy or thalamotomy operations, and attaching the electrode to a small 
electrical stimulator. With continuous stimulation, the high frequency emitted by the 
electrode modulates the activity of the basal ganglia circuit and concomitantly alleviates 
motor symptoms in PD patients. DBS is currently considered to be the most effective for 
treating the primary symptoms--tremor, bradykinesia and rigidity, as well as the motor 
complications of drug treatment. DBS has been shown to be safe and efficacious. 
Complications directly related to DBS are usually slight and could generally be reduced 
or eliminated by adjusting the stimulation variables (Walter, et al., 2004). Progress made 
in understanding the effects of stimulation at the neuronal level should eventually 
improve the effectiveness of this therapy (Anderson et al., 2006).  
 
1.4.3 Neurorestorative Strategy 
Since PD is primarily a result of progressive dopaminergic neuronal degeneration in 
the SNpc, an intuitive therapeutic approach is to replace the lost neurons through cell-
based transplantation. This strategy offers hope of a cure for the PD patient. During the 
1980s and 1990s, cell transplantation was proposed as a replacement therapy for 
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dopaminergic cell loss. PD patients initially received autologous transplants of adrenal 
medullary tissue with negligible improvement (Backlund et al., 1985; Lindvall et al., 
1987). Subsequent larger studies revealed several problems, including poor survival of 
graft and a prohibitively high mortality rate in patients.Transplantation of dopaminergic 
neurons derived from ventral midbrain tissues of aborted foetuses came to be the next 
promising alternative. Fetal cells transplanted into the brains of patients with PD can 
survive and mature for up to 8 years after the surgery, helping to alleviate the debilitating 
tremors seen in the disease (Ren´e Drucker-C, et al., 2004). In spite of functional 
improvements observed with fetal transplantation, the difficulties in obtaining human 
embryonic tissues, ethical problems, and other limitations have attracted attention to 
source for other tissue possibilities.  
The recent advent of human stem cell suggests a potential source for transplantation 
material. Stem cells offer the potential to provide a virtually unlimited supply of 
optimised dopaminergic neurons that are more uniform in composition compared to foetal 
mesencephalic dopaminergic neurons. Of the several types of stem cells that have the 
capability of differentiating into dopaminergic neurons, such as embryonic stem (ES) 
cells, adult neural stem cells and bone marrow derived stromal cells, ES cells are 
currently thought to be the best candidate for transplantation in PD. However, although 
stem cell transplantation has shown very encouraging results in several animal studies 
(Lindvall, et al., 1987; Snyder, et al., 2005), several roadblocks still stand in the way, 
including concerns regarding exposing cells to xenogenic factors during the expansion 
and differentiation phases, the possibility of tumor formation if cells are not properly 
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differentiated, and the possibility of tissue rejection. Another challenge is to ensure that 
stem cells differentiate and forms normal synaptic input and functional connectivity to the 
striatum. Accordingly, stem cell transplantation for PD should appropriately remain 
within the confines of the laboratory until these problems could be overcome. 
 
1.4.4 Neuroprotective Strategy 
 
Parallel to the development of neurorestorative therapies is the evaluation of 
neuroprotective strategies. The search for compounds that can slow or halt the 
progression of PD is an active area of clinical research. These agents include PD 
medications, amino acids, trophic factors, enzymes and antibiotics (Fahn, et al., 2004).  
The MAO-B inhibitors, selegiline and rasagiline, are expected to reduce the 
formation of DOPAC and hydrogen peroxide from oxidative deamination of DA. In so 
doing, these drugs would decrease the formation of oxyradicals from hydrogen peroxide 
generated by DA metabolism and could thus exert neuroprotective functions in 
dopaminergic neurons. The protective effect of both selegiline and rasagiline may also 
occur through the prevention of the GAPDH cell death cascade by blocking the S-
nitrosylation of GAPDH, the binding of GAPDH to Siah (a protein E3 ligase that aids in 
the translocation of GAPDH to the nucleus), and the subsequent Siah-mediated 
degradation of nuclear proteins that leads to cell death (Hara, et al., 2006). In clinical 
trials, administration of selegiline to PD patients delayed symptomatic treatment by 9 
months, and provided a statistically significant decreased risk for developing freezing of 
gait. However, because of its mild but prolonged symptomatic effects, it is not clear from 
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the study whether the benefits experienced by the patients tested were derived from 
selegiline-mediated symptomatic or neuroprotective effect.  
The glial cell-derived neurotrophic factor (GDNF) is known to promote the survival 
of dopaminergic neurons. However, a rigorous randomized, placebo controlled, double-
blind phase II study that subsequent followed did not record significant efficacy (Fahn, et 
al., 2004). Another neuroprotective candidate is Coenzyme Q10. It was hypothesized that 
this antioxidant and electron transport chain component might correct the mitochondrial 
complex I dysfunction and CoQ10 deficiency consistently seen in PD patients. However, 
none of the patients treated showed a delay in their need for DA therapy (Shults, et al., 
2002). Based on a recent futility study design, the anti-inflammatory, anti-caspase drug 
minocycline and the pro-mitochondrial compound creatine were both considered as 
neuroprotectants in PD (NET-PD Investigators, 2006). While many more potential 
neuroprotective compounds are currently being evaluated (Ravina, et al., 2003), 
significant efforts are also being directed at understanding the molecular pathways 
leading to PD pathogenesis. It is hoped that the clarification of the pathogenic factors 
involved will allow the development of approaches to modulate them, thereby to retard or 
prevent the progression of PD.  
 
1.5 Molecular Pathogenesis of PD 
Much as the discovery of cellular pathology of dopaminergic neuron death in PD led 
to a revolution in symptomatic therapy, a better understanding of the molecular pathology 
of PD will suggest novel therapeutic strategies. However, the cause of sporadic PD has 
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remained elusive. Favored hypotheses include combinations of environmental factors and 
genetic susceptibilities, as well as normal aging. Aging is an unequivocal risk factor in the 
development of sporadic PD. Intimately associated with aging is the increased burden of 
oxidative and mitochondrial stress (Jazwinski, et al., 1998; Khalyavkin, et al., 2003), 
particularly in dopaminergic neuronal populations. Notably, postmortem studies have 
consistently shown mitochondrial impairment and oxidative damage in PD brains (Jenner, 
et al., 1998). Mitochondrial dysfunction and oxidative stress are thus considered as key 
players in pathogenesis of sporadic PD. Recently, several lines of evidence also suggest 
that aberration of the ubiquitin-proteasome system plays a key role in PD pathogenesis. 
 
1.5.1 Oxidative stress and mitochondrial dysfunction 
Postmortem studies of the brains of patients with sporadic PD reveal increased 
oxidative damage of lipids (peroxidation) and proteins (carbonylation) (Bowling, et al., 
1995). It is well known that dopaminergic neurons in the brain are particularly exposed to 
oxidative stress because the metabolism of DA produces various reactive oxygen species 
(ROS) (peroxide, superoxide and hydroxyl radicals). If not handled properly, the ROS 
generated could create a considerable damaging environment. Further, DA could auto-
oxidize to DA-quinone, a reactive species that has been demonstrated to covalently 
modify cellular macromolecules, including parkin and α-synuclein (Conway et al., 2001), 
and contribute to DA-induced neurotoxicity.  
The findings of decreased complex I activity in the brains of people with PD suggest 
that mitochondrial dysfunction might exacerbate oxidative stress-induced toxicity in PD. 
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The remarkably exclusive degeneration of dopaminergic neurons following exposure to 
mitochondrial neurotoxins (such as MPTP and rotenone) suggests that dysfunction of the 
mitochondrial pathway could confer the selective vulnerability of dopaminergic neurons 
in PD, although the mechanism remains obscure (Langston, et al., 1983; Betarbet, et al., 
2000). Clearly, preservation of mitochondrial integrity and function would promote 
dopaminergic neuronal survivability.  
 
1.5.2 Ubiquitin–proteasome system and PD 
The ubiquitin proteasome system (UPS) is a major cellular protease machinery 
important in maintaining cellular homeostasis through the clearance of unwanted 
proteins. In this system, proteins destined for degradation are covalently tagged with 
ubiquitin, a 76 amino acid residue protein, by the sequential actions of ubiquitin-
activating (E1), -conjugating (E2) and ligating (E3) enzymes (Pickart, 2001). The ligation 
process is usually repeated many times to form a polyubiquitin chain in which the C-
terminus glycine residue of each ubiquitin unit is linked to a specific lysine (K) residue 
(most commonly K-48) of the previous ubiquitin. The polyubiquitinated substrate is then 
targeted to the 26S proteasome to be enzymatically degraded. Individual ubiquitin 
monomers are regenerated in the process by the actions of deubiquitininating enzymes 
(DUBs). The 26S proteasome is a large protease complex consisting of a barrel-shaped 
20S proteolytic core in association with two 19S (PA700) regulatory caps, one on each 
side of the barrel’s openings (Fig 1.2). The components of the 19S cap play vital roles in 
the initial steps of substrate proteolysis including the recognition, unfolding, and 
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translocation of substrate proteins into the lumen of the proteolytic core. Energy in the 
form of ATP is required to drive the UPS machinery. 
It is noteworthy that LBs associated with PD are enriched with ubiquitin, a 
phenomenon that suggests functional impairments of the UPS degradation machinery in 
affected cells. Supporting this, McNaught and colleagues observed a significant reduction 
in the levels of PA700 expression in the SNpc of post-mortem PD brains relative to 
control brains; PA700 levels are otherwise elevated in other regions of the PD brain such 
as the frontal cortex and striatum. Selective decrease in the level of proteasomal core 
subunits within the SN was also noted. Further, in vitro assay of SN extracts from PD 
brains revealed a marked decrease in the activity of the 20S proteasome, a finding 
corroborated by Spillantini and co-workers. Together, these results demonstrate structural 
and functional impairments of the UPS in sporadic PD, although it remains unclear 
whether UPS disruption is a cause or consequence of the neurodegenerative process.  
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Figure 1.2 UPS and PD. Under normal conditions, proteins destined for proteasomal degradation 
are tagged with a chain of ubiquitin (UB) via multiple rounds of a linear reaction catalyzed by 
ubiquitin-activating (E1), -conjugating (E2) and -ligating enzymes (E3). An example of an E3 is 
parkin. Ubiquitination reactions are reversed by the action of deubiquitinating enzymes (DUBs) 
of which UCHL1 is a member. Age-related changes, exogenous stress, mitochondrial alterations 
and PD-linked genetic mutations of parkin, UCHL1 and -synuclein promote disruption of the 
UPS and conceivably result in the accumulation of protein aggregates or abnormal protein 
intermediates that may be directly detrimental to neuronal survival. Lewy bodies are thought to 
form as an attempt by the cell to sequester these abnormal proteins. The enhancement of protein 
re-folding by chaperones such as Hsp70 and the clearance of protein aggregates via the 
stimulation of autophagy could help mitigate UPS dysfunction. Such strategies may offer 
innovative approaches in the treatment of PD. 
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1.5.3 Environment factors and mitochondria dysfunction 
The first hint that exogenous factors could lead to sporadic PD came from 1-Methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) studies. In the early 1980s, MPTP was 
accidentally discovered to induce a parkinsonian syndrome in young drug addicts, after 
they unintentionally self-administered MPTP-contaminated “synthetic heroin” via 
intravenous injection. Subsequent studies revealed that it is 1-methyl-4-phenyl pyridium 
(MPP+), the active metabolite of MPTP that resulted in dopaminergic neuronal death 
(Langston, 1983). MPP+ selectively targets DA neurons via its affinity for the DA 
transporter. Once taken in, MPP+ generates widespread oxidative stress through 
inhibition of complex I that eventually kills DA neurons (Greenamyre, et al., 2001). 
Complex I inhibition by MPTP can directly result in increased oxidative stress, 
particularly through the production of O2·-. It also causes depletion of ATP, which is 
responsible for loading dopamine into synaptic vesicles by vesicular monoamine 
transporter (VMAT). ATP depletion may result in increased DA level, which in turn 
cause indirect product of oxidative stress through the generation of dopamine oxidation 
by-products (Andersen, et al., 2004).  
Epidemiological studies have also identified certain environmental agents, such as 
pesticides and herbicides, as being risk factors for PD. The combinative administration of 
herbicide 1,1’-dimethyl-4,4’-5 bipyridinium (paraquat) and the fungicide manganese 
ethylenepistithiocarbamate (maneb) to mice leads to progressive and irreversible DA 
neurons degeneration (Thiruchelvam, et al., 2003). Paraquat is a complex I inhibitor with 
structural similarity to MPP+, and it triggers up-regulation and aggregation of α-
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synuclein, a PD-linked gene product, in mouse brains (Manning-Bog, et al., 2002). 
Rotenone, another complex I inhibitor widely used as insecticide and fish poison, 
produces Parkinsonism in rats when administered intravenously or subcutaneously 
(Betarbet, et al., 2000). Being extremely lipophilic, rotenone can freely cross cellular 
membranes independently of any transporters, and accumulates in mitochondria. 
Rotenone is not concentrated in DA neurons, yet it induces selective DA cell death, which 
suggests that DA neurons are uniquely sensitive to complex I impairments (Sherer, et al., 
2003). Furthermore, the slow and chronic nature of rotenone toxicity leads to 
intraneuronal filamentous protein deposit containing α-synuclein and ubiquitin that are 
remarkably similar to authentic LBs (Betarbet, et al., 2000).  
The fact that all three complex I inhibitors cause dopaminergic cell death and induce 
the formation of LB-like filamentous inclusions as well as the systemic defect in complex 
I (either through genetic or acquired alterations in PD) supports the notion that 
impairments in complex I may be central to the pathogenesis of DA neuronal demise in 
sporadic PD. Most, if not all, known neuronal cell death pathways are directly or 
indirectly related to complex I defects, including excitotoxicity, reactive oxygen species–
induced injury, caspase-dependent and caspase-independent apoptosis, necrosis, and 
inflammation induced injury (Dawson et al., 2003). The discovery of toxins that induce a 
Parkinsonian condition both in animal models and in humans supports the possibility of 
an environmental trigger. 
 
1.5.4 Monogenetic causes of PD 
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PD has been considered as a sporadic and nongenetic disorder until distinct genetic 
loci were identified to be associated with the disease. Mutations in 7 identified genes have 
been found to be the unambiguous cause of several forms of familial PD in the past 10 
years (Table 1.1). Although monogenetic PD is clinically and pathologically distinct from 
sporadic PD, both of them share many overlapping features including the principal 
nigrostriatal DA degeneration (Hardy, et al. 2003), which suggests common pathogenic 
mechanisms in disease pathogenesis. Therefore, understanding the function of the genes 
linked to different monogenic forms of PD could provide us with a better knowledge of 
the molecular pathways responsible for DA neuron degeneration in PD. The known 
functions of each of the PD-linked gene product and how their dysfunctions may 
contribute to disease pathogenesis are discussed below. 
 
Table 1.1 Loci and genes linked to familial PD 
Locus Chromosome location Gene  Inheritance  Clinical phenotype  Reference  
PARK1 4q21-q23 α-synuclein AD Earlier onset Polymeropolous et al. 1997 
PARK2 6q25.2-q27 parkin usually AR Earlier onset, slow  progression Kitada et al. 1998 
PARK3 2p13 Unknown  AD Classic PD Gasser et al. 1998 
PARK4 4q α-synuclein AD Classic PD Singleton et al. 2003 
PARK5 4p14 UCHL1 AD Earlier onset, slow  progression Leroy et al. 1998 
PARK6 1p35-p36 PINK1 AR Earlier onset, slow  progression Valente et al. 2004 
PARK7 1p36 DJ-1 AR Earlier onset, slow  progression Bonifati et al. 2003 
PARK8 12p11.2-q13.1  LRRK2 AD Classic PD 
Funayama et al. 2002; 
Paisan-Ruiz, et al., 2004; 
Zimprich, A. et al., 2004 
PARK9 1p36 ATP13A2 AR Earlier onset Ramirez et al., 2006 
PARK10 1p32 Unknown unclear Classic PD Hicks et al. 2002 
PARK11 2q36-q37 Unknown unclear Classic PD Pankratz et al. 2003 
AD, autosomal dominant; AR, autosomal recessive; early onset: typically before 40 years of age. Classic PD: 65 years onwards. 
 
1.6 PD linked genes 
1.6.1 α-synuclein 
The first genetic mutation linked to PD occurs in a gene that encodes α-synuclein. A 
point mutation, A53T, on the α-synuclein protein turned it into a pathogenic form 
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(Polymeropolous et al. 1997). Subsequently, two additional missense mutations linked to 
PD, encoding A30P and E46K, as well as gene duplications and triplications were 
discovered on the α-synuclein gene. Patients harboring gene triplications have an early 
onset, rapidly progressive form of parkinsonism, whereas those with a duplication of 
wild-type gene have a less severe phenotype and a late onset, slower disease progression 
than those with triplications (Eriksen, et al. 2005, Muenter, et al. 1998). In addition, 
polymorphisms within the α-synuclein promoter are also associated with an increased PD 
risk (Pals, et al. 2004; Hadjigeorgiou, et al. 2005). The evidences above suggest that α-
synuclein gene dosage correlates with disease severity. Another important finding is that 
α-synuclein represents a major component of Lewy body (Spillantini, et al. 1997). 
Together, these findings suggest an important role of α-synuclein in the pathogenesis of 
both sporadic and certain inherited forms of PD.  
Although the function of α-synuclein remains uncertain, it has been shown to bind 
synaptic vesicles (Rhoades E, et al., 2006). Missense and triplication mutants of α-
synuclein, phosphorylation of α-synuclein, ROS, and mitochondrial dysfunction can 
promote α-synuclein protofibrils formation; the latter can form pores that could lead to 
permeabilization of the vesicle membranes, thereby releasing excess dopamine into the 
cytosol (Lashuel, et al., 2002). Formation of protofibrils is enhanced and stabilized by 
dopamine quinones derived from the oxidation of dopamine, which could account for the 
selective toxicity of α-synuclein in the substantia nigra (Conway, et al., 2001). Recent 
work further revealed that α-synuclein might act as a co-chaperone with cysteine-string 
protein (CSPα) to serve a protective role against injury at nerve terminals (Chandra, et al. 
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2005). Other evidences also suggest that the abnormal protein aggregation of α-synuclein 
may inhibit normal cellular functions, such as axonal transport and protein degradation, 
by promoting derangements in the ubiquitin-proteasomal or chaperone-mediated 




Mutations of DJ-1 account for only an estimated 1-2% in the early-onset PD cases 
(Abou-Sleiman, et al. 2003). DJ-1 is abundantly and ubiquitously expressed in the brain 
and other body tissues. Subcellular distribution of DJ-1 is primarily cytoplasmic with a 
smaller pool of mitochondrial-associated protein (Zhang, L. et al., 2005). Although the 
exact function of the DJ-1 protein is unknown, current evidence suggests that it may act 
as an antioxidant, oxidation/reduction sensor, chaperone, and/or protease (Moore, et al., 
2005). Of these putative functions, the most relevant in terms of the pathogenesis of PD is 
DJ-1’s potential protective role aganist oxidative stress, either as antioxidant protein or a 
redox sensor (Canet-Aviles, et al., 2004). When exposed to an oxidative stressor, such as 
paraquat or H2O2, DJ-1 undergoes an acidic shift in pI-value by modifying its cysteine 
residues, which quench ROS and protect cells against stress-induced death.  
PD-linked DJ-1 mutations disrupt protein activity by either destabilizing the protein 
or affecting its subcellular localization. The clinically relevant L166P mutation produces 
a highly unstable protein rapidly degraded by the 20S/26S proteasome, via impairment of 
the ability of DJ-1 to form homodimer (Miller, et al., 2003; Moore, et al., 2003; Olzmann, 
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et al., 2004). Further, the L166P, M26I and D149A mutations all show reduced nuclear 
localization and increased mitochondrial localization (Xu, et al. 2005; Bonifati, et al. 
2003). The reduced access to nuclear proteins, such as p54NRB and PSF might increase 
PSF-induced apoptosis (Junn, E. et al. 2005). However, the mitochondrial function of DJ-
1 needs to be further determined to understand whether the mutagenecity associated with 
increased mitochondrial localization is due to a mitochondrial gain of function or to a loss 
of access to binding partners in different cellular compartments. DJ-1 also functions as a 
redox sensitive molecular chaperone that protects cells from aggregation of α-synuclein 
and the neurofilament subunit NFL under oxidative stress (Shendelman, et al., 2004). 
There is speculation as well that DJ-1 play a role in the regulation of apoptosis as a 
negative regulator of PTEN and through interactions with several apoptosis-regulating 
proteins (Abou-Sleiman, et al., 2006). Further studies in vivo may support the role of 
neuroprotective function of DJ-1. 
 
1.6.3 PINK1 
Mutations in PTEN-induced putative kinase 1 (PINK1) gene were identified in 2004. 
The prevalence of PINK-1 mutation is between that of parkin and DJ-1 and is present in 
the homozygous state in 2–3% of early-onset patients (Klein, et al., 2005; Tan, et al., 
2005). Interestingly, all studies of PINK1 mutations in sporadic early-onset PD have 
identified a higher number of patients than controls carrying a single heterozygous 
mutation, which suggest that heterozygous PINK1 mutations could represent a risk factor 
to develop PD, either through haploinsufficiency or a dominant negative mechanism 
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(Rogaeva, et al., 2004; Valente, et al., 2004; Healy, et al., 2004; Abou-Sleiman, et al., 
2006b). This hypothesis is supported by the results of the mentioned PET study, where 
asymptomatic gene carriers showed significant reduction of striatal 18F-dopa update 
compared with controls, indicating preclinical nigrostriatal dysfunction (Khan, et al., 
2002; Kessler, et al., 2005). PINK-1 is a mitochondrial protein kinase whose substrates 
are unknown (Silvestri, et al., 2005). PINK-1 is induced by PTEN, the same protein 
whose activity is suppressed by DJ-1. PINK-1 mutation may lead to mitochondrial 
dysfunction and increased sensitivity to cellular stress through a defect in the apoptosis 
pathway (Petit, et al., 2005). Two recent studies indicate that PINK-1 appears to be 
essential in mitochondrial function, as Drosophila lacking PINK-1 have substantial 
mitochondrial defects resulting in apoptotic muscle degeneration and male sterility. 
Interestingly, parkin rescues the PINK-1 loss-of-function phenotype and acts downstream 
of PINK-1, suggesting that parkin and PINK-1 share common biochemical pathway that 
influences mitochondrial integrity (Clark, et al., 2006; Park, et al., 2006). 
Most reported mutations are distributed throughout the serine/threonine protein 
kinase domain. Disruption of kinase activity is the most possible disease mechanism. A 
subset of mutations is located in the N-terminal region between the mitochondrial 
targeting motif and the kinase domain (approximately amino acid residues 30–150), 
which could disrupt mitochondrial localization or processing (Abou-Sleiman, et al., 
2006a). Evidence suggests that overexpression of selective PINK-1 missence mutations 
affects mitochondrial function and cell viability under stress, via reducing mitochondrial 
membrane potential (∆ψm). 
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1.6.4 LRRK2 
Mutations of Leucine-rich repeat kinase 2 (LRRK2) have recently been shown to 
cause autosomal dominant PD previously linked to the PARK8 locus (Paisan-Ruiz, et al., 
2004; Zimprich, A. et al., 2004). LRRK2 mutations are estimated to account for 5–6% of 
familial cases, and up to an unprecedented 1-3% of sporadic cases (Gilks, et al.; 2005). 
The delineation of LRRK2-mediated pathogenic pathway holds great promise for 
furthering our understanding of the etiology of the disease. 
LRRK2 is a large protein that includes Roc (Ras in complex protein), COR (C-
terminal of Roc), leucine-rich repeat, mixed lineage kinase, WD40 (a putative protein-
protein interaction domain terminating in a tryptophan-aspartic acid dipeptide), and 
ankryin domains (Paisan-Ruiz, et al., 2005). Little is known about LRRK2 function. 
However, some interesting preliminary in vitro studies suggest that it is a kinase which 
capable of autophosphorylation (West, et al., 2005). Significantly, three PD-associated 
mutations, two in the kinase domain (G2019S and I2020T) and one in the ROC/COR 
GTPase domain (R1441C) increase LRRK2 autophosphorylation, suggesting a dominant 
gain of function mechanism (Gloeckner, et al., 2005; West, et al., 2005). In addition, 
LRRK2 might be associated with the outer mitochondrial membrane (OMM) (West, et 
al., 2005) and can bind parkin (Smith, et al. 2005). 
The biology of LRRK2 and PINK-1 suggest that protein phosphorylation plays a 
vital role in PD pathogenesis. Further, toxicity associated with α-synuclein 
phosphorylation in Drosophila model also indicates that abnormal protein 
phosphorylation may be responsible for the disease (Chen, et al., 2005). Together, these 
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Ubiquitin carboxyl-terminal esterase L1 (UCHL-1), a deubiquitinating enzyme and 
highly abundant, neuronspecific protein, has been associated with the PD, but the genetic 
evidence for its pathogenicity is weak as only a single mutation (I93M) has been 
identified in one family (Leroy et al. 1998). Presently, the assumption is that the lone 
I93M UCHL1 mutation may be an extremely rare cause of PD, or is a benign substitution. 
 
1.6.6 ATP13A2 
Loss-of-function mutations of ATP13A2, a neuronal P-type ATPase gene was 
described very recently to cause an autosomal recessive form of early on set parkinsonism 
with pyramidal degeneration and dementia (Ramirez, et al., 2006). The wild-type protein 
was located in the lysosome of transiently transfected cells, the unstable truncated 
mutants were retained in the endoplasmic reticulum and degraded by the proteasome. The 




In 1998, mutations in the parkin gene was firstly described in Japan as a causative 
gene of autosomal recessive junvenile parkinsonism (ARJP) (Kitada et al., 1998). This 
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form of inherited parkinsonism is characterized pathologically by a severe loss of nigral 
dopaminergic neurons and the absence of classic Lewy bodies in most (Mori, et al., 1998; 
Hayashi, et al., 2001; van de Warrenburg, et al., 2001) but not all cases (Farrer, et al., 
2001). Clinically, ARJP occurs at an early age (typically before 40 years old) and is 
usually associated with dystonia and diurnal fluctuations as well as early and severe L-
DOPA induced dyskinesia and sleep benefit (Saito, et al., 2004). Following the discovery 
of parkin mutations in Japanese ARJP patients, several families with recessively inherited 
PD throughout the world were also found to carry parkin mutations (Lucking et al., 2000; 
Mata et al., 2004). This is in stark contrast to the restricted occurrence of α-synuclein, 
UCHL-1 and DJ-1 mutations. Indeed, mutations in parkin are currently considered to be 
one of the main contributors to familial PD, the other being LRRK2 mutations. 
1.7.1 Parkin mutations 
Familial PD-linked mutations in parkin are heterogenous. More than 90 different 
mutations in the parkin gene have been described so far which include point mutations 
(missense mutations, frame shifts, nonsense mutations, and splice site mutations), and 
exon rearrangements (deletions, duplications, and triplications) (Fig 1.2). This 
heterogeneity in parkin mutations may be in part responsible for the wide age of disease 
onset in ARJP, which ranges from junvenile and early onset to after 70 years. Despite the 
heterogeneity, there is generally no discernable difference in the clinical manifestations 
among PD patients carrying different parkin mutations, suggesting that substitutions of 
amino acids resulting from missense mutations are as detrimental to parkin function as 
are the truncation and deletion mutations. However, mutations occurring in the functional 
Introduction    26 
domains of parkin appear to result in an earlier age of disease onset compared to 
mutations in regions with unknown function (Lohmann et al., 2003). 
PD due to parkin mutations is classically transmitted in an autosomal recessive 
inheritance, with most of the clinical AR-JP cases associated with parkin mutations 
occuring as either homozygous or compound heterozygous mutations. However, several 
cases have been published in which, despite extensive screening, only one of the alleles 
appears to be mutated (Farrer et al. 2001; West et al. 2002a). This raises the possibility of 
dominant effect of the mutations, or alternatively, an expanded risk associated with parkin 
haploinsufficiency (West et al., 2002a; Foroud et al., 2003). Heterozygous loss of parkin 
function has been demonstrated to influence the rate of dopaminergic cell death in 
patients (Hilker et al., 2001). Parkin variability could thus be considered a risk factor for 
the development of PD, and its relationship to idiopathic PD is further supported by the 
recent association of parkin gene promoter with late-onset PD (West et al., 2002b). 
 
Fig. 1.3. Point mutation and exon deletion, duplication and triplication of parkin. 
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1.7.2 Parkin gene organization and regulation  
The parkin gene spans more than 1.43 Mb, containing 12 exons that are separated by 
extended intronic regions (Kitada et al. 1998; West et al. 2001). Although it is one of the 
largest genes in the human genome, the coding sequence of Parkin is only 4.5 kb, 
occupying 0.1% of the gene loci. The role of the large introns which account for about 
99.9% of Parkin is not known. Interestingly, the parkin promoter has been found to 
function as a bidirectional promoter, regulating not only transcription of parkin, but 
transcription of a gene named parkin coregulated gene (PACRG) as well (West et al. 
2003). PACRG spans 0.6 Mb, upstream of and antisense to PARK2. The (patho-) 
physiological relevance of the corresponding gene product is not fully understood, 
although it has been demonstrated to be a component of LB and could protect 
dopaminergic neurons against cell death (Imai et al., 2003)  
Although very little is known about the transcriptional regulation of parkin, it is 
apparent that many elements controlling parkin expression exist within the gene. 
Evidence showed that parkin mRNA level could be modulated by several conditions and 
agents, such as cellular unfolded protein stress (Imai et al., 2000), acute and chronic 
administration of haloperidol, a dopamine-D2 receptor antagonist, and a neurotoxic dose 
of methamphetamine (Nakahara et al., 2001; Nakahara et al., 2003). Recent study 
suggests the association between parkin gene promoter with late-onset PD (West, et al., 
2002b). Given its key role in PD, it would be important to elucidate the regulatory 
elements on the parkin gene that governs its expression.  
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1.7.3 Parkin expression 
Parkin is an evolutionary conserved gene product, with orthologs in Caenorhabditis 
elegans, Drosophila melanogaster, mouse, rat, and several other species (Horowitz et al. 
1999; Culetto, et al., 2000; Kitada et al. 2000; Bae et al. 2003). Parkin expresses in a wide 
range of tissues including brain, heart, intestines, skeletal muscle, kidney and testis 
(Kitada, et al., 1998). The ubiquitous expression of parkin correlates with features 
exhibited by its promoter suggesting that parkin may have housekeeping roles (West, et 
al., 2001). In the brain, parkin expression is not limited to regions involved in PD. 
Although high levels of parkin are present in the substantia nigra (SN) (Shimura, et al., 
1999), parkin immunoreactivity also occurs in the hippocampus, thalamus, cerebellum 
and various cortical regions (Zarate-Lagunes, et al., 2001). However, the physiological 
roles of parkin in other tissues remain unknown. Ultrastructurally, the parkin protein is 
present heterogeneously in various cellular locations including the cytosol, endoplasmic 
reticulum, Golgi apparatus, outer nuclear and mitochondrial membrane, and in post-
synaptic densities (D'Agata, et al., 2000; D'Agata, et al., 2002). Parkin also appears to 
associate with actin filaments, suggesting a potential role in vesicular transport (Huynh, et 
al., 2000). Generally, the nucleus is devoid of parkin.  
 
1.7.4 Parkin structure and function 
The parkin protein is 465 amino acids long. Structurally, parkin has an ubiquitin-like 
(UBL) domain at its N-terminus, a RING box domain at its C-terminus and a unique 
middle segment that links the two domains (Fig 1.3). The RING box, containing two 
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RING finger motifs (RING 1 and RING 2) flanking a Cys-rich in-between RING (IBR), 
is crucial for the enzymatic activity of parkin (Imai et al., 2000; Shimura et al., 2000; 
Zhang et al., 2000). Notably, many clinically relevant point mutations on parkin localize 
to the RING box region (Fig. 1.3) (Mata et al., 2004). Parkin functions as an ubiquitin 
protein ligase associated with the UPS. Substrates polyubiquitinated by parkin would be 
recognized by and hence degraded via proteasome system (Pickart, 2001). The function 
of parkin as an E3 ligase thus indicates that defects in ubiquitination is a key mechanism 
behind parkin mutations leading to PD.  
Although the UBL domain shares 32% identity and 62% similarity with ubiquitin 
(Kitada, et al., 1998), its function is not well characterized. However, Sakata et al have 
demonstrated that the UBL domain of parkin binds Rpn10, a proteasomal subunit and 
their interaction facilitates the targeting of polyubiquitinated parkin substrates to the 
proteasome (Sakata et al., 2003). Interestingly, the UBL domain could be released from 
the RING box via a caspase-mediated proteolysis event that occurs after an aspartate 
residue residing at position 126 (D126) within the unique middle segment (Kahns, et al., 
2002). Whether this released UBL domain fulfil any cellular role is not known.  
At the extreme C-terminal end of the parkin protein is a class II PDZ-binding motif 
bearing the amino acid sequence FDV. This motif in parkin is responsible for its binding 
to CASK (Fallon, et al., 2001), a mammalian homolog of Caenorhabditis elegans Lin 2. 
The interaction of parkin and CASK is apparently involved in the subcellular localization 
of parkin within postsynaptic densities in brain (Fallon, et al., 2001). 
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1.7.5 Substrates of parkin 
The ubiquitination activity of parkin, indicative of its role in governing intracellular 
protein turnover, suggests that defective protein handling is responsible for parkin-related 
PD. Consistent with this suggestion, several reports have shown that pathological 
mutations of parkin disrupt parkin binding either to its cognate E2s (UBCH7 and 
UBCH8) or to its substrates, resulting in a failure of parkin to ubiquitinate its target 
substrates (Imai, et al., 2000; Shimura, et al., 2000; Zhang, et al., 2000b; Chung, et al., 
2001). It is therefore conceivable that a loss of parkin function would result in a toxic 
accumulation of its substrates, eventually killing the cell. Supporting this speculation, 
observations show that some reported substrates of parkin accumulate in brains of PD 
patients carrying parkin mutations (Imai et al., 2001; Shimura et al., 2001; Choi et al., 
2003; Staropoli, et al., 2003). To date, at least ten parkin substrates have been described  
(Lim et al., 2003; Lim and Lim, 2003). Since none of the parkin substrates are found 
exclusively in the substantia nigra, it remains unclear why the nigral dopaminergic 
neurons are preferentially susceptible. Nonetheless, the direct involvement of parkin in 
the ubiquitination of proteins supports the current popular hypothesis that the UPS plays a 
key role in the pathogenesis of PD.  
 
CDCrel-1 & CDCrel-2A 
Cell division control related protein 1 (CDCrel-1, also known as SEPT5), a synaptic 
vesicle polypeptide, is the first identified substrate of parkin (Zhang, et al., 2000). It 
belongs to the septin family, which also includes GTPases involved in cytokinesis. 
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CDCrel-1 is suggested to be involved into regulation of synaptic vesicles release (Beites, 
et al., 1999). More recent studies conducted in CDCrel-1 null mice demonstrates its 
redundancy in neuronal development and function (Peng, et al., 2002), but it remains to 
be seen if CDCrel-1 elevation in the absence of parkin-mediated degradation could 
disrupt dopamine release and lead to PD. CDCrel-2A is a newly described parkin-binding 
protein that was identified using a yeast-two-hydrid screen (Choi et al., 2003). 
Structurally, CDCrel-2A and CDCrel-1 share extensive homology except for their N-
terminal regions. The existence of CDCrel-2A might explain the functional redundancy of 
CDCrel-1 in CDCrel-1 null mice. Parkin interacts with, and regulates the degradation of 
CDCrel 2A. Parkin also co-localizes with CDCrel-2A in neuronal cell bodies and 
synapses (Choi et al., 2003). The association of both CDCrel members with parkin 
suggests an important functional relationship between parkin and the septins and points 
towards dysfunction in synpatic vesicle traffic as a possible disease mechanism. 
 
O-glycosylated α-synuclein (αSP22) 
α-synuclein was an obvious and hotly pursued candidate parkin substrate, 
particularly so since mutations in α-synuclein cause PD and overexpression of α-
synuclein as a transgene in animals recapitulate some of the behavioral and pathologic 
features of human PD (Dawson, et al., 2002). Elevation of α-synuclein in the absence of 
parkin-mediated degradation as a cause of nigral neuronal death seemed an extremely 
attractive proposition. However, several groups failed to demonstrate parkin interaction 
and ubiquitination of α-synuclein (Chung, et al., 2001). It turned out that α-synuclein 
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needs to undergo a complex post-translational modification, involving O-glycosylation, 
before it becomes a substrate for parkin (Shimura, et al., 2001). This type of complex 
glycosylation, more commonly found in extracellular proteins, is highly unusual for a 
cytoplasmic protein. Parkin interaction with glycosylated α-synuclein (αSP22) is highly 
selective, as the major non-glycosylated form of α-synuclein is totally inert to parkin 
(Shimura, et al., 2001). Curiously, most laboratories have not been able to detect the 
glycosylated form of α-synuclein. Additionally,  αSP22 to date has not been described in 
the several transgenic mouse models overexpressing α-synuclein. One possible 
explanation is that this particular α-synuclein species is extremely labile and its detection 
requires stringent adherence to the techniques described by Shimura et al (Shimura, et al., 
2001). It is also unclear whether α-synuclein toxicity is mediated by αSP22. Further 
characterization of this α-synuclein species would clarify the relevance to its role in the 
pathogenesis of PD. Although parkin fails to interact and ubiquitinate the major form of 
α-synuclein, a report indicates that it could protect neurons against mutant α-synuclein-
mediated toxicity in a manner dependent on parkin ubiquitin ligase activity (Petrucelli, et 
al., 2002). Cells overexpressing A53T mutant α-synuclein have reduced proteasomal 
activity and are particularly sensitive to proteasomal inhibition. This sensitization to 
proteasomal inhibition appears to confer selective toxicity in catecholaminergic neuronal 
population of primary midbrain cultures overexpressing mutant α-synuclein. 
Overexpression of parkin in these cells protects them against mutant α-synuclein-
mediated toxicity in a manner dependent on parkin ubiquitin ligase activity. While parkin 
does not increase net proteasomal activity, knockdown of parkin using antisense 
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technology increases the sensitivity of cells to proteasomal inhibition. Thus, parkin and α-
synuclein are linked by common effects on a pathway associated with selective cell death 
in catecholaminergic neurons. 
 
Synphilin-1 
Synphilin-1, an interactor of α-synuclein, is a synaptic vesicle enriched protein that 
has previously been shown to form Lewy body-like inclusions when co-expressed with α-
synuclein (Engelender, et al., 1999). Synphilin-1 is found in Lewy bodies and abnormal 
accumulation of synphilin-1 is specific for brain lesions in which α-synuclein is a major 
component (Wakabayashi, et al., 2000). Chung and colleagues identified synphilin-1 as a 
direct target for parkin-mediated ubiquitination and further showed that parkin 
ubiquitinates proteins within cytosolic inclusions formed by co-expression of synphilin-1 
and α-synuclein (Chung, et al., 2001). The results suggest a molecular association 
between the formation of Lewy bodies, the UPS, parkin and synphilin-1, and also link the 
major non-glycosylated form of α-synuclein and parkin in a common biochemical 
pathway through their interactions with synphilin-1. 
Interestingly, synphilin-1 is normally ubiquitinated by parkin in a non-classical, 
proteasomal-independent manner that involves lysine 63 (K63)-linked polyubiquitin 
chain formation, which does not affect its turnover rate (Lim, et al., 2005). Parkin-
mediated degradation of synphilin-1 only occurs at an unusually high parkin to synphilin-
1 ratio or when primed for K48-ubiquitination (Lim, et al., 2005). Parkin thus appears to 
function as a unique E3 ubiquitin ligase possessing dual enzymatic activities that mediate 
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opposite outcomes on its substrates. 
Although not much is known about the biological function of synphilin-1, the parkin-
mediated ubiquitination of proteins contained with LB-like inclusions generated in the 
cell by co-expression of α-synuclein and synphilin-1 occurs predominantly via K63 of 
ubiquitin (Lim, et al., 2005), suggesting the role of K63 ubiqutination of synphilin-1 in 
LB formation. More work need to be done to clarify the relevance of parkin-mediated 
K63 ubiquitnation in PD pathogenesis.  
 
Parkin-associated endothelial like receptor (Pael-R) 
The observation that parkin is up regulated in response to cellular unfolded protein 
stress suggests a more general role for parkin in the ubiquitin degradation pathway (Imai, 
et al., 2000). Elevation of parkin relieves unfolded protein-mediated toxicity through 
ubiquitinating and targeting improperly folded protein to the proteasome for clearance. 
The identification of Pael-R (Imai, et al., 2001), a putative G-protein coupled 
transmembrane receptor, as a parkin substrate when it becomes unfolded, support the 
proposed role for parkin in the unfolded protein response (UPR). Parkin protects against 
unfolded Pael-R-mediated cytotoxicity by facilitating unfolded Pael-R removal in the 
proteasome through ubiquitination (Imai, et al., 2001). For this purpose, parkin recruits a 
different set of E2s, UBCH6 and UBCH7, which locate to the endoplasmic recticulum 
(ER). A collaborator in parkin-mediated ubiquitination of Pael-R is a protein called CHIP 
(Imai, et al., 2001), a mammalian E4-like molecule that positively regulates parkin 
activity. CHIP and the molecular chaperone Hsp70 are both binding partner of parkin and 
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all three proteins form a complex with Pael-R. Interestingly, the association of Hsp70 
with Pael-R inhibits the E3 ligase activity of parkin. Apparently, CHIP facilitates parkin-
mediated ubiquitination of Pael-R by promoting the dissociation of Hsp70 from parkin 
and Pael-R. The participation of parkin in the UPR aligns with a body of evidence 
implicating environmental-induced cellular stress as an etiology of PD (Zhang, et al., 
2001). An in vivo study shows that pan-neuronal expression of Pael-R in Drosophila 
results in an age-dependent selective degeneration of its dopaminergic neurons. Co-
expression of parkin reduces Pael-R levels and suppresses its neurotoxicity, whereas 
silencing endogenous Drosophila parkin through RNA interference promotes Pael-R 
accumulation and augments its toxicity. These findings indicate that Pael-R is a genuine 
in vivo target for parkin and suggest that Pael-R accumulation is a direct cause of nigral 
cell death in ARPD. Accumulation of insoluble aggregates of Pael-R was found in brain 
of patients with ARPD (Yang, et al., 2003). 
 
p38 
Corti and colleagues first demonstrated that the p38 subunit of aminoacyl-tRNA 
synthetase complex, involved in biogenesis of brain proteins, undergoes ubiquitination by 
parkin (Corti, et al., 2003). Moreover, overexpression of p38 induces significant cell 
death against which parkin provided protection. Ko and colleagues further clearly 
identified p38 as an important authentic pathophysiologic substrate of parkin with the 
finding of upregulated p38 in the ventral midbrain/hindbrain of both young and old parkin 
null mice, as well as increased level of p38 in brains of AR-JP and idiopathic PD and 
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diffuse Lewy body disease. Overexpression of p38 in the substantia nigra in mice leads to 
loss of dopaminergic neurons (Ko, et al., 2005). A recent report (Hampe, et al., 2006) 
demonstrated that parkin promotes the multimonoubiquitylation of its substrate p38, 
rather than its polyubiquitylation in mammalian cells, suggesting that parkin may mediate 
polyubiquitylation or proteasome-independent monoubiquitylation depending on the 
protein context. The discovery of monoubiquitylated parkin species in cells indicate a 
novel post-translational modification potentially involved in the regulation of parkin 




The elucidation of the cell cycle regulatory protein cyclin E, an interactor of hSel-10, 
as a parkin substrate is consistent with parkin playing its role in a multiprotein ubiquitin 
ligase complex consisting of parkin, hSel-10 and Cullin-1 (Staropoli, et al., 2003). 
Interestingly, ubiquitination of cyclin E by parkin appears to be phosphorylation-
dependent. This may be related to the WD40 repeats on hSel-10, which recognize 
phosphoserine (threonine)-containing ubiquitination signals (Pickart, et al., 2001). 
Ubiquitination and degradation of phosphorylated cyclin E by the SCFhSel-10 complex 
underlies the regulation of cell cycle entry into S phase. In postmitotic neurons, cyclins 
accumulation has been implicated in triggering apoptosis. Not surprisingly, the regulation 
of cyclin E levels by parkin has apparent effects on cellular apoptosis. Primary neuronal 
cultures rendered deficient in parkin by RNA interference displayed increased 
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accumulation of cyclin E that correlates with increased cleaved poly (ADP-ribose) 
polymerase, a marker of apoptosis. Furthermore, cyclin E also accumulates in substantia 
nigra extracts from parkin-deficient ARPD brains, suggesting its involvement in PD 
pathogenesis (Staropoli, et al., 2003). Accumulation of cyclin E as a result of parkin 
deficiency appears to preferentially sensitize midbrain dopamine neurons to kainate 
excitotoxicity and promotes their apoptosis. Conversely, overexpression of parkin 
attenuates the accumulation of cyclin E in these neurons and protects them from apoptosis 
as a result of toxin treatment (Staropoli, et al., 2003). The sensitization of neurons to 
kainate-induced apoptosis may thus be one of the underlying mechanisms governing the 
selective nigral neurons in ARPD. 
 
Other substrates of parkin 
α- and β-tubulins - Microtubules are polymers of tubulin α-/β- heterodimers. 
Misfolded tubulin monomers are highly toxic and quickly degraded through a unknown 
mechanism. Parkin was found to ubiquitinate misfolded microtubular proteins α- and β-
tubulins and thus enhances their degradation (Ren, et al., 2003).  
 
Synaptotagmin XI - Synaptotagmin XI found both in Lewy bodies and healthy 
neurons of substantia nigra is another synaptic protein substrate for ubiquitination by 
parkin (Huynn, et al., 2003). Being located in neurotransmitter secretory granules, it is 
involved in exocytosis stimulated by calcium ions. In the case of parkin inactivation, 
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synaptotagmin cannot be ubiquitinated and this may be the reason underlying 
impairments of dopamine release. 
 
Polyglutamine proteins (polyQ) - Accumulation of aberrant polyglutamine proteins 
in cells is typical not only for PD, but also for some other neurodegenerative diseases 
such as Huntington’s disease and spinocerebellar ataxias. Tsai and coworkers 
demonstrated that parkin ubiquitinates a chaperone-bound polyglutamine protein and 
targets it for proteasome degradation (Tsai, et al., 2003).  
 
Notably, the expression levels of many of the above parkin substrates are found to be 
elevated in brains of patients with parkin mutations. These observations strongly support 
the hypothesis that parkin dysfunction leads to the mishandling of proteins, resulting in 
PD. Parkin-mediated degradation of its substrate thus fulfils a critical role in 
dopaminergic neuronal survival. However, given that parkin is a unique multifunctional 
ubiquitin ligase capable of mediating mono-, K48- & K63-linked ubiquitination of 
variable substrates, other mechanisms of neurotoxicity independent of substrate 
accumulation cannot be ruled out. 
 
1.7.6 Parkin and mitochondrial function 
The first in vivo study linking parkin to mitochondrial function was conducted in the 
Drosophila. Parkin null mutant flies developed severe mitochondrial pathology associated 
with reduced lifespan, apoptosis, flight muscle degeneration and male sterility (Greene, et 
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al., 2003). Microarray analysis in these flies revealed upregulation of genes involved in 
oxidative stress and electron transport. Subsequently, findings from mammalian models 
also support a role for parkin in maintaining mitochondrial function. Although parkin 
deficiency in mice brought about either by exon 2, 3 or 7 deletion apparently did not 
cause dopaminergic degeneration (Goldberg, et al., 2003; Itier, et al., 2003; Perez, et al., 
2005, Von Coelln et al., 2004), deletion of exon 3 of parkin in mice results in nigrostriatal 
dysfunction and reduced expression of several proteins involved in mitochondrial 
function, such as subunits of complexes I and IV. Parkin-deficient mice also exhibit 
reduced mitochondrial respiratory capacity and decreased resistance to oxidative stress 
typical for PD (Palacino et al., 2004). It is unclear how parkin regulates mitochondrial 
function. Parkin might be directly involved in maintaining mitochondrial integrity. 
Supporting this, Parkin is found to be localized to the outer mitochondrial membrane 
(OMM), where it is important in preventing mitochondrial swelling and rupture 
secondary to ceramide toxicity (Darios, et al., 2003). It is also likely that parkin might 
indirectly maintain mitochondrial function. Parkin may help clearing oxidatively 
damaged proteins via UPS.  
Parkin expression is upregulated after exposure to the complex I inhibitor MPP+ in 
neuronal cells (Hyun, et al., 2005). However, parkin function itself can be modified by 
oxidative stress (LaVoie, et al., 2005). Furthermore, nitrosylated forms of parkin are 
detectable in both the brains of patients with PD and the brains from MPTP and rotenone 
treated animals, which suggests that inactivation of parkin might be a crucial step in the 
pathogenesis of sporadic PD (Chung, et al., 2004; Yao, et al., 2004). These evidences 
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suggest that parkin might attenuate oxidative stress-related damage that could affect 
mitochondrial integrity and cause dopaminergic neuron susceptibility. 
 
1.7.7 Parkin and neurodegeneration  
It is currently widely accepted that parkin acts as a broad-spectrum neuroprotectant 
against diverse cellular insults including α-synuclein toxicity, proteasomal dysfunction, 
unfolded protein stress, kainate-induced excitotoxicity and ceramide-induced 
mitochondrion apoptosis, manganese-induced cell death and Pael-R and p38/JTv-1 
accumulation (Cookson, 2003; Feany and Pallanck, 2003). Additionally, parkin also 
appears to promote the clearance of abnormal accumulated polyglutamine proteins (Tsai 
et al., 2003). Given the multipurpose neuroprotective roles parkin plays, it is conceivable 
that events that disrupt parkin function will promote neuronal demise. 
The challenge now is to elucidate definitively the pathogenic mechanisms associated 
with parkin dysfunction that leads to PD. An age-old question that remains is why 
selective neuronal death occurs in neurodegenerative diseases such as PD. Parkin 
ubiquitous presence in the brain certainly suggests the involvement of additional factors 
in this selectivity. It is not known if environmental events or endogenous factors within 
the brain predispose the SN dopaminergic neuron to toxicity mediated by parkin 
substrates accumulation. However, loss of parkin function could sensitize cells to 
proteasomal inhibition and kainate-mediated toxicity that somehow render the nigral 
neurons more susceptible to insults (Staropoli, et al., 2003; Petrucelli, et al., 2002). Parkin 
mutations also appear to increase oxidative stress and nitric oxide production in cells, 
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sensitizing them to death induced by other insults (Hyun, et al., 2002). The SN, especially 
prone to oxidative stress, must have evolved mechanisms to safeguard its survivability 
against such stresses. The participation of parkin in the UPR, whose activity is required to 
avoid the accumulation of damaged proteins that are detrimental to neuronal survival, 
thus makes a lot of sense.  
 
1.8 Rationale & objectives  
The pivotal role parkin plays in maintaining dopaminergic neuronal survival is 
underscored by our current recognition that parkin dysfunction represents not only a 
predominant cause of familial parkinsonism but also a formal risk factor for the more 
common, sporadic form of PD. Accordingly, keen research on parkin over the last six to 
eight years has led to an explosion of knowledge regarding parkin function in the brain. 
However, although many aspects of parkin biology and pathobiology have been clarified 
since the gene was first reported nearly a decade ago to be causative of autosomal 
recessive juvenile Parkinsonism, the paradigm of parkin function remains kaleidoscopic. 
For example, it was originally hypothesized that mutations of parkin leads to the 
impairment of parkin’s catalytic activity. However, a number of recent studies have 
indicated that many disease-linked point mutants of parkin retain substantial catalytic 
activity (Imai et al. 2000; Zhang et al. 2000; Chung et al. 2001; Gu et al. 2003; Matsuda 
et al., 2006; Hampe et al., 2006). Clearly, catalytic impairment of parkin cannot be the 
sole contributor to parkin dysfunction. Another controversy relates to the transmission of 
parkin mutations. Although parkin mutations are commonly thought to be recessive, 
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emerging evidence suggest that heterozygous parkin mutations may confer increased 
susceptibility to PD (Hilker et al., 2001; Hilker et al., 2002; Lohmann et al., 2003; 
Oliveira et al., 2003; Khan et al., 2005; Clark et al., 2006; Sun et al., 2006) . Whilst parkin 
haploinsufficiency may explain the increased risk for PD associated with single parkin 
mutations, the possibility that parkin heterozygous mutations may be pathogenic cannot 
be excluded. The overall objective of this project is to understand how parkin function 
becomes altered in familial PD as well as possibly in sporadic PD. 
To understand how the plethora of mutations on parkin contributes to its dysfunction, 
it is necessary to conduct a systematic functional analysis of parkin mutations. The first 
part of this thesis thus examined the effects of parkin mutations on its biochemical and 
cellular properties comprehensively. Interestingly, we found that a large number of parkin 
mutations lead to alterations in the solubility and cellular localization of the protein.  
During the course of this study, it has occurred to us that the effects brought about by 
several parkin mutations is highly reminiscent to that brought about by aging (Pawlyk et 
al., 2003), thereby suggesting that age-related factors could mimic clinically relevant 
mutations in producing parkin dysfunction. Accordingly, the second part of the thesis 
investigated this possibility and demonstrated that a wide array of oxidative stressors 
alters parkin solubility and cause parkin aggregation, thereby suggesting a mechanism for 
parkin dysfunction in the pathogenesis of idiopathic PD. In the final part of the thesis, I 
examined the effects of parkin mutant overexpression in vivo, and showed that 
overexpression of parkin R275W mutant in the Drosophila generates marked 
neurotoxicity in select dopaminergic cluster and concomitantly produces locomotion 
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deficits. My results thus provide in vivo evidence demonstrating that parkin R275W 
mutant expression mediates pathogenic outcomes, and suggest the interesting possibility 
that select parkin mutations may potentially act in a dominant-negative manner. Taken 
together, the results presented in this thesis have helped refine our current paradigm of 
parkin function, and support the relevance of parkin dysfunction in both inherited and 
idiopathic PD.   
Materials and Methods    44 
CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 Materials  
 
2.1.1 cDNAs 
The FLAG-tagged parkin expression construct was a kind gift from Professor R. 
Takahashi (Kyoto University). All the parkin missense mutants described in this thesis 
were generated by means of PCR site-directed mutagenesis using FLAG-tagged parkin 
cDNA as a template. The mutagenesis reactions were based on the QuickChangeTM 
method (Stratagene, La Jolla, CA, USA). The various parkin mutant constructs were 
completely sequenced to ensure that they contain only the introduced mutations. The 
sequence of primers used in mutagenesis are shown in Appendix C. Myc-tagged 
synphilin-1, CDCrel-1 and synuclein cDNAs have previously been described (Zhang et 
al. 2000; Chung et al. 2001). For Drosophila study, wild-type and mutant human parkin 
(R275W or G328E) cDNAs were introduced into the GAL4-responsive pUAST 
expression vector. Sequences of cloned products were verified before they were 
microinjected into the embryos. 
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2.1.2 Antibodies  
The following antibodies were used: monoclonal and rabbit polyclonal anti-Flag 
(Sigma, St Louis, MO, USA), monoclonal anti-myc (Roche, Indianapolis, IN, USA), 
monoclonal anti-β actin (Sigma), rabbit polyclonal anti-ubiquitin (Dako A/S, Glostrup, 
Denmark), anti γ-tubulin (Sigma), fluorescein-conjugated anti-mouse or anti-rabbit IgG 
(Jackson ImmunoResearch), rhodamine-conjugated antimouse or anti rabbit IgG 
(Molecular Probes). Polyclonal anti-parkin (Cell Signalling Technologies), monoclonal 
anti-c-myc-peroxidase conjugates (Roche), monoclonal anti-HA-peroxidase conjugate 
(Roche), Rhodamine-conjugated anti-mouse IgG (Molecular Probes). Monoclonal mouse 
anti-human parkin Prk8 (Signet), anti-tubulin (Sigma), rabbit anti-TH (Pel-Freez 
Biologicals), rat anti-elav (Developmental Studies Hybridoma Bank) were used in the 
Drosophila work. Typically, antibodies were used at a concentration of 0.2 µg/mL for 
immunoblotting and 0.1 µg/mL for immunocytochemistry. 
 
2.1.3 Reagents 
Lactacystin was purchased from Affiniti Research. All the other reagents were 
purchased from Sigma (St Louis, MO, USA) unless otherwise stated. Stock solutions of 
the following chemicals were prepared and stored at -20°C: Nocodozole (final 
concentration in cell culture medium 2 µg/mL); MG-132 (1 M in DMSO); rotenone (10 
mM in DMSO); MPP+ (10 mM in dH2O); paraquat (1 M in PBS); canavanine (0.5 M in 
H2O); FeCl2 (1 M in 0.1 M HCl); dopamine (0.5 M in H2O supplemented with 0.1 M 
vitamin C). 
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2.2 Methods  
 
2.2.1 Cell Culture  
Human Embryonic Kidney (HEK) 293 cells and SH-SY5Y cells were grown in 
DMEM containing 10% FBS in a 5% CO2 atmosphere. For stress studies, parkin stable 
cells were either untreated or treated with rotenone (25 or 50 nM for 6 days), MPP+ (200 
or 500 mM for 5 days) and paraquat (1 mM for 4 days). The cells in culture were replaced 
with fresh media daily, each containing appropriate dose of the various stressors. Primary 
neuronal cells were obtained from 14.5-16 days mouse embryo midbrain tissue. 
Trypsinize tissues to release neuron cells and plate them with normal serum containing 
medium. Change medium with Neurobasal Media after cells settle down. 
 
2.2.2 Transfections, Preparation of Cell Lysates and Western Blot Analysis 
Cells were transiently transfected with various expression vectors using 
LipofectAMINE PLUS reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Two days later, transfected cells were lysed in PBST buffer 
containing 1% Triton X-100, 10 µg/mL aprotinin and 1 mM PMSF in PBS and 
sedimented at 125,000 g for 30 min at 4°C. Supernatants from the initial fractionation 
were saved as the Triton-X-soluble fractions (S), and the pellets were washed once with 
PBST buffer before re-extraction with SDS buffer (PBST containing 1% SDS in place of 
Triton X-100). After sedimentation at 125,000 g for 30 min at 4°C, the supernatants were 
saved as the SDS fractions (P). For some experiments, an intermediate strength extraction 
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buffer (RIPA) containing 50 mM Tris-HCL, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% 
sodium deoxycholate and 1% Nonidet P-40 was used in between the S and P extractions. 
Equivalent amount of proteins among different S and P fractions were resolved by means 
of SDS–PAGE and the levels of various ectopically expressed proteins were analyzed by 
means of western blotting procedures using ECL detection reagents (Amersham, Little 
Chalfont, Buckinghamshire, UK). In initial expression studies, the proteasome inhibitor 
lactacystin was used to rule out that some poorly expressing parkin mutants is due to their 
rapid degradation by the ubiquitin proteasome system. In these studies, transfected cells 
were treated with 5 µM clasto-lactacystin β-lactone at 24 h post-transfection for an 
additional 24 h. 
 
2.2.3 Immunocytochemistry and Confocal Microscopy 
5×104 HEK 293 or SH-SY5Y cells were seeded onto polylysine coated sterile glass 
coverslips in a 24-well culture plate a day prior to transfection. After attachment, cells 
were transfected as described above with 0.25 µg of the appropriate constructs. Two days 
later, cells were washed once with PBS and fixed in 3% paraformaldehyde (w/v) for 20 
min. The fixed cells were washed three times with PBS before permeabilzation in 0.2% 
Triton X-100 (v/v) in PBS for 5 min. Blocking was then carried out with 5% goat serum 
in PBS for 1 h. This was followed by incubation in primary antibodies for 1 h at 25°C and 
secondary antibodies for another hour at 25°C. Immunofluorescent images were acquired 
on an Olympus confocal microscope. Negative controls omitting each primary antibody 
were performed in each case and no significant staining was seen (data not shown). To 
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determine the number of cells containing aggregates, at least 100 FLAG-parkin positive 
cells were examined and counted from each of the three independent wells per 
experiment. Cells were counted in a blinded manner and quantitative results reported are 
an average of at least 3 experiments. Statistical significance was determined using 
Student’s paired t-test for all comparisons. 
 
2.2.4 Cell viability and proteasome activity analysis 
Quantitation of cell survival was performed using two methods: flow cytometry and 
Trypan blue exclusion assay. For the flow cytometric analysis, cells were seeded at a 
concentration of 1 × 106/ml. After treatment, cells were trypsinized and propidium iodide 
(1 µg/ml) was added 5 min before flow cytometric analysis by the Coulter imaging 
system (BD). A count of 10 000 cells were taken and percentage of cell death was 
calculated using winMDIv2.8 (BD). Proteasomal activities after chronic rotenone 
exposure were determined by incubating lysates (10–15 µg of protein) with substrates 
Suc-LLVY-AMC for 1.5 h at 37°C. The relative amount of AMC released was measured 
using a fluorometer equipped with a 380/460 nm filter set (TECAN). 
Statistical significance for all the quantitative data obtained was analyzed using one-way 
ANOVA (SPSS 13.0) (*P < 0.05, **P < 0.001) unless otherwise stated. 
 
2.2.5 Animals and MPP+ injections 
Studies involving mice and human tissues were conducted by our collaborators at 
Johns Hopkins University School of Medicine, USA. All procedures involving animals 
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were approved by and conformed to the guidelines of the Institutional Animal Care 
Committee of Johns Hopkins University. Eight-week-old male C57/bl mice (Charles 
River Laboratories, Wilmington, MA, USA) (n=5 per group) received an acute paradigm 
of four intraperitoneal injections of MPP+ and HCl (20 mg/kg free base; Sigma) in saline 
at 2 h intervals on 1 day and control mice received equivalent volumes of saline at the 
same frequency. Animals were sacrificed by decapitation at 2, 4, 24, 48, 72 and 96 h after 
the last MPP+ injection and their ventral midbrain and striata were quickly dissected out 
on ice and immediately frozen in -80°C and processed for western blot analysis. 
       Human brain tissue was obtained through the brain donation program of the Morris 
K. Udall Parkinson’s Disease Research Center at Johns Hopkins Medical Institutions 
(JHMI) according to HIPAA regulations. This research proposal involves anonymous 
autopsy material that lacks identifiers of gender, race or ethnicity. The JHMI Joint 
Committee on Clinical Investigations decided that the studies in this proposal are exempt 
from Human Subjects Approval because of Federal Register 46.101 exemption number 4. 
 
2.2.6 Preparation of human and mouse brain tissues 
Caudate tissues from three control brain and frontal cortical tissues from two control 
and nine caudate tissues from PD/DLB brains were age matched and used to analyze 
parkin solubility. Detergent-soluble and -insoluble fractions were prepared from human 
brain tissues and mouse brain tissues, such as ventral midbrain and striatum, by 
homogenization of samples in lysis buffer [10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 5 
mM EDTA, 0.5% Nonidet P-40, 10 mM Na-b-glycerophosphate, phosphate inhibitor 
Materials and Methods    50 
mixture I and II (Sigma), complete protease inhibitor mixture (Roche)] by using a Diax 
900 homogenizer (Heidolph, Cinnaminson, NJ, USA). After homogenization, samples 
were rotated at 4°C for 30 min for complete lysis, then the homogenate was centrifuged 
(10 000g, 4°C, 20 min) and the resulting pellet and supernatant fractions were collected. 
The pellet fractions were washed once in lysis buffer containing detergent, and the 
resulting pellet was solubilized in lysis buffer containing 1% SDS. Protein concentrations 
of both soluble and insoluble fractions were determined using the BCA kit (Pierce, 
Rockford, IL, USA) with BSA standards and analyzed by western blot. Western blotting 
was carried out with anti-parkin (PRK8 mouse monoclonal) and anti-β-actin (Sigma) 
antibodies. Detection was performed with enhanced chemiluminescence (Amersham 
Biosciences, Piscataway, NJ, USA). 
 
2.2.7 Bioinformatics 
Amino acid sequences of parkin from human (O60260), rat (NP064478), mouse 
(NP057903), Fugu (AAS79348), zebrafish (NP001017635), Drosophila (AAM43930), 
Anopheles (XP316606) and C. elegans (CAB04599) were retrieved from NCBI and 
aligned using CLUSTALW (Thompson, et al., 1994). The structural coordinates for the 
RING domain of c-Cbl (1FBV) and HHARI (1WD2) were obtained from Protein Data 
Base (PDB). Parkin RING1 and RING2 were modeled against the templates of c-Cbl and 
HHARI respectively using the alignment interface of the SWISS-MODEL program 
(Schwede, et al., 2003). All structures were viewed and manipulated (aligned structure 
analysis, superimpositions, computation of molecular surface and on-screen mutations) 
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using Swiss-PdbViewer v3.7b2 (SPdbV) (Guex, et al., 1999). 
 
2.2.8 Fly stocks 
The parkin null mutant flies (park1) were kind gifts from Drs. J. Chung and K.S. Cho 
(Korea Advanced Institute of Science and Technology, Korea) (Cha et al., 2005) while the 
fly lines for elav-Gal4, Ddc-Gal4, 24B-Gal4 and mata-Gal4 were obtained from the 
Bloomington Stock Center (Bloomington, IN, USA). 
 
2.2.9 Western Blot analysis and Immunohistochemistry for Drosophila 
For Western blot analysis, 100µl embryos or head extracts from 50 adult flies per 
strain were prepared by homogenization in PBS buffer containing 1% Triton X-100, 10 
µg/ml aprotinin and 1mM PMSF (PBST) before sedimentation at 14,000 rpm for 15 min 
at 4oC. Supernatants from the initial fractionation were saved as Triton-X-soluble 
fractions (S), and the pellets were washed once with PBST buffer before re-extraction 
with SDS buffer (PBST containing 1% SDS in place of Triton X-100). After 
sedimentation at 14,000 rpm for 15 min at 4oC, the supernatants were saved as the SDS 
fractions (P). Equivalent amount of proteins among different S and P fractions were 
resolved by means of SDS-PAGE and probed with mouse anti-human parkin Prk8 
(1:2000, Signet) or anti-tubulin (1:500, Sigma). Detection was performed with enhanced 
chemiluminescence (Amersham Biosciences). Immunohistochemical analysis of whole-
mount adult fly brains were prepared according to published protocols and stained with 
rabbit anti-TH (1:200, Pel-Freez Biologicals), rat anti-elav (1:10, Developmental Studies 
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Hybridoma Bank), rat anti-5-HT (1:50, Chemicon) or mouse anti-human parkin Prk8 
(1:1000, Signet) as primary antibodies. We analyzed dopaminergic neurons in different 
cluster according to the method described by Whitworth et al (Whitworth et al., 2005).  
 
2.2.10 Drosophila Muscle Histology and Transmission Electron Microscopy Analysis 
For transmission electron microscopy (TEM), muscle tissues were prepared by 
dissecting thoraces from 20 day-old adult flies. These sections were then fixed overnight 
in 2.5% glutaraldehyde in 0.1 M phosphatebuffer, pH 7.2 before being postfixed in 1% 
OsO4 for 1h. Subsequently, they were dehydrated in an ethanol series and embedded in 
Spurr’s resin. Ultrathin sections were stained with uranyl acetate and lead citrate and 
observed under a JEM-1230 electron microscope. 
 
2.2.11 Climbing assays and rotenone treatment  
Climbing assays were carried out according to the method described by Coulom and 
Birman (Coulom and Birman, 2004). Three groups of twenty female adult flies that 
express the transgenes under the direction of the Ddc driver were anesthetized and placed 
in a vertical plastic column (length 25 cm; diameter 1.5 cm). Age-matched wild type and 
parkin null flies were used as controls. After a 1-hour recovery period from CO2 
exposure, flies were gently tapped to the bottom of the column. The number of flies that 
reached the top of column at 1 min was then counted. Three trials were performed in each 
experiment at 15 min intervals. The scores represent the mean percentage of flies that 
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reached the top against the total number tested. Results are presented as mean±SEM of 
the scores obtained in three independent experiments. In rotenone-treated flies, flies were 
fed with cornmeal-agar medium containing 50 µM rotenone (Sigma) immediately at post-
eclosion and during the entire experimental period. Statistical significance for all the 
quantitative data obtained was analyzed using Student’s t-test (*P <0.05, **P < 0.01) 
unless otherwise stated. 
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CHAPTER 3 
 
ALTERATIONS IN THE SOLUBILITY AND INTRACELLULAR 
LOCALIZATION OF PARKIN BY SEVERAL PARKIN MUTATIONS 
 
3.1 Overview 
Parkin functions as a ubiquitin ligase associated with the ubiquitin-proteasome 
system (UPS), the latter is important in maintaining cellular homeostasis through the 
clearance of unwanted proteins (Pickart 2001). The RING box domain of parkin is 
essential for its catalytic activity (Imai et al. 2000; Shimura et al. 2000; Zhang et al. 
2000). Notably, many clinically relevant point mutations on parkin occur in this region 
(Mata et al. 2004). As protein ubiquitination is usually linked to proteasomal degradation 
(Pickart 2001), it is widely speculated that the absence of functional parkin would lead to 
the toxic accumulation of its substrates within susceptible neurons, eventually leading to 
their demise. Consistent with this hypothesis are the observations that numerous reported 
substrates of parkin accumulate in brains of PD patients carrying parkin mutations (Imai 
et al. 2001; Shimura et al. 2001; Choi, et al., 2003; Staropoli et al. 2003). Several other 
reports have also implicated neuroprotective roles of parkin in response to diverse cellular 
insults including α-synuclein toxicity, proteasomal dysfunction, unfolded protein stress 
and kainateinduced excitotoxicity (Feany and Pallanck 2003). Taking all these findings 
together, it thus seems reasonable to assume that the catalytic activity of parkin is 
required for the proper maintenance of dopaminergic neuronal function. However, a 
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number of recent studies have indicated that many disease-linked point mutants of parkin 
retain substantial catalytic activity (Imai et al., 2000; Zhang et al., 2000; Chung et al., 
2001; Gu et al., 2003; Matsuda et al., 2006; Hampe et al., 2006). Clearly, catalytic 
impairment of parkin cannot be the sole contributor to parkin dysfunction. 
 To understand how the plethora of mutations on parkin contributes to its 
dysfunction, a systematic analysis of a significant number of parkin point mutants (22 in 
total), which represent the majority of parkin missense/nonsense mutations reported to 
date, was conducted (Fig 3.1A). It was found that more than half of these mutations, 
including many located outside of the parkin RING fingers, produce alteration in the 
solubility of parkin which influences its detergent extraction property. This mutation-
mediated alteration in parkin solubility is also associated with its propensity to form 
intracellular, aggresome-like, protein aggregates. However, they do not represent sites 
where parkin substrates CDCrel-1 and synphilin-1 become sequestered, whereas 
colocalize with another substrate p38. As protein aggregation sequesters the functional 
forms away from their normal sites of action, our results suggest that alterations in parkin 
solubility and intracellular localization may underlie the molecular basis of the loss of 




3.2.1 A large number of familial PD-linked point mutations on parkin influence its 
solubility in cells  
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The initial expression studies of the parkin point mutants in HEK 293 cells indicated 
that most of these mutants, except for A82E, M192L, K211N, T240R, T415N, G430D 
and P437L are expressed poorly relative to wild-type parkin (Fig. 3.1B). We reasoned at 
first that the poor expression level of the majority of parkin mutants examined could be 
due to their rapid degradation via the UPS. However, treating cells transfected with 
several poorly expressing species of parkin mutants with the proteasome inhibitor, 
lactacystin, did not significantly improve their subsequent detection by means of western 
blot (Fig. 3.1C). As we were examining the expression of parkin in transfected cell 
extracts prepared using a mild detergent (Triton-X-100), we reasoned that any alteration 
of parkin solubility by its mutations could influence its protein extraction property and 
hence, its detection under our experimental conditions. To address this possibility, we 
performed sequential extraction of the transfected cells with Triton-X-100 and SDS, 
respectively, to examine the population of parkin in both the Triton-X-100-soluble (S) 
and -insoluble (P) fractions. Interestingly, we found that transfected wild-type parkin 
resides in both fractions. The extraction profile of parkin mutants that ‘expressed well’, 
including A82E, M192L, K211N, T240R, T415N, G430D and P437L, are essentially 
similar to that of wild-type parkin. However, all the other mutants that are barely 
detectable in the S-fractions show robust immunoreactivities in the P-fractions (Fig.3.1B). 
Further, the expression levels of these mutants compare well to wild-type parkin in the P-
fraction. Although the relative ratio of expression of three mutants, R42P, C268X and 
Q311X, to wild-type parkin remains low in the SDS-pool, they nonetheless represent a 
significant increase over their respective Triton-X-100-pool (Fig. 3.1B). Apparently, the 
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‘poorly expressed’ mutants are preferentially localized to an intracellular location that is 
resistant to Triton-X-100 extraction. In examining the extraction profile of the various 
parkin species, we also noticed that many of them show the presence of high molecular 
weight complexes that are particularly evident in the P-fractions. This is consistent with 
previous studies conducted by others with FLAG tagged parkin (Imai et al. 2000; Junn et 
al. 2002). The high molecular weight parkin smears we observed possibly represent 
ubiquitinated parkin species.  
 To dissect the differential extractibility of the various parkin mutants ectopically 
expressed in HEK 293 cells further, we repeated our serial extraction experiments with a 
more elaborate set of buffers: PBS; PBS + 1% Triton-X-100 (PBST); RIPA and PBS + 
1% SDS (SDS), that cover a broader range of extraction strength. We found that the 
Triton-X-100 soluble parkin species are easily extractable by sonicating the transfected 
cell pellet with PBS alone, while the Triton-X-100-insoluble species remain insoluble in 
all the extraction buffers except the one containing 1% SDS (Figs 3.2A & B). 
Presumably, the Triton-X-100 soluble forms of parkin reside freely in the cytosol while 
the Triton-X-100-resistant forms of parkin protein exist as protein aggregates. We also 
expressed a subset of parkin mutants in SH-SY5Y neuroblastoma cells to see if their 
respective extraction profile observed earlier is similar in a different cell line. As shown 
in Fig. 3.2C, the extraction properties of these mutants remain unchanged when expressed 
in the neuroblastoma cell line. Taken together, our results suggest that a large number of 
familial PD-associated point mutations on parkin result in altered solubility of the protein 
and as such, influence its detergent extraction property.  








Fig. 3.1 Biochemical distribution of wild-type parkin and various parkin mutants in 
transfected cells. (A) Schematic figure of parkin illustrating the positions of the various point 
mutations of parkin constructs used in this study. (B) Representative anti-FLAG immunoblots of 
cell extracts sequentially prepared with Triton-X-100 (S) and SDS (P) from HEK 293 cells 
transfected either with wild-type parkin or various parkin mutants (as indicated). The blots were 
stripped and reprobed with anti-actin antibody to reflect loading variations. The experiment was 









Fig. 3.2 Differential extractibility of various parkin mutants. (A) Anti-FLAG immunoblots of 
cell extracts sequentially prepared with PBS and PBS + 1% Triton-X-100 (PBST) from HEK 293 
cells transfected either with wild-type parkin or parkin mutants that are readily extractable with 
PBST. (B) Anti-FLAG immunoblots of cell extracts sequentially prepared with PBST, RIPA and 
SDS buffers from HEK 293 cells transfected either with wild-type parkin or parkin mutants that 
are not readily extractable with PBST. (C) Anti-FLAG immunoblots of cell extracts sequentially 
prepared with PBST (S) and SDS (P) from SH-SY5Y cells transfected either with wild-type 
parkin or a subset of parkin mutants (as indicated). The various blots were stripped and reprobed 
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3.2.2 Parkin mutants with altered solubility have a propensity to form aggresome-
like structures in cells.  
We were curious to know whether the mutation-mediated alteration in the solubility 
of parkin affects the intracellular distribution of the protein. To examine this, we 
transfected each of our parkin mutants into SH-SY5Y cells. Consistent with previous 
reports by others (Cookson, et al. 2003b; Gu, et al. 2003), we found that normal parkin is 
uniformly expressed throughout the cytoplasm in the majority of the transfected cells 
(Fig. 3.3A). Mutants that share similar extraction property to wild-type parkin (A82E, 
M192L, K211N, T240R, T415N, G430D and P437L), are localized in the same fashion as 
wild-type parkin within the transfected cells (Fig. 3.3A). Although occasional parkin-
immunoreactive aggregates occur in these cells, they account for fewer than 4% of the 
population of transfected cells (Fig. 3.3C). However, among the mutants that are 
predominantly found in the Triton-X-100 insoluble pellet, about 75% show a propensity 
to form intracellular protein aggregates (Fig. 3.3B). On average, the occurrence of parkin-
immunoreactive aggregates in cells transfected with these detergent-resistant mutants is 
about 30%, but some mutants like C289G and C441R formed aggregates in as much as 
60% of the transfected cells (Fig. 3.3C). There is however, no absolute correlation 
between the extent of detergent insolubility of the parkin mutants and the number of 
inclusions formed (Fig. 3.3D). Notably, many of these parkin mutant-mediated aggregates 
tend to concentrate into a single, mostly perinuclear, mass that is reminiscent of the 
aggresome, a centriole-associated structure (Kopito 2000) (Fig. 3.3B). To further explore 
the potential centrosomal recruitment of parkin mutant-mediated aggregates, we 
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transfected SHSY5Y cells with a subset of parkin mutants (C268X, C441R) that showed 
the highest tendency to form intracellular aggregates and costained the cells with parkin 
and γ-tubulin, a centrosome marker. We observe that the major perinuclear aggregate 
formed by each mutant colocalized with γ-tubulin. Further, these perinuclear aggregates 
are also enriched with ubiquitin (Figs 3.4A, B). Expectedly, treatment of the cells with 
nocodozole, a microtubule depolymerizing agent, led to the dispersion of the perinuclear 
aggregates into multiple smaller aggregates scattered throughout the cytoplasm (Fig. 
3.4C). Thus, parkin mutant-mediated aggregates appear to resemble an aggresome, an 
observation that is consistent with previous demonstration by others that the R275W and 
C289G formed aggresome-like structures when overexpressed in cells (Cookson et al. 
2003b; Gu et al. 2003). Taken together, these results suggest that mutations on parkin that 
decrease its solubility tend to affect the cellular distribution of the protein, leading to the 


































Parkin Mutants Promote its Aggregation    63 
 
Fig. 3.3 Localization of parkin mutants in transfected SH-SY5Y cells. SH-SY5Y cells were 
transfected with various FLAG-tagged parkin constructs (as indicated) and stained for 
exogenously expressed parkin using anti-FLAG antibody (red). (A) Vector transfected cells 
showed no background staining whereas transfection with either wildtype parkin or Triton-X-100 
soluble parkin mutants showed uniform cytoplasmic staining. (B) Triton-X-100 insoluble parkin 
mutants expressed in SH-SY5Y cells tend to form inclusion-like structures that accumulate 
around the perinucleus (arrows) (C) Graph showing the percentage of cells containing anti-
FLAG-positive aggregates. Bars shown are the means from at least 3 independent experiments, 
and the error bars indicate the mean±SEM. Statistical variance, whenever significant, are 
indicated (*p < 0.01; **p < 0.001, Student’s t-test). (D) Graph showing the correlation between 









































































































































Fig. 3.4 Parkin mutant-mediated inclusions resemble aggresomes. (A) SH-SY5Y cells 
transfected with the following FLAG-tagged parkin mutants, C268X and C441R, were 
coimmunostained with anti-ubiquitin (red) and anti-FLAG (green) antibodies. The merged 
pictures show colocalization of the anti-ubiquitin and anti-FLAG staining (yellow). (B) As in (A) 
except that coimmunostaining of cells were performed with anti-c-tubulin (red) and anti-FLAG 
(green). The merged pictures in this case show colocalization of the anti-γ-tubulin and anti-FLAG 
staining (yellow). (C) Merged pictures showing the dispersion of the anti-γtubulin/ anti-FLAG-
immunopositive aggregates (yellow) in transfected cells treated with 2 µg/mL nocodozole. These 
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3.2.3 The parkin substrates CDCrel-1, Synphilin-1 and p38 cellular localization in 
the parkin-mutant overexpressed SH-SY5Y cells 
Mutations of parkin could affect its enzyme activity by abolishing its recruitment of 
its substrates or cognate E2s, or both. Hence, catalytically impaired parkin retains the 
potential to bind substrate. Indeed, previous reports indicate that some familial-linked PD 
mutations of parkin do not significantly abolish the ability of parkin to recruit its 
substrates, CDCrel-1 and Synphilin-1 (Zhang et al. 2000; Chung et al. 2001). We were 
therefore curious to know if these substrates of parkin are bound to the parkin mutant 
mediated aggregates. To address this possibility, we expressed either CDCrel-1 or 
Synphilin-1 in SH-SY5Y cell in the presence of wild-type parkin or the parkin mutants, 
A82E, which does not form inclusions, C268X, R275W, C289G or C441R, which have 
the highest propensities to form protein inclusions. As the major form of α-synuclein 
does not interact with parkin, but is nonetheless a major component of Lewy body, we 
also coexpressed α-synuclein with each of these parkin species. Examination of the 
various transfected cells reveals that CDCrel-1, Synphilin-1 and α-synuclein, like parkin, 
are homogeneously distributed in the cytoplasm. Hence, all of these proteins overlap with 
the evenly distributed wild type parkin and the A82E mutant (Fig. 3.5). While α-
synuclein does not colocalize with any of the parkin mutant-mediated aggregates, neither 
CDCrel-1 nor Synphilin-1 is recruited to these aggregates (Fig. 3.5). Hence, aggregates 
formed by parkin mutants in these cases do not appear to represent sites within which 
CDCrel-1 and Synphilin-1 are sequestered. 
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Fig. 3.5 The parkin substrates CDCrel-1 and Synphilin-1 are not sequestered within parkin 
mutant-mediated aggregates. SH-SY5Y cells were cotransfected with various FLAG-tagged 
parkin species and the following myc-tagged constructs: (A) CDCrel-1, (B) Synphilin-1 and (C) 
α-synuclein. Cells were coimmunostained with anti-myc (green) and anti-FLAG (red). The 
merged pictures in each case show colocalization of the anti-myc and anti-FLAG staining 
(yellow). Where inclusions are observed, they are indicated by arrows. These results were 
replicated 3 times. 
 
CC 
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However, co-expression of various parkin mutants with another substrate p38 in SHSY5Y 
cells shows the co-localization of p38 with parkin mutant-mediated inclusions (Fig. 3.6). 




Fig. 3.6 The parkin substrates p38 co-localize with parkin mutant-mediated aggregates. SH-
SY5Y cells were cotransfected with various FLAG-tagged parkin species and HA-tagged p38. 
Cells were coimmunostained with anti-Flag (green) and anti-HA (red). The merged pictures in 
each case show colocalization of the anti-Flag and anti-HA staining (yellow). These results were 
replicated 3 times. 
 
Interestingly, parkin aggregates apparently also colocalize with tyrosine hydroxylase, a 

















Fig 3.7 Parkin mutant-mediated aggregates colocalize with Tyrosine hydroxylase (TH). 
SHSY5Y cells were transfected with various FLAG-tagged parkin constructs (as indicated) and 
stained for exogenously expressed parkin using anti-FLAG antibody (green). Endogenous TH was 
stained with anti-TH antibody (red). 
 
3.3 Discussion 
To date, numerous biochemical studies aimed at understanding how familial PD-
associated point mutations in parkin affects its function have been conducted. Although 
informative, the findings from these studies require careful interpretation as they are often 
derived from the characterization of a limited number of parkin mutants. For example, 
two recent studies utilizing 4–5 parkin point mutants demonstrated that mutations in 
parkin occuring at either RING 1 or 2 result in altered intracellular localization of the 
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protein (Cookson et al. 2003b; Gu et al. 2003). Here, we report the characterization of 22 
clinically relevant parkin point mutants that represent the majority of parkin missense and 
nonsense mutations reported to date. We found that more than half of these parkin 
mutants, including many that do not reside within parkin RING fingers, produce 
alterations in the solubility of the proteins and result in their aggregation within the cell. 
We further show that the mutant-mediated aggregates share features of an aggresome, but 
do not represent sites within which parkin substrates such as CDCrel-1 and Synphilin-1 
are sequestered. However, they co-localize with another substrate p38. Based on their 
respective detergent extractibility and tendency to form intracellular aggregates, we can 
broadly categorize the parkin point mutants examined into three groups: I –soluble; II – 
insoluble with low propensity to form inclusions; and III – insoluble with high propensity 











Fig. 3.8 Categorization of parkin mutants. Based on their respective detergent extractibility and 
their propensity to form intracellular aggregates, the parkin mutants examined can be categorized 
into 3 groups: Group I – Soluble; II – Insoluble with low tendency to form inclusions; and III – 
Insoluble with high tendency to form inclusions. S and P fractions refer to Triton-X-100 and SDS 
extractable fractions, respectively. 
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While parkin-mediated inclusion formation has been initially reported by Junn et al. 
(2002) and subsequently by other investigators, significant inclusion formation by parkin 
in these studies only take place in the presence of proteasomal impairment (Junn et al. 
2002; Ardley et al. 2003; Zhao et al. 2003). Consistent with these studies, we did not 
observe a propensity for wild-type parkin to form inclusion under basal conditions. It is 
therefore interesting for us to note in our present study that several parkin mutations 
located at various lengths of the protein could produce inclusions in the absence of 
exogenously added proteasome inhibitors. However, we cannot rule out at this moment 
that the overexpression of these inclusion-forming mutants could compromise 
proteasomal activity, and thereby promoting their aggregation. It remain curious to us 
why the Group I parkin species, including wild-type parkin, that are readily extractable 
with Triton-X-100 have a low propensity to aggregate within the cell despite also having 
a significant population represented in the detergent-insoluble pool.  
We are similarly intrigued by the low tendencies of Group II parkin mutants to 
generate intracellular inclusions. Presumably, the degree of misfolding among different 
parkin mutants, as discussed later, contributes to their relative propensities to form protein 
inclusion. Although our study presented here is in general agreement with several 
previous reports by others, there are some differences relating to the expression profile 
and inclusion forming ability of a few mutants (Table 3.1). In such cases, we thought that 
differences in the extraction methodology, choice of cell line or epitope tag may be the 
reasons for our conflicting observations.  
 
Parkin Mutants Promote its Aggregation    73 
Table 3.1 Association of parkin mutations with inclusion formation.a 
 
 
To address the above, our lab has generated several myc-tagged parkin mutants and 
expressed them in SH-SY5Y cells but found that both the myc-tagged and FLAG-tagged 
versions of our mutants behave similarly in terms of their detergent extraction and 
inclusion formation properties (Siriam et al., 2005). We also repeated our localization 
studies in HEK 293 cells and observed a largely similar distribution of normal and mutant 
parkin species consistent with their detergent extraction properties, except that the 
Parkin Mutants Promote its Aggregation    74 
tendency of some mutants (R256C, C212Y and C431F) to form inclusion becomes less 
pronounced in HEK293 cells compared to SH-SY5Y cells (Fig. 3.9). Hence, the choice of 
cell lines used does appear to be important in the case of these selected mutants and may 





Fig 3.9 Localization of parkin mutants in transfected HEK293 cells. HEK293 cells were 
transfected with various FLAG-tagged parkin constructs (as indicated) and stained for 
exogenously expressed parkin using anti-FLAG antibody (green). Mutants predominantly 
localised in the Triton-X-insoluble pool have a propensity to form protein inclusion when 
expressed in cells (arrowed). 
 
It is noteworthy to mention that parkin C441R, which has a high propensity to generate 
inclusions in SH-SY5Y cells, retains the ability to promote inclusion formation in 
primary dopaminergic neurons (Fig. 3.10). 
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Fig. 3.10 Parkin mutant forms inclusion in primary neuron cells. Primary neuron cells were 
transfected with FLAG-tagged parkin constructs and stained for exogenously expressed parkin 
using anti-FLAG antibody (green). Endogenous TH was stained with anti-TH antibody (red). 
 
Several reports have indicated that many disease-linked point mutants of parkin 
retain substantial catalytic activity, suggesting that mutations in parkin do not always 
produce a simple loss of function (Chung et al. 2001; Gu et al. 2003). Our observation 
that a large number of parkin mutants (Group III, Fig. 3.8) have a tendency to become 
aggregated suggests that protein misfolding may underlie the molecular basis of the loss 
of parkin function caused by these parkin mutations. Notably, all the four nonsense 
mutations in parkin we examined belong to this group. These mutants, which are 
truncated at various lengths from the C-terminus of the protein, are presumably folded 
incorrectly due to large structural changes associated with their truncations. As a result, 
they probably tend to exist as detergent-insoluble aggregates. Indeed, the inclusion-
forming W453X parkin mutant has been demonstrated to adopt a misfolded conformation 
spontaneously (Winklhofer et al. 2003). In this case, the deletion of only three C-terminal 
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amino acids of parkin is sufficient to induce a detergent-insoluble conformation. Hence, 
the larger deletion of parkin C-terminus associated with the C268X, Q311X and E409X 
mutants would be expected to produce a similar, if not a more pronounced, alteration in 
parkin structure. Since the catalytically essential RING box is partially or totally missing 
in these mutants, it is also easy to understand why these mutants would also be non-
functional.  
Interestingly, many missense parkin mutants containing just one amino-acid 
substitution behave in the same manner to these truncation mutants in terms of their 
detergent extractibility and intracellular localization. A simple yet logical explanation to 
why a single mutation on parkin could mirror the same effect brought about by large 
region of truncation is that the residues affected in these mutants are absolutely critical in 
maintaining the native structure of parkin. Consistent with this notion are our 
observations that, detergent-resistant aggregates occur in all the three parkin mutants 
examined (C289G, C431F and C441R) that contain mutations affecting the RING-
cysteine residues (Fig. 3.11). C289 and C441, which are highly conserved cysteine 
residues in RING1 and RING2 co-coordinating with Zn, define the structure and function 
of a RING finger and their mutations are expected to alter the RING conformation 
tremendously (Morett and Bork 1999; Zheng et al. 2000). Presumably, the other 
important residues affected act in similar ways. However, we cannot completely exclude 
the possibility that the altered biochemical properties of parkin mutants could be due to 
changes in their interaction with other proteins or other cellular components, such as 
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membranes. Undoubtedly, structural studies of the various parkin mutants would provide 








Fig. 3.11 Modeling of parkin RING1 & RING2 tertiary structure.  Predicted tertiary structure 
of RING1 (A) and RING2 (B) domain of parkin showing the co-ordination of zinc atom by the 
invariant cysteines (yellow) and the position of non-invariant cysteines (cyan).  
 
It is conceivable that the aggregation of parkin would sequester the protein away 
from its normal site of action and as a result, deplete the cell of its soluble pool of 
functional parkin. Thus, despite being reported to be catalytically active, the aggregation-
prone R275W mutant may not have enough soluble forms in the cell to cope with the 
protein load normally handled efficiently by wild-type parkin. The same situation 
probably applies to parkin mutants sharing similar properties to the R275W mutant. As 
functional parkin has been shown to fulfil multiple neuroprotective roles (Feany and 
Pallanck 2003), its depletion in the cell as a result of rapid aggregation would be expected 
to increase the susceptibility of the cell to apoptosis following insults. Our speculation is 
in agreement with emerging evidence indicating that parkin haploinsufficiency, as well as 
parkin promoter variability, are associated with the development of PD and the ensuing 
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hypothesis that the expression level of parkin is important in maintaining neuronal 
survivability (West et al. 2002a, b; Foroud et al. 2003).  
 A very intriguing feature of parkin-proven PD cases is the apparent lack of Lewy 
bodies (LBs) reported in a number of, albeit limited (about 8), detailed pathological 
examinations (Mata et al. 2004). This has led to the popular speculation that functional 
parkin is required for the formation of LBs. However, alternate pathologies describing the 
presence of tau-positive inclusion and LBs have also been reported (Farrer et al. 2001; 
Mata et al. 2004). The latter case occurs in a patient with a null mutation in one parkin 
allele and a R275W substitution in another (Farrer et al. 2001). Since the R275W retain 
catalytic activity (Chung et al. 2001) and at the same time has a propensity to become 
aggregated, our results may help explain the alternate pathology observed. It is tempting 
to speculate that the other aggregation-prone Group III mutants may also be associated 
LB formation. Indeed, the aggregates mediated by this group of parkin mutants appear to 
be aggresome-like and may represent a precursor  to LB. Curiously, although α-synuclein 
is a major constituent of LBs, we were not able to detect its recruitment into aggresomes 
mediated by the parkin mutant overexpression. Our result is however, consistent with the 
report by Muqit et al. describing the absence of α-synuclein immunoreactivities in parkin 
positive aggresomes (Muqit et al. 2004). Likewise, α-synuclein is absent in aggregates 
induced by proteasome inhibition (Paxinou et al. 2001). Although the R275W mutant-
mediated inclusion overlapped with the distribution of endogenous α-synuclein in the 
study conducted by Cookson et al., there was no specific recruitment of α-synuclein into 
aggresome (Cookson et al. 2003). However, some investigators were able to detect α-
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synuclein in aggresomes (Junn et al. 2002; Lee et al. 2002). At this moment, we do not 
know if the inconsistencies are due to differences in cell lines and antibodies used, or they 
reflect the limitations of cell culture system in recapitulating in vivo events accurately. 
Similar to our observation with α-synuclein, neither synphilin-1 nor CDCrel-1 is 
recruited into the parkin mutant-mediated aggregates. Whereas the occurrence of CDCrel-
1 in Lewy body remains to be established, synphilin-1, like α-synuclein, is a known 
component of LB (Wakabayashi et al. 2000). Since p38 is present in LBs in patients with 
idiopathic PD (Corti, et al., 2003), the co-localization of p38 with parkin mutant-mediated 
aggregates may support that these parkin mutants play a role in LB formation. It is 
conceivable that the biogenesis of LBs in dopaminergic neurons in vivo requires the 
participation of multiple players and conditions that are not present in our cell culture 
models. Nonetheless, the propensity of the Group III parkin mutants to form aggregates 
within cells suggests that their capabilities of mediating inclusion formation in vivo may 
ultimately culminate into LBs. 
In summary, we demonstrate here that numerous mutations occuring at different 
regions of the parkin protein could exert profound effects on its structural integrity, 
resulting in its aggregation. The subsequent depletion of the cytoplasmic pool of soluble 
parkin may underlie the molecular basis of the loss of function in these mutants. Although 
the molecular mechanisms underlying the loss of function in Group I & II parkin mutants 
remain to be determined, we believe that mutations in these two groups of mutants are 
likely to directly affect the interaction between parkin and its important cellular partners. 
However, it remains a challenge to understand how parkin mutants with distinctly 
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different biochemical properties perturb cellular pathways that eventually converge into 
the same final pathogenic outcome.  
 
 
Results presented in this chapter have been published in the Journal of Neurochemistry  
(Wang et al., 2005) 
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CHAPTER 4 
 
STRESS-INDUCED ALTERATIONS IN PARKIN SOLUBILITY 
PROMOTE PARKIN AGGREGATION AND COMPROMISE 
PARKIN’S PROTECTIVE FUNCTION 
 
4.1 Overview 
To date, the descriptions of parkin-related PD include patients with homozygous 
mutations, compound heterozygous mutations as well as those with a single mutation 
(Mata, et al., 2004). Although PD due to parkin mutations is classically transmitted in an 
autosomal recessive inheritance, the existence of patients with single mutations raises the 
possibility of an expanded risk associated with parkin haploinsufficiency (Mata, et al., 
2004; Foroud, et al, 2003; Kann, et al., 2005). Supporting this possibility is the recent 
association of parkin gene promoter with late-onset PD (West, et al., 2002b). Parkin 
variability could thus be considered as a risk factor for the development of PD.  
The importance of parkin expression to neuronal survival is probably related to the 
multitude of neuroprotective roles it appears to serve (Feany, et al., 2003). Parkin 
apparently confers protection to neurons against a diversity of cellular insults including 
manganese-induced cell death (Higashi, et al., 2004), α-synuclein toxicity (Petrucelli, et 
al., 2002), proteasomal dysfunction (Tsai, et al., 2003), Pael-R (Yang, et al., 2003) and 
p38/JTv-1 (Ko., et al, 2005) accumulation and kainate-induced excitotoxicity (Staropoli, 
et al., 2003). Additionally, parkin also confers neuronal resistance towards stimuli that 
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promote mitochondria-dependent apoptosis and dopamine-mediated toxicity (Darois, et 
al., 2003; Jiang, et al., 2004). Given the multipurpose neuroprotective roles of parkin, it is 
conceivable that any depletion in the level or activity of parkin would significantly 
compromise neuronal survivability. Indeed, familial PD linked mutations of parkin 
frequently lead to a reduction or ablation of parkin catalytic competency (Zhang, et al., 
2000; Chung, et al., 2001). Similarly, the inhibition of parkin activity by BAG5 enhances 
dopamine neuron death in an in vivo model of PD (Kalia, et al., 2004). Conversely, 
animals with overexpressed parkin have reduced α-synuclein induced neuronal pathology 
compared with normal control animals (Lo Bianco, et al. 2004; Yamada, et al., 2005). 
Recent report demonstrated that parkin solubility in the brain becomes altered with 
age (Pawlyk, et al., 2003). As parkin appears to function as a broad-spectrum 
neuroprotectant, the resulting increase in parkin insolubility with age may underlie the 
progressive susceptibility of the neurons to stress. Interestingly, as discussed in the 
previous chapter, we also observed that many familial PD-linked mutations of parkin 
produce alterations in its solubility in a manner that is highly reminiscent of our 
observations with the aged brain (Wang, et al., 2005; Sriram, et al., 2005). The 
converging effects on parkin brought about by aging and PD-causing mutations are 
probably not trivial and suggest that age-dependent modulators affecting the parkin 
protein in the same way caused by clinically relevant parkin mutations would increase an 
individual’s risk of developing PD. 
Here we used both cellular and animal models to investigate the effects of various 
environmental and intrinsic factors that are linked to PD on parkin solubility. We found 
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that several of these stressors, including neurotoxins (MPP+, rotenone, 6-
hydroxydopamine), paraquat, NO, dopamine and iron, induce alterations in parkin 
solubility and result in its intracellular aggregation. Furthermore, the depletion of soluble, 
functional forms of parkin is associated with reduced proteasomal activities and increased 
cell death. Interestingly, we also observed variations in parkin distribution in post-mortem 
human PD brains relative to normal controls, which provide further support to our 
findings. Taken together, our results suggest that conditions promoting parkin insolubility 
compromise parkin’s protective function and predispose the neurons to degeneration 




4.2.1 Various PD-linked stressors induce changes in parkin solubility 
To facilitate our investigation on the effects of exogenous modulators on parkin 
solubility, we have generated SHSY5Y neuroblastoma cells stably expressing FLAG-
tagged parkin (SH-Parkin) or containing vector alone as a control (SH-Vector). Three 
individual parkin-positive clones (numbers 1, 2 and 6) were selected for our experiments 
to minimize clonal variation. All of these parkin-positive clones express parkin at a much 
higher level when compared with vector control or parental cells but are otherwise similar 
morphologically (Fig. 4.1A and 4.1B). Using the sequential fractionation method 
described in Materials and Methods, we observed that the majority of the expressed 
FLAG-parkin resides in the detergent-soluble (S) fractions (Fig. 4.1C). 
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As the treatment of cells with an acute dose (20 mM) of hydrogen peroxide (H2O2) 
has previously been shown by Winklhofer et al. (2003) to induce parkin to adopt a 
detergent insoluble conformation, we initially performed the earlier mentioned 
experiment with our parkin stable cell lines to see if we could reproduce the observed 
effect on parkin. Consistent with Winklhofer’s finding, we observed a significant shift in 
parkin extractibility towards the detergent-insoluble (P) fractions following H2O2-induced 
oxidative stress (Fig. 4.1C). Interestingly, treatment of cells with the proteasome 
inhibitor, MG-132, led to a similar shift in parkin extractibility (Fig. 4.1C). Thus, both 
oxidative and proteolytic stresses appear to be capable of modifying parkin solubility. 
Chung et al. (2004) has recently described the S-nitrosylation of parkin in sporadic PD. 
To examine whether nitrosative stress induces a similar effect on parkin solubility 
observed earlier, we treated SH-Parkin cells with NOC-18, a NO-donor previously 
described to be effective in bringing about the S-nitrosylation of parkin (Chung, et al., 
2004). When 500 µM of NOC-18 was used to treat the cells, the amount of detergent-
soluble parkin showed a dramatic relocalization to the P-fractions (Fig. 4.1D). NO assays 
performed with 2,3-diaminonapthalene revealed that parkin is S-nitrosylated more 
prominently in cells treated with 500 µM NOC-18 than those treated with 100 µM NOC-
18 (Fig. 4.1E). These results suggest that the S-nitrosylation of parkin could alter the 
































Figure 4.1 Effects of oxidative, proteolytic and nitrosative stress on parkin stable cell lines. 
(A) Phase-contrast images of normal SH-SY5Y neuroblastoma cells and three individual clones 
stably expressing FLAG-tagged parkin (nos 1, 2 and 6) showing no apparent difference in their 
morphology. (B) Anti-FLAG and antiparkin immunoblots of total cell lysates prepared from 
normal SH-SY5Y (2), SH-Vector (V) and the parkin stable clones (nos 1, 2 and 6). (C and D) 
Anti-FLAG immunoblots of cell extracts sequentially prepared with Triton X-100 (S) and SDS 
(P) from untreated parkin stable cell lines or those treated either with 20 mM H2O2 (30 min), 1 
µM MG-132 (16 h) or 0.5 mM NOC-18 (24 h) as indicated. Equal loading of the different cell 
lysates was verified by anti-β-actin immunoblotting. (E) Bar graph showing S-nitrosylated parkin 
as detected by a fluorometric method described by Chung et al. (2004). Anti-FLAG immunoblot 
(inset) shows equivalent amount of FLAG-parkin immunoprecipitated. These results represent 
mean±SEM of five separate experiments. *P<0.05, **P<0.01 versus control group (one-way 
ANOVA). (F) Anti-FLAG immunoblots of cell extracts similarly prepared showing a dose-
dependent shift in parkin solubility towards the P-fractions following H2O2 treatment (12 h). 
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We next examined the effects of treating the parkin stable cell lines with the 
parkinsonian neurotoxins, MPP+, rotenone and 6-hydroxydopamine (6-OHDA), because 
these agents are well known to trigger oxidative stress and selective dopaminergic 
neuronal death in injected animals. Not surprisingly, treatment of the SH-Parkin cells 
with all the three neurotoxins resulted in a significant population of parkin being shifted 
to the P-fractions (Fig. 4.2A). These neurotoxin-mediated alterations in parkin solubility 
appear to be dose and time-dependent. In all three cases, a progressive shift in parkin 
extractibility from the S- to the P-fractions was apparent with increasing dose of the 
neurotoxic treatment (Fig. 4.2B). Although the solubility of parkin was relatively 
unaffected at lower doses of these neurotoxins, prolonging the treatment at these doses for 
a few days likewise led to a shift in parkin extractibility towards detergent insolubility 
(Fig. 4.4C, Fig 4.5B). Expectedly, we observed a similar alteration in parkin solubility, as 
previously described, when the stable cell lines were treated with the PD-linked herbicide, 
paraquat, as well as with the metal, iron (Fe2+) (Fig. 4.2C). Further, we also examined the 
effects of dopamine treatment on parkin solubility properties because dysregulated 
dopamine homeostasis is known to cause significant endogenous stress (Lotharius, et al., 
2002). Consistent with our earlier observations, the translocation of soluble parkin into 
the detergent-insoluble fractions following dopamine treatment of SH-Parkin cells occurs 
in a dose-dependent manner (Fig. 4.2D).  





Figure 4.2 Stress-induced alterations in parkin solubility. Anti-FLAG immunoblots of cell 
extracts sequentially prepared with Triton X-100 (S) and SDS (P) from untreated parkin stable 
cell lines or those treated with the indicated doses of (A) rotenone (24 h), MPP+ (24 h), 6-OHDA 
(3 h). (C) Paraquat (24 h), iron and canavanine (16 h). (B and D) Anti-FLAG immunoblots of cell 
extracts similarly prepared showing a dose-dependent shift in parkin solubility towards the P-
fractions following rotenone, MPP+ and dopamine treatment (20 h), as indicated. Equal loading 
of the different cell lysates was verified by anti-β-actin immunoblotting. Each of these 
experiments was repeated at least three times. 
D 
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Taken together, our results suggest that various forms of cellular stress, originating 
both exogenously and endogenously, could modify parkin structure and lead to its 
misfolding, thereby altering the protein solubility. Supporting this, we could reproduce 
our earlier observations by treating the SH-Parkin cells with canavanine (Tsirigotis, et 
al.,2001), an amino acid analog that promotes protein misfolding by substituting for 
arginine during translation (Fig. 4.2C). Presumably, misfolded parkin aggregates and 
becomes resistant to normal detergent extraction. 
 
4.2.2 Stress-induced alterations in parkin solubility promote parkin aggregation 
To investigate if stress-induced alteration in parkin solubility is associated with its 
propensity to form intracellular aggregates, we examined the localization of FLAG-parkin 
in untreated SH-Parkin cells as well as in cells treated with rotenone, MPP+ and paraquat. 
As the percentage of cell death is markedly increased at acute doses of these toxins, we 
performed our localization studies here with lower doses of these stressors in order to 
reduce the amount of cell death. Consistent with our previous report (Wang, et al., 2005; 
Sriram, et al., 2005), we found that parkin in untreated cells is uniformly expressed 
throughout the cytoplasm (Fig. 4.3). In SH-Parkin cells treated with the parkinsonian 
neurotoxins rotenone and MPP+ at their respective dose that would produce alteration in 
parkin solubility (Fig 4.4C & Fig. 4.6B), we observed prominent parkin aggregates within 
the cell, which accumulate in the perinuclear region (Fig. 4.3). Similarly, treatment of 
SH-Parkin cells with paraquat produced FLAG-parkin positive inclusions. These results 
are reminiscent of our previous observation that parkin mutations that alter the protein 
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solubility tend to trigger its intracellular aggregation (Wang, et al., 2005; Sriram, et al., 
2005). Our results here show that stress-induced alteration in parkin solubility similarly 




Figure 4.3 Stress-induced alterations in parkin solubility promote the formation of 
intracellular parkin-positive inclusions. Representative confocal images of anti-FLAG 
immunostained (red) parkin stable cells showing uniform cytoplasmic staining in untreated cells 
and FLAG-positive inclusions (arrows) in cells treated with the various stressors, as indicated. 
Anti-FLAG immunostained SH-Vector controls cells showed no background staining. 
 
4.2.3 Stress-induced alterations in parkin solubility compromise parkin’s protective 
function 
It is conceivable that the changes in parkin solubility triggering its aggregation could 
deplete the cell of soluble functional parkin and concomitantly compromise parkin’s 
protective function. To enable us to ascertain this, we treated the SH-Parkin and control 
cells with the lipid-soluble neurotoxin, rotenone, to first establish parkin’s potential 
protective effects towards this neurotoxic insult. For this experiment, we treated the cells 
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with low doses of rotenone to better recapitulate the slow progression of dopaminergic 
neuronal death in PD. After 6 days of chronic rotenone treatment, especially at the 25 and 
50 nM doses, we noticed a dramatic morphological difference between the SH-Parkin and 
control cells (Fig. 4.4A). Although a significant population of the SH-Vector cells at these 
doses of rotenone treatment became rounded and reflective, i.e. indicative of dying cells, 
it is apparent that the SH-Parkin cells were relatively spared of these features (Fig. 4.4A). 
Quantitative measurement of cell death at this time point by means of flow cytometry 
(Fig. 4.4B) correlates well with our morphological observations. Although we observed 
some cell death (20%) in the untreated control cells after 6 days of culture, a significantly 
higher average percentage of cell death was evident when these cells were treated with 25 
(50%) and 50 nM rotenone (60%) (Fig. 4.4B). Cells expressing exogenous parkin 
recorded a dramatically better survival rate at these doses of rotenone treatment. Indeed, 
although the average percentage survivability of SH-Parkin cells at 50 nM rotenone 
treatment is apparently reduced when compared with untreated SH-Parkin cells, it is still 
significantly better compared with SH-Vector cells treated with either 50 or even 25 nM 
rotenone (Fig. 4.4B). Our results thus indicate that overexpressed parkin could afford 
cellular protection against rotenone-induced cell death.  
 To examine whether an association exists between the parkin solubility and the 
degree of its cellular protection, we performed anti-parkin or anti-FLAG immunoblotting 
of lysates prepared from rotenone-treated or -untreated SH-Parkin and controls cells. 
Anti-parkin immunoblotting of lysates prepared from SH-Vector cells treated with 
rotenone at doses above 25 nM reveals a complete shift of the endogenous parkin protein 
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to the detergent-insoluble fractions (Fig. 4.4C). It is noteworthy that at these doses of 
rotenone treatment, the control cells showed significantly more cell death when compared 
with untreated cells (Fig. 4.4B). Although a dose-dependent shift in the population of 
exogenous parkin to the detergent-insoluble fractions is also observed in lysates prepared 
from rotenone-treated SH-Parkin cells, as revealed by anti-FLAG immunoblotting, the 
complete shift of FLAG-tagged parkin from S- to P-fractions occurred only at the highest 
dose of rotenone used (Fig. 4.4C). At 25 nM rotenone treatment, a significant population 
of exogenous parkin remained in the detergent-soluble fractions, which correlates with 
the higher survival rate seen in these cells compared with their corresponding control 
cells (Fig. 4.4B). We obtained essentially similar results when we repeated the earlier 
mentioned experiments with MPP+ in place of rotenone (Fig. 4.5). Our results thus 
suggest that stress-induced relocalization of soluble parkin into detergent-insoluble 
fractions is inversely related to the extent of its cellular protection. 
 
4.2.4 Protective effect of parkin related to its ability to preserve proteasomal 
function 
We were curious about the mechanism of parkin-mediated cellular protection against 
rotenone-induced stress and wondered, in accordance with our recent speculation (Lim, et 
al. 2005) and also reports by others (Petrucelli, et al. 2002; Tsai, et al. 2003), whether 
parkin could exert its protective functions by preserving proteasome function in times of 
cellular stress. To investigate this, we conducted in vitro proteasomal assays with lysates 
prepared from rotenone-treated SH-Parkin and SH-Vector cells as previously described. 
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We compared the respective extent of proteasomal impairment in each of these cell types 
following stress application and plotted the bar graph accordingly by assigning a single 
arbitrary proteasomal activity unit to each of the untreated cell types (Fig. 4.4D). It 
becomes immediately apparent that there is a dose-dependent decrease in the proteasome 
activities in these cells following their treatment with rotenone (Fig. 4.4D). However, at 
higher doses of rotenone treatment, the SH-Vector cells appear to be much more 
susceptible to rotenone-induced proteasomal impairment among the cell lines examined 
(Fig. 4.4D). Collectively, SH-Parkin clones show a statistically higher proteasomal 
activity when compared with SH-Vector cells at 25 nM or higher rotenone treatment (Fig. 
4.4D). The drastic decrease in the proteasomal activities of control cells at these rotenone 
doses compared with untreated cells is consistent with the dramatic increase in their cell 
death as described earlier (Fig. 4.4B). Conversely, there is an association between the 
better maintenance of functional proteasomes in SH-Parkin cells and the greater 
survivability of these cells in times of stress (compare Fig. 4.4B and 4.4D). Our results 
therefore strengthen the suggestion that one mechanism by which parkin could afford 
cellular protection against stress-induced cell death is through the preservation of 




















Figure 4.4 Stress-induced alterations in parkin solubility compromise parkin protective 
function. (A) Representative phase-contrast images of SH-SY5Y control cells (SH-Vector) and 
cells stably expressing parkin (SH-Parkin) showing a dose-dependent increase in the population 
of rounded, refractile cells 6 days after treatment with the indicated doses of rotenone. (B) The 
cell viability was measured and plotted as a bar graph (SH-Parkin nos 1, 2 and 6 depicted by dark, 
medium and light shade bars, respectively, and SH-Vector depicted by black bars). Data represent 
mean±SEM of three duplicate determinations.*P<0.05, **P<0.01 versus control group (one-way 
ANOVA). (C) Anti-parkin and anti-FLAG immunoblots of cell extracts sequentially prepared 
with Triton X-100 (S) and SDS (P) from vector and parkin stable cell lines 6 days after treatment 
with the indicated doses of rotenone. (D) Bar graph showing the dose-dependent decrease in the 
chymotrypsin-like proteasome activities of SH-Parkin (nos 1, dark; 2, medium; 6, light shade) and 
control cells (black) following 6 days of rotenone treatment relative to their respective untreated 
counterparts. Data represent mean±SEM of three duplicate determinations. *P<0.05, **P<0.01 




 Parkin solubility alteration compromise its protective function    94 
 
Figure 4.5 Overexpressed parkin protects cells against MPP+-induced toxicity (A) 
Representative phase-contrast images of SH-SY5Y control cells (SH-Vector) and cells stably 
expressing parkin (SH-Parkin) showing a dose-dependent increase in the population of rounded, 
refractile cells 5 days after treatment with the indicated doses of MPP+. (B) Anti-FLAG 
immunoblots of cell extracts sequentially prepared with Triton-X-100 (S) and SDS (P) from wild-
type and mutant parkin stable cell lines 5 days after treatment with the indicated doses of MPP+. 
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4.2.5 Familial PD-linked parkin mutations predispose parkin solubility alterations 
by stress and compromise its protective function 
As described in the previous chapter, we have previously classified familial PD-
linked parkin missense mutants into two broad groups on the basis of their detergent 
solubility properties, i.e. detergent-soluble versus-insoluble mutants (Wang, et al. 2005). 
Here, we examined the effect of stress on the properties of the detergent-soluble parkin 
mutants. To facilitate our investigation, we generated stable SH-SY5Y cells expressing 
the detergent-soluble parkin A82E (SH-A82E) and T240R mutants (SH-T240R). We then 
repeated the experiments described in Figure 4.4 with these parkin mutant stable cell 
lines. After 6 days of chronic rotenone treatment, detergent-soluble and -insoluble lysates 
were prepared from the neurotoxin-treated or -untreated SH-SY5Y stable cell lines. 
Following anti-FLAG immunoblotting of the fractionated lysates, we noticed a dose-
dependent shift of FLAG-parkin into the P-fractions similar to what we have observed 
earlier (compare Figs 4.6A and 4.4C). Interestingly, both the parkin mutants examined 
appear to be more susceptible to rotenone-induced solubility alteration (Fig. 4.6A). 
Although the wild-type FLAG-tagged parkin apparently shift completely to the P-
fractions at 50 nM rotenone treatment, the phenomenon occurs at earlier rotenone doses, 
i.e. 25 and 10 nM, respectively, for the A82E and T240R parkin mutants (Fig. 4.6A). 
Quantitative measurement of cell death in these rotenone-treated cell lines reveals that 
stable SH-SY5Y cell lines expressing the parkin T240R mutant are as susceptible to 
neurotoxin-induced cell death as the SH-Vector control (Fig. 4.6B), which correlates well 
with our morphological observations (Fig 4.6E). Associated with this, the proteasome 
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activities in the SH-T240R cells, relative to SH-Vector control, show no enhanced 
resistance to impairment caused by the treatment (Fig. 4.6D). In contrast, the A82E 
parkin mutant affords significant cellular protection against cell death and proteasomal 
impairment brought about by the neurotoxin. However, at 25 nM rotenone treatment, 
where the A82E mutant relocalizes completely to the P-fraction, its protective effects 
decrease significantly compared with wildtype FLAG-parkin (Fig. 4.6B and D). 
Although the degree of cellular protection afforded by these parkin mutants correlates 
well with their propensity to become directed to the detergent-insoluble fractions in the 
presence of rotenone, it is apparent that their respective catalytic competency plays a 
deterministic role in improving the survivability of cells that express them. To examine 
their enzymatic activity relative to wild-type parkin, we conducted in vivo ubiquitination 
assays using synphilin-1, a known parkin target, as a substrate. Consistent with our 
previous report (Chung, et al. 2001), the parkin T240R mutant exhibited a significantly 
reduced catalytic activity compared with wild-type parkin (Fig. 4.5C). In contrast, the 
A82E mutant ubiquitinates synphilin-1 almost as efficiently as wild-type parkin (Fig. 
4.5C). Taken together, our results support the importance of parkin catalytic activity for 
its protective functions and at the same time suggest that the higher propensity of soluble 
parkin mutants to stress-induced alteration is an alternative mechanism underlying their 
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Figure 4.6 Familial PD-linked parkin mutants predispose parkin to stress-induced solubility 
alterations. (A) Anti-FLAG immunoblots of cell extracts sequentially prepared with Triton X-
100 (S) and SDS (P) from wild-type and mutant parkin stable cell lines 6 days after treatment 
with the indicated doses of rotenone. (B) Bar graph showing the percentage cell viability in SH-
Parkin WT (dark shade), SH-Parkin A82E (medium shade), SH-Parkin T240R (light shade) and 
SH-Vector (black) measured at 6 days after rotenone treatment. Data represent mean±SEM of 
three duplicate determinations. *P< 0.05, **P<0.01 versus control group (one-way ANOVA). (C) 
Anti-HA and anti-myc immunoblots of synphilin immunoprecipitates (IPmyc) prepared from SH-
SY5Y cells transfected with myc-tagged synphilin-1 in the presence of HA-tagged ubiquitin 
without or with the various FLAG-tagged parkin forms. Lysates prepared from these variously 
transfected cells were also subjected to anti-myc or anti-FLAG immunoblotting to show their 
expression (INPUT). These experiments were duplicated. (D) Bar graph showing the dose-
dependent decrease in the chymotrypsin-like proteasome activities of SH-Parkin WT (dark 
shade), SH-Parkin A82E (medium shade), SH-Parkin T240R (light shade) and SH-Vector (black) 
following 6 days of rotenone treatment relative to their respective untreated counterparts. Data 
represent mean±SEM of three duplicate determinations. *P<0.05, **P<0.01 versus control group 
(one-way ANOVA). (E) Representative phase-contrast images of SH-SY5Y control cells 
(Vector), cells stably expressing parkin (Parkin) and mutants A82E, T240R showing a dose-
dependent increase in the population of rounded, refractile cells 6 days after treatment with the 
indicated doses of rotenone. 
 
4.2.6 Parkin solubility alterations in the brains of MPP+-treated mice 
To extend our earlier mentioned cell culture studies further, as well as to investigate 
the physiological relevance of parkin solubility alterations following neurotoxic stress, 
my colleges in Johns Hopkins University School of Medicine examined the effects of 
MPP+ on the biochemical distribution of mouse brain parkin in vivo. We performed anti-
parkin immunoblotting of detergent-soluble and -insoluble lysates prepared from the 
ventral midbrain and striatal regions of mice treated with an acute paradigm of MPP+. 
Consistent with our cellular studies described earlier, we observed a time dependent 
increase in the amounts of insoluble parkin in both the ventral midbrain (Fig. 4.7A) and 
striatal regions (Fig. 4.7B) of mice after the last MPP+ treatment following an acute 
intoxication paradigm. Significant amounts of insoluble parkin immunoreactivity started 
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appearing at 24 and 48 h post-MPP+ injection in the ventral midbrain and striatal 
preparations, respectively, and persisted through the time course examined (Fig. 4.7A and 
B). Interestingly, the level of soluble striatal parkin increased transiently at 24 h post-
MPP+ injections and its subsequent decrease corresponded to the appearance of the 
insoluble forms (Fig. 4.7B). The results we gathered from our cell culture and animal 
studies here are thus in general agreement with each other and collectively point towards 
the pathophysiological relevance of altered parkin function associated with its 




Figure 4.7. Significant increase in detergent-insoluble parkin in the mouse brain following 
MPP+ treatment. Detergent-soluble and -insoluble fractions of brain lysates prepared from (A) 
ventral midbrain and (B) striatum of mice after treatment with MPP+ for 2, 4, 24, 48, 72 and 96 h 
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4.2.7 Variations in parkin distribution between normal and PD human brains 
Previously, it has been demonstrated an age-dependent decrease in parkin solubility 
in human brains (Pawlyk, et al., 2003). Given the neuroprotective roles of parkin, we 
wondered whether the aging brain undergoing stress linked to PD would respond by 
elevating its levels of parkin to counteract the protein depleted into the insoluble fraction. 
The replacement of soluble parkin would be conceivably important in helping the brain 
mitigate the ill effects posed by the insults and concomitantly prolong its neuronal 
survival. Accordingly, we performed anti-parkin immunoblotting with detergent-soluble 
and -insoluble lysates prepared from post-mortem normal and PD human brains. The 
mean age of these samples is 83.6 and 81.5 years, respectively (Table 1). The sequential 
detergent extraction procedure used to extract the brain tissues, as described in Materials 
and Methods, is similar to the one described previously (Pawlyk, et al. 2003), except that 
1% (instead of 2%) SDS was used in our final extraction. Consistently, we observed a 
dramatic relocalization of brain parkin from the detergent-soluble to the detergent-
insoluble fractions in the caudate and cingulate cortex regions from control brains (Fig. 
4.8). Although the amount of detergent-insoluble parkin associated with the samples from 
PD brains are expectedly significantly higher than those derived from control brains (Fig. 
4.8), the phenomenon could be related to a remarkable corresponding increase in soluble 
parkin levels in the majority of the PD brains. Although the average amount of detergent-
insoluble parkin in PD brains increased by 16% over their control counterparts, the mean 
elevation of soluble parkin in PD brains is a dramatic 2.5-fold in the PD brains relative to 
their controls (Fig. 4.8). It would thus appear that an increase in endogenous parkin level 
 Parkin solubility alteration compromise its protective function    101 
in the brain accompanies the disease, presumably to counter the loss of the protein into 











Figure 4.8. Variations in brain parkin distribution between normal and PD individuals. (A) 
Soluble fractions and (B) insoluble fractions of brain lysates from caudate (n = 3) and cingulate 
cortex (n = 2) of control and sporadic PD caudate brains (n = 9) were subjected to SDS–PAGE 
and immunoblotted with anti-parkin and anti-actin antibodies. The levels of parkin protein in the 
(C) soluble and (D) insoluble fractions were normalized to their respective actin levels and 
quantified and the results obtained plotted on a histogram (*P<0.05, **P<0.01, Student’s t-test). 
 
Table 4.1 Brain region, diagnosis, age and post mortem delay (PMD). 
 
Subjects Brain region Diagnosis Age PMD 
Control 1 Caudate - 83 5 
Control 2 Caudate - 79 10 
Control 3 Caudate - 81 20 
Control 4 Cingulate - 83 5 
Control 5 Cingulate - 92 19 
     
Patient 1 Caudate PD/LB CHG LIMBIC, Porencephalic Cyst 81 8.75 
Patient 2 Caudate PD/LB CHG Neocortical 80 19 
Patient 3 Caudate PD/LB CHG 84 17.5 
Patient 4 Caudate PD/LB CHG Limbic 83 14 
Patient 5 Caudate PD/DLB 77 5 
Patient 6 Caudate PD/LB CHG Neocortical 84 13 
Patient 7 Caudate PD/LB CHG 88 19.5 
Patient 8 Caudate PD 73 6 
Patient 9 Caudate PD W/Dementia, LBD Neocortical 84 5 
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4.3 Discussion 
Although the debate surrounding the respective roles of environmental and genetic 
factors in the etiology of sporadic PD has persisted since the disease was first described in 
the early 19th century, current evidence favors a synergistic interaction between 
exogenous toxic agents and endogenous elements in bringing about the neurodegenerative 
process (Dawson et al. 2003; Di et al. 2002). Indeed, several reports have demonstrated a 
pathogenic relationship between the environmental stress factors and the PD-linked gene 
product, α-synuclein (Ostrerova-Golts et al. 2000; Paxinou et al. 2001; Sherer et al. 
2002). In our current report, we show that several environmental stress factors linked to 
PD, as well as endogenous dopamine, produce alterations in parkin solubility and 
concomitantly compromise its protective function. Our results therefore further strengthen 
the relationship between environmental factors and genetic susceptibilities in the 
development of PD. 
In recent years, it has become increasingly clear that parkin plays a pivotal role in 
maintaining dopaminergic neuronal survivability. It has been demonstrated that familial 
PD-linked mutations in parkin led to its dysfunction either through direct catalytic 
impairment or through the alteration of the protein’s structural and biochemical 
properties, leading to a decrease in its detergent solubility (Zhang et al. 2000; Chung et al. 
2001; Cornelia et al. 2006; Wang et al. 2005a; Sriram et al. 2005). Hence, it is 
conceivable that exogenous and/or endogenous factors that affect parkin in a way that 
mirrors the impact of parkin mutations on the protein would increase the vulnerability of 
dopaminergic neurons to degenerate. Interestingly, brain parkin becomes progressively 
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more detergent-insoluble with normal aging (Pawlyk et al., 2003). As age represents an 
unequivocal risk factor for PD, the depletion of soluble parkin with age is unlikely to be a 
trivial association. We believe that age-mediated parkin solubility changes are likely a 
cumulative event promoted by the continuous spectrum of insults experienced by the 
brain throughout its lifetime. Shedding some light on these, our results indicate that 
oxidative, nitrosative and proteolytic stress could modify parkin in a manner analogous to 
that mediated by several of its clinically relevant mutations, as well as by normal aging. 
The resulting relocalization of detergent-soluble parkin into insoluble fractions suggests 
that one mechanism of environmental neurotoxicity triggering the demise of 
dopaminergic neurons in PD is through the progressive depletion of soluble functional 
parkin. 
As parkin functions as a broad-spectrum neuroprotectant, the susceptibility of the 
stress-prone dopaminergic neurons to degeneration in the absence of functional parkin is 
easy to comprehend. This is indeed the case with our cell culture studies described earlier. 
Although overexpressed parkin helps the SH-SY5Y neuroblastoma cells mitigate 
externally applied stress (rotenone and MPP+) rather effectively, it could do so only until 
a point, beyond which soluble parkin becomes fully depleted and could afford no extra 
protection to the cells expressing it. Similarly, the depletion of soluble endogenous parkin 
coincides with the onset of significant rotenone-induced cell death in control cells, 
suggesting again that parkin is protective only until a certain point. This phenomenon is at 
the same time curiously paradoxical; as it appears that an important factor chosen by the 
cell to provide a critical defense against environmentally triggered stress would later 
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become the victim itself. An important corollary to this is that during times of heightened 
stress, increasing the level of endogenous parkin expression to counter the loss of the 
protein into insoluble pools would help ensure neuronal survivability. Supporting this, my 
college found that parkin mRNA expression in SH-SY5Y cells increased several fold in 
response to various stressors including rotenone, iron and paraquat (Fig. 4.9). 
Furthermore, the unfolded protein stress also promotes the elevation of parkin expression, 
which acts to relieve the stress (Imai et al. 2000). Conceivably, cells that fail to produce 
functional parkin in sufficient amount would be less able to cope with stress. In this 
regard, it is important to note that the caudate region of the PD brain, where a significant 
upregulation of parkin levels occurs (Fig. 4.8), is relatively spared from degeneration 
during the disease progression. Although it is tempting to think that the selective 
vulnerability of dopaminergic neurons seen in sporadic PD may be related to their failure 
in replacing cytosolic parkin lost to the insoluble pool, a more detailed analysis of parkin 
distribution in different regions of the PD brains would be required to evaluate this 
speculation. Nonetheless, such a scenario remains a formal possibility. Indeed, a selective 
loss of the proteasome α-subunit in the SNc but not in the frontal cortex and striatum in 
PD has been recently reported (McNaught et al., 2003). Further, an important component 
of the proteasome complex (PA700) failed to upregulate in the SNc, although it occurred 
in the frontal cortex and striatum in PD compared with control (McNaught, et al. 2003). 
Our results may thus help to explain the expanded risk for PD associated with parkin 
haploinsufficiency, as well as with normal aging. Indirectly, our results also support the 
utility of parkin gene therapy as a means to mitigate the progression of the disease. 
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Figure 4.9 Upregulation of endogenous parkin mRNA expression in response to rotenone, 
paraquat and iron treatment. Bar graph showing the relative levels of endogenous parkin 
mRNA in untreated SH-SY5Y cells or those treated with 50 nM Rotenone, 5 mM Paraquat or 10 
mM Iron for 24 h, as measured by means of real time PCR quantitation. The mRNA levels of 
parkin were normalized to GAPDH level for each reaction. Data represents mean±SEM of 3 
duplicate determinations. *P < 0.05, **P < 0.001 vs control group (One-way ANOVA). 
 
Recently, Jiang et al. (2004) demonstrated that overexpression of parkin in SH-SY5Y 
cells significantly reduced the amount of intracellular oxyradicals, suggesting that the 
protective effect of parkin is afforded by its ability to suppress oxidative stress. Consistent 
with this, we found here that parkin attenuates rotenone-induced cell death. It is evident 
from our results that a plausible mechanism responsible for the protective function of 
parkin against stress-induced toxicity is through the preservation of proteasome activity. 
This is consistent with previous reports by others (Petrucelli et al., 2002; Tsai et al., 
2003). The maintenance of a viable proteasome by parkin is clearly dependent on its E3 
ligase activity. However, whether parkin-mediated K48-linked ubiquitination, or a newly 
described K63-linked ubiquitination activity of parkin (Doss-Pepe 2005; Lim et al., 
2005), is required in this protection is unknown. Interestingly, mutations in parkin that do 
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not overtly alter the protein activity or solubility appear to predispose the protein to 
solubility alteration by environmental stress. Hence, the A82E parkin mutant afforded 
significantly less protection against rotenone-induced toxicity when compared with the 
wild-type protein, despite having comparable catalytic activity. In contrast, being 
catalytic impaired and even more susceptible to stress-induced alteration than the A82E 
parkin mutant, the T240R mutant offers virtually no protection against rotenone-induced 
toxicity. Taken together, our previous (Zhang et al. 2000; Chung et al. 2001; Wang et al. 
2005a; Sriram et al. 2005) and current work on the parkin mutants demonstrate that 
mutations in parkin could impair the protein function in more than one way, including 
frank catalytic impairment, direct alteration of the protein solubility and localization or 
simply a predisposition to such alterations.  
 Notably, most, if not all, of the stressors we have used in this study are associated 
with oxidative stress. The occurrence of oxidative stress in PD is consistently supported 
by both post-mortem studies and by studies demonstrating the capacity of oxidative stress 
and oxidizing toxins to induce nigral cell degeneration (Jenner et al. 2003). Although a 
myriad of cellular macromolecules could be damaged by oxidative free radicals, enzymes 
whose structure and function are dependent on catalytic cysteine are expected to be more 
susceptible to the consequence of oxidative modification. The tyrosine phosphatase 
family of enzymes, all of which contain catalytic cysteines in their active sites, is one 
example (Tonks et al. 2005). RING-finger E3 ligases, such as parkin, are also 
characterized by their cysteine-rich catalytic moiety that represent targets for oxidative 
modification. Furthermore, we and others have demonstrated the importance of these 
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RING-finger cysteines in maintaining the native structure of parkin (Cookson et al. 2003; 
Gu et al. 2003; Wang et al. 2005a; Sriram et al. 2005). Thus, it is not surprising that 
several of the stress factors we have examined could produce alterations in the structural 
and biochemical properties of parkin, as they are associated with the production of 
oxidative free radicals. Similarly, nitrosative modification of parkin has been shown to 
occur on the protein’s RING finger cysteines (Chung et al. 2004; Yao et al. 2004), which 
would explain the associated solubility changes observed. Further, our results showing 
that S-nitrosylated parkin’s tendency to adopt a detergent-insoluble conformation would 
support a negative role for this type of modification on parkin. 
 Taken together, our results provide a mechanistic link between putative etiologic 
environmental (and endogenous) factors and dysfunction of a key PD-linked gene product 




Results presented in this chapter have been published in Human Molecular Genetics  




Parkin R275W mutant causes DA degeneration in vivo    108 
CHAPTER 5 
 
DROSOPHILA OVEREXPRESSING PARKIN R275W MUTANT 




 Although initially described as a recessive disorder, emerging evidence suggest that 
heterozygous parkin mutations may confer increased susceptibility to PD (Hilker et al. 
2001; Hilker et al. 2002; Oliveira et al. 2003; Khan et al. 2005; Clark et al. 2006; Sun et 
al. 2006). Whilst parkin haploinsufficiency may explain for the increased risk for PD 
associated with single parkin mutations, the possibility that some parkin heterozygous 
mutations may be pathogenic cannot be excluded. Moreover, certain missense mutations 
seem to be inherited in an autosomal dominant manner (Oliveira et al. 2003). Two parkin 
mutations that frequently occur in heterozygous state are R275W and G328E (Table A1). 
We have recently demonstrated that these parkin mutants exhibit different properties from 
the wild-type protein when expressed in cells (Sriram et al. 2005; Wang et al. 2005a). 
However, their respective effect in vivo remains to be established.  
 Recently, the Drosophila has emerged as a good system to model parkin dysfunction. 
While parkin-deficient mice did not exhibit robust signs of parkinsonism (Perez and 
Palmiter, 2005), Drosophila parkin null mutants exhibit dopaminergic neurodegeneration 
in the adult brains and concomitant locomotion defects (Cha et al. 2005; Whitworth et al. 
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2005), a phenotype that faithfully mirrors the human condition. Further, important 
relationship between pathways regulated by parkin and PINK1 has also been established 
recently through Drosophila studies (Clark et al. 2006; Park et al. 2006; Yang et al. 
2006).  
 To better understand the effects of parkin mutations in vivo, we generated transgenic 
Drosophila overexpressing the human parkin missense mutants, R275W and G328E. We 
found that flies overexpressing R275W (but not wild-type or G328E) parkin display an 
age-dependent degeneration of specific dopaminergic neuronal clusters and exhibit 
accelerated impairment in climbing ability with age or in response to rotenone treatment 
when compared to control flies. Further, R275W mutant flies also exhibit prominent 
mitochondrial abnormalities in their flight muscles. Interestingly, these effects mediated 
by parkin R275W mutant are similar to those triggered by the loss of endogenous parkin 
in parkin null flies. Taken together, our results demonstrate that the expression of human 
R275W in Drosophila promotes dopaminergic neurodegeneration and mitochondrial 
dysfunction and suggest the interesting possibility that select parkin mutations may 




5.2.1 Parkin R275W mutant expression in Drosophila promotes a similar pattern of 
dopaminergic neurodegeneration to that observed in parkin null flies. 
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Since the expression of toxic human proteins in Drosophila have allowed the 
accurate modeling of several human diseases, including PD (Muqit and Feany 2002), we 
believe that any pathogenic effects exerted by parkin mutants will manifest within 
specific dopaminergic neuronal clusters in transgenic flies producing them. To examine 
the effects of parkin R275W and G328E expression in vivo, we overexpressed these 
missense mutants in Drosophila under the regulation of the GAL4/UAS promoter. As a 
control, we also generated Drosophila producing wild-type human parkin. 
Driven by an elav-GAL4 driver, a pan-neuronal driver, expression of human wild-
type parkin or mutant R275W and G328E parkin in adult transgenic Drosophila brains 
expectedly does not compromise the overall anatomical integrity of the brain (Fig. 5.1A). 
Interestingly, anti-human parkin immunoblotting of lysates prepared from the brains of 
these flies reveals an expression pattern of the various transgenic parkin species that is 
similar to their respective expression profile seen in our previous cell culture studies (Fig. 
5.1B) (Wang et al. 2005a). Whereas “soluble” normal human parkin shows abundant anti-
parkin staining in the detergent-soluble (S) fraction, the “insoluble” parkin mutants 
R275W and G328E show dramatically weaker staining (Fig. 5.1B). However, we did not 
observe the expected relocalization of the R275W and G328E parkin mutants to the 
detergent-insoluble (P) fraction of the fly brain lysate (Fig. 5.1B), suggesting that 
insoluble parkin species are either actively degraded in vivo or that adult Drosophila 
neurons cannot tolerate high expression levels of these mutants. Supporting this, we 
observe more comparable level of expression among the three parkin species when they 
are expressed in Drosophila embryos under the control of mata-GAL4 driver (Fig 5.2). 




Figure 5.1. Pan-neuronal expression of parkin mutants in transgenic Drosophila. Anti-human 
parkin (hparkin) (green) and anti-elav (red) immunostaining of whole-mount adult brains derived 
from 20 day-old transgenic flies expressing normal or mutant parkin species, as indicated. (B) Left 
panels, anti-parkin immunoblot of detergent-soluble (S) and detergent-insoluble (P) fractionated 
brain lysates derived from 20-day-old wild-type or transgenic adult fly brains. Right panels, as 
above except that three times more brain lysates from R275W flies were loaded relative to those 
from wild-type parkin expressing flies. Membranes were stripped and reprobed with anti- tubulin 
to reflect loading variations. Asteriks denotes non-specific bands (Genotype: elav/+; UAS-
hParkin/+, control elav/+). 
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Fig 5.2. UAS-parkin expressions in Drosophila embryos. Embryos from UAS-hparkin cross 
with MATA-Gal4 are collected by 24 hours and homogenized for western blot analysis. yw: 
yellow white, as wild type drosophia (Genotype: mata-Gal4/+; UAS-hparkin/+).  
 
Since the loss of parkin function in Drosophila has recently been shown to result in 
progressive degeneration of dopaminergic neurons in the protocerebral posterior lateral 
(PPL) 1 cluster in the adult brain (Whitworth et al. 2005), we wondered whether the 
R275W or G328E parkin mutant flies could produce this feature. To facilitate our study, 
we used a driver line containing the promoter for the DOPA carboxylase gene (Ddc-
GAL4), a promoter specific to TH-positive dopaminergic neurons, that allows the 
dopaminergic neuronal-specific expression of the transgenes in the adult fly brain. 
Consistent with previous report (Whitworth et al. 2005), we observe an obvious loss of 
dopaminergic neurons in the PPL1 cluster of parkin null flies compared to age-matched 
control flies (Fig. 5.3A). Strikingly, overexpression of the R275W parkin mutant in flies 
produces a similar neurodegeneration pattern as parkin null flies, whereas the population 
of PPL1 neurons remains intact in flies expressing wild-type parkin and the G328E 
mutant (Fig. 5.3A). Quantitative analysis of different dopaminergic neuronal clusters in 
the brains of the various transgenic flies at different time points reveals a selective, age-
dependent, progressive loss of dopaminergic neurons in flies expressing the parkin 
R275W mutant (Fig. 5.3B). At 2-day post-eclosion, the R275W transgenic flies lost about 
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20% of its dopaminergic neurons in the PPL1 cluster (relative to age-matched controls) 
but not in other dopaminergic neuronal clusters including PAL, PPL2, PPM1/2 and PPM3 
(Fig. 5.3B). At 20-day post-eclosion, the relative percentage neuronal lost in the PPL1 
cluster in R275W flies increased remarkably to 50% (Fig. 5.3B). Notably, this rate of 
PPL1 dopaminergic neurodegeneration in R275W flies is similar to that exhibited by the 
parkin null flies (Fig. 5.3B). On the other hand, no marked degeneration of the PPL1 
neurons is observed with transgenic flies overexpressing normal parkin or the G328E 
mutant at the time points examined relative to age-matched controls (Fig. 5.3B). Besides 
the PPL1 cluster, the R275W mutant flies also show a significant reduction of TH-
positive neurons in the PAM cluster compared to control flies (Fig. 5.3C). This defect is 
again very similar to that seen in parkin null flies (Fig. 5.3C), but is not observed in flies 
expressing wild-type or G328E human parkin (Fig. 5.3C). Dopaminergic neurons in PAL, 
PPL2, PPM1/2 and PPM3 clusters remain essentially unaffected at 20-day post-eclosion 
in all the transgenic flies examined. To complement our above findings, we also examined 
the PPL1 cluster in brains section of elav-GAL4 driven wild-type and R275W parkin 
expressing flies. We found that flies expressing R275W parkin in a pan-neuronal fashion 
similarly exhibit marked PPL1 neuronal loss compared to their corresponding wild type 
parkin counterparts (Fig. 5.4A). This pattern of dopaminergic neurodegeneration is rather 
selective, as we did not observe any obvious loss of serotonergic neurons in these flies 
(Fig. 5.4B). Quantitatively, the total number of serotonergic neurons in elav-GAL4 driven 
wild-type and R275W parkin expressing flies remains comparable at 20-day post-eclosion 
(Fig. 5.4C). Taken together, our results demonstrate that overexpression of the R275W 
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parkin mutant in Drosophila promotes the degeneration of select dopaminergic neuronal 
clusters in a similar manner to that resulted from the loss of endogenous parkin. 
 
Figure 5.3 Expression of parkin R275W mutant in flies promotes dopaminergic neuronal 
degeneration in select clusters. (A) Representative confocal microscopy images showing TH-
positive (red) dopaminergic neurons in the PPL1 cluster of 20-day-old control and parkin null 
flies (PK-/-) as well as in transgenic flies expressing wild-type (WT) or mutant parkin species, as 
indicated. (B) Bar-graph showing the number of dopaminergic (DA) neurons in different clusters 
of the various fly species, as depicted by different shades shown in the figure (*P < 0.05, **P < 
0.01, Student’s t-test, n=10). (C) Representative confocal microscopy images showing TH-
positive (red) dopaminergic neurons in the PAM cluster of 20-day-old control and parkin null flies 
(PK-/-) as well as in transgenic flies expressing normal or mutant parkin species, as indicated. 
PAM cluster in top panels (Boxed) are shown at higher magnification in corresponding bottom 
panels (Genotype: Ddc-Gal4/+; UAS-hParkin/+, control Ddc-Gal4/+).  
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Figure 5.4. Selective neuronal loss in R275W mutant flies. Representative confocal microscopy 
images showing (A) TH-positive (red) dopaminergic neurons in the PPL1 cluster and (B) 5-HT-
positive neurons (red) of 20-day-old transgenic flies expressing wild-type (WT) or R275W mutant 
parkin under the elav-GAL4 driver, as indicated. (Genotype:  elav/+; UAS-hParkin/+) (C) Bar-
graph showing the number of serotonergic neurons in flies as described above, as indicated (n.s. = 
not significant). 
5.2.2 Parkin R275W mutant flies exhibit locomotor deficits 
To examine whether R275W parkin-induced degeneration of dopaminergic neurons 
in transgenic flies influences their geotactic climbing behavior, we tested the climbing 
ability of the various transgenic flies at 5-day intervals for a period of 30 days (Fig. 5.4). 
At 10-day post-eclosion, we begin to observe significant and comparable impairment in 
the climbing ability of parkin null flies and those overexpressing the R275W mutant 
relative to age-matched controls (Fig. 5.4). The climbing defects in these flies 
progressively become worse in an age-dependent manner (Fig. 5.4). At the end of the 
experiment, both the R275W and parkin null flies could manage only about 10% success 
rate compared to control flies. Conversely, flies that overexpress wild-type or G328E 
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parkin did not exhibit significantly different locomotor ability from their corresponding 
age-matched control counterparts throughout the period tested (Fig. 5.4). Thus, the 
progressive loss of dopaminergic neurons in R275W mutant flies is associated with their 
declining locomotor ability, as in the case observed with parkin null flies. 
 
Figure 5.4 Parkin null and transgenic parkin R275W flies exhibit impaired climbing ability. 
Bar graph showing the percentage of flies at different days post-eclosion that reached the top of 
assay column after 1 min. The various fly strains examined are depicted by different shades 
shown in the figure (*P < 0.05, **P < 0.01, Student’s t-test, n=20.) (Genotype: Ddc-Gal4/+; 
UAS-hParkin/+, control Ddc-Gal4/+). 
 
5.2.3 Parkin R275W mutant flies are more susceptible to rotenone-induced 
neurotoxicity 
Next, we challenged the various transgenic flies with rotenone to examine the relative 
susceptibility of their dopaminergic neurons to degeneration in response to a PD-linked 
environmental neurotoxin. We found that parkin null flies are especially susceptible to 
rotenone-induced toxicity and have excluded them from this study. Consistent with 
previously reported effect of rotenone on dopaminergic neuronal survival in Drosophila 
(Coulom and Birman 2004), examination of TH-positive, PPL1 dopaminergic neurons of 
flies treated with rotenone for 15 days reveals a significant loss in all the fly brains, 
although flies overexpressing wild-type human parkin appear to be least affected among 
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those examined (Fig. 5.5A). Morphologically, of the surviving PPL1 neurons examined, 
the ones in the R275W fly brain seem to be the most compromised (Fig. 5.5A). 
Quantitative analysis of the dopaminergic neuronal population in these rotenone-treated 
flies reveals an accelerated loss of dopaminergic neurons in all clusters compared to 
untreated flies (Compare Fig. 5.5B with Fig. 5.3B). However, when compared to treated 
control flies, the PPL1 neurons in R275W transgenic flies are modestly but significantly 
more susceptible to rotenone-induced degeneration (Fig. 5.5B). Conversely, 
overexpression of normal human parkin in flies afforded considerable protection to at 
least three clusters (PPL1, PPL2 & PAM) of dopaminergic neurons against rotenone-
mediated neurotoxicity (Fig. 5.5B). This is consistent with the known neuroprotective 
roles of parkin (Cookson 2003; Feany and Pallanck 2003) and our recent finding 
demonstrating that overexpressed parkin could protect cells against rotenone-induced 
toxicity in vitro (Wang et al. 2005b). The degree of dopaminergic neuronal loss in these 
flies correlates well with their respective climbing ability, measured over a 15-day period 
(Fig. 5.5C). Consistent with an accelerated loss of dopaminergic neurons, the rotenone-
treated flies examined show a correspondingly accelerated decline in their locomotory 
function that progresses with age (Compare Fig. 5.5C with Fig. 5.4), with the R275W 
mutant flies exhibiting the most drastic climbing impairment relative to control flies over 
time (Fig. 5.5B). The latter aligns with the greater susceptibility of select clusters of 
dopaminergic neurons in R275W flies to rotenone-induced dysfunction (Fig. 5.5A & B). 
Interestingly, the protective effects of overexpressed wild-type human parkin over PPL1, 
PPL2 and PAM neurodegeneration in flies apparently translates to better locomotor 
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performance, which is especially evident at day 15 of the climbing assay (Fig. 5.5C). 
Taken together, our results suggest that parkin R275W-expressing flies are more 
susceptible to rotenone-induced neurodegeneration and concomitant impairment in 
climbing ability, whereas overexpression of human parkin in flies could significantly 




Figure 5.5 Exposure to rotenone accelerates PPL1 dopaminergic neurodegeneration and 
locomotor deficits in transgenic parkin R275W mutant flies. (A) Representative confocal 
microscopy images showing TH-positive (red) dopaminergic neurons in the PPL1 cluster of 15 
day-old, rotenone-treated, transgenic flies expressing wild-type (WT) or mutant parkin species, as 
indicated (B) Bar-graph showing the number of dopaminergic (DA) neurons in different clusters 
of the various fly species treated with rotenone, as depicted by different shades shown in the 
figure (*P < 0.05, **P < 0.01, Student’s t-test, n=10). (C) Bar graph showing the climbing scores 
of the various rotneone-treated flies at different days post-eclosion, as depicted by different 
shades shown in the figure (*P < 0.05, **P < 0.01 Student’s t-test, n>20.) (Genotype: Ddc-
Gal4/+; UAS-hParkin/+, control Ddc-Gal4/+). 
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5.2.4 Expression of parkin R275W mutant in parkin null flies does not accelerate the 
degeneration of dopaminergic neurons 
Given the opposing outcomes mediated by the overexpression of wild-type human parkin 
and the R275W mutant in flies, we examined their respective effects on the dopaminergic 
neuronal integrity in parkin null background. We overexpressed wild-type or R275W 
human parkin in homozygous Drosophila parkin null mutant and these flies were 
designated hparkin/- and R275W/- respectively. When driven by the Ddc-GAL4 driver, 
the reduction of dopaminergic neurons in the PPL1 clusters in 20-day-old R275W/- flies 
is comparable to that exhibited by the parkin null mutant alone (Fig. 5.6A & B). On the 
other hand, overexpression of normal human parkin in parkin null flies significantly 
protects the PPL1 and PAM neurons from degenerating (Fig. 5.6A & B). Not surprisingly, 
the performance of R275W/- flies on the climbing assay is significantly poorer when 
compared to hparkin/- (Fig. 5.6C).  Intriguingly, R275W/- flies also present themselves as 
poorer climbers when compared to age-matched R275W flies (Fig. 5.6C). Taking into 
account that R275W and parkin null flies exhibit comparable climbing ability (Fig. 5.4), 
the expression of R275W parkin mutant against parkin null background thus appears to 
aggravate the locomotory deficit of the latter. We remain curious by this observation, as 
the overexpression of R275W parkin mutant does not appear to accelerate the 
degeneration of dopaminergic neurons in parkin null flies. It is possible that R275W 
parkin mutant expression may affect the function of the surviving neurons. 
 




Figure 5.6 Overexpression of wild-type and R275W parkin in parkin null flies exert 
different effects on dopaminergic neuronal survivability. (A) Bar-graph showing the number 
of dopaminergic (DA) neurons in different clusters of 20-day-old hparkin/- and R275W/- flies, as 
depicted by different shades shown in the figure. Data for control and parkin null flies were 
derived from Figure 2 (*P < 0.05, **P < 0.01, Student’s t-test, n=10). (B) Representative confocal 
microscopy images showing TH-positive (red) dopaminergic neurons in the PPL1 cluster of 20-
day-old old hparkin/- and R275W/- flies, as indicated. (C) Bar graph showing the climbing scores 
of the various mutant flies, as indicated, at 20 days post-eclosion (Genotype: UAS-hParkin, park1/ 
park1, Ddc-Gal4, control Ddc-Gal4/+). 
 
5.2.4 Parkin R275W mutant flies exhibit pleiomorphic mitochondrial abnormalities 
Since the loss of parkin in flies has consistently been shown to result in muscle-
associated mitochondrial pathology (Greene et al. 2003; Pesah et al. 2004; Clark et al. 
2006; Park et al. 2006; Yang et al. 2006), we generated transgenic flies expressing the 
various parkin species under the direction of a muscle-specific promoter (24B-GAL4) to 
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examine their respective contribution towards the maintenance of mitochondrial integrity. 
Consistent with previous reports (Greene et al. 2003; Pesah et al. 2004), we detected 
prominent mitochondrial defects in the indirect flight muscles of parkin null flies (Fig. 5.7 
G & H).  Although muscle-specific expression of parkin R275W in flies did not produce 
as severe mitochondrial pathology as parkin null flies, their indirect flight muscles are 
nonetheless typified by a significant number of abnormal mitochondrion (Fig. 5.7C & D). 
Further, parkin R275W flies exhibit markedly pleiomorphic mitochondrial pathologies 
(Fig. 5.8). While a large number of these organelles contain enlarged vacuolar structures 
surrounded by layers of concentric membranes (Fig. 5.7D & 5.8), some have disorganized 
cisternae while others, degenerated membranes (Fig. 5.8). On the other hand, none of 
these abnormal mitochondrial structures are prevalent in 24B-GAL4 driven transgenic 
flies expressing wild-type (Fig 5.7A & B) or G328E mutant parkin (Fig 5.7E & F). In 
these flies, the mitochondria in the indirect flight muscles are generally intact (Fig. 5.7 A, 
B, E & F). Whilst not exactly recapitulating the defective mitochondrial phenotype of the 
Drosophila parkin null mutant, it is interesting to note that muscle-specific expression of 
parkin R275W flies also produces marked mitochondrial abnormalities. We also 
examined the mitochondrial morphology of hparkin/- and R275W/- flies with the 
transgenes expression driven by 24B-GAL4 driver. Consistent with our earlier 
observation that overexpression of wild-type human parkin in parkin null flies affords 
significant protection against dopaminergic neuronal degeneration, we observed 
significant mitigation of the mitochondrial pathology in parkin null flies in the presence 
of wild-type human parkin expression (Fig. 5.7I-L). On the other hand, the abnormal 
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mitochondrial morphology associated with parkin null flies persists in the presence of 
R275W mutant expression (Fig. 5.7K-L). Thus, wild type human parkin, but not R275W 




Figure 5.7 Mitochondrial defects in parkin R275W mutant flies. TEM analysis of indirect 
flight muscles of 20 day-old flies expressing wild-type human parkin (A & B), R275W (C & D), 
G328E (E & F) or lacking endogenous parkin (G & H)  (Genotype: 24B-Gal4/+; UAShParkin/+). 
The same analysis is performed in 2-day old parkin null flies (I & J) or those expressing wild-type 
human parkin (K & L) or R275W (M & N) against parkin null background. (Genotype: UAS-
hParkin, park1/ park1, 24B-Gal4). Scale bar, 1 µM (A,C,E,G,I,K,M); 0.5 µM (B,D,F,H,J,L,N). 
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Figure 5.8 Mitochondrial abnormalities in R275W mutant flies.  TEM images showing 
pleiomorphic mitochondrial pathologies in the indirect flight muscles of 20 day-old flies 
expressing R275W mutant parkin. (Genotype:  24B-Gal4/+; UAS-hParkin/+). 
 
5.3 Discussion 
The major finding of our study in this chapter is that parkin R275W mutant 
expression in vivo could exert neurotoxic effects in the presence of the wild-type protein. 
When expressed as a transgene in Drosophila, parkin R275W mutant triggers the 
degeneration of dopaminergic neurons in select clusters and concomitantly results in 
locomotor deficits. Further, flies expressing the mutant also promote mitochondrial 
abnormalities and appear more susceptible to rotenone-induced neurotoxicity. Taken 
together, our results suggest that the expression of select parkin mutations in vivo may 
confer increased susceptibility of dopaminergic neurons to degeneration. 
Although parkin-linked disease transmission is presumed to occur in a recessive 
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fashion, the expanding number of reports associating single parkin mutation with 
increased risk for PD has raised questions on the mode of disease transmission by parkin 
mutations (West and Maidment 2004; Clark et al. 2006; Sun et al. 2006). To date, several 
parkin mutations occuring on different regions of the protein have been found in 
heterozygous carriers (Table A1). Interestingly, heterozygous PD cases harboring the 
R275W mutation are a recurrent theme in these studies (Table A1). However, the 
identification of heterozygous parkin mutations remains controversial largely due to 
technical difficulties in screening the enormous, 1.4Mb-large, parkin gene. Accordingly, 
additional mutations, particularly in the introns or gene regulatory regions of the parkin 
gene, may have been missed out in studies implicating the existence of single parkin 
mutation. Indeed, West and colleagues demonstrated that single parkin mutation cases are 
often overestimated in the literature (West et al. 2002). Importantly, they also found in 
half of their samples examined that single parkin mutations exist as bona-fide 
heterozygous mutations (West et al. 2002; West and Maidment 2004). Another concern 
over heterozygous parkin mutation carriers is that they may occur incidentally. However, 
at least two recent case-control studies of the parkin gene in early and late onset PD 
reveal the presence of several heterozygous parkin mutations, including R275W, that are 
not found in control individuals thereby providing a direct association between 
heterozygous parkin mutations and increased susceptibility for PD (Oliveira et al. 2003; 
Clark et al. 2006). Notwithstanding the controversy surrounding the existence of single 
parkin mutations, whether and how heterozygous parkin condition affects dopaminergic 
neuronal survivability remains obscure.  
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The importance of functional parkin to dopaminergic neuronal survival is 
probably related to the multitude of neuroprotective roles it serves (Cookson 2003; Feany 
and Pallanck 2003). Parkin functions as a ubiquitin ligase associated with protein 
homeostasis and apparently confers protection to neurons against a diversity of cellular 
insults including maganese-induced cell death, α-synuclein toxicity, proteasomal 
dysfunction, Pael-R and p38/JTv-1 accumulation, kainate-induced excitotoxicity and 
dopamine-mediated toxicity (Cookson 2003; Feany and Pallanck 2003; LaVoie et al. 
2005; Wang et al. 2005b). Our current study also provides further support to parkin’s 
neuroprotective function. We found that flies overexpressing wild-type human parkin are 
more resistant to rotenone-induced degeneration and associated locomotor defects. 
Moreover, expression of wild-type human parkin in parkin null flies effectively prevents 
select dopaminergic neurons from degenerating. Although hparkin/- flies apparently 
failed to improve their climbing scores relative to parkin null flies, this is likely due to the 
inability of Ddc-GAL4 driven hparkin expression to compensate for the widespread 
muscle pathology in parkin null flies as reported by others (Greene et al. 2003; Pesah et 
al. 2004) and in this study. Notably, when driven by 24B-GAL4, wild-type but not 
R275W human parkin expression in parkin null flies significantly mitigates the 
mitochondrial phenotype of the latter. This is consistent with previous reports by others 
showing that expression of wild-type Drosophila parkin using 24B-GAL4 could rescue 
dparkin null phenotype (Greene et al. 2003; Pesah et al. 2004). The apparent protection 
against dopaminergic neurodegeneration and mitochondrial pathology in parkin null flies 
by wild-type human parkin suggests a certain degree of functional conservation between 
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human and fly parkin.  
 Given its broad-spectrum neuroprotective roles, one could envisage that parkin 
haploinsufficiency could increase the risk of heterozygous parkin mutation carriers for 
PD. Supporting the importance of optimal parkin expression to dopaminergic neuronal 
survivability, we (as discussed in previous chapters) and others have demonstrated that 
age, mutations and PD-linked stress could deplete the availability of soluble functional 
parkin in the brain (LaVoie et al. 2005; Sriram et al. 2005; Wang et al. 2005a; Wang et al. 
2005b), and as such, may underlie the progressive susceptibility of the brain to 
degeneration. Further, a promoter variant of parkin associated with a lower expression of 
parkin occurs more commonly in PD cases than in controls (West et al., 2002). However, 
the possibility that dominant-negative mutations might account for a proportion of single 
parkin mutation-linked PD cases cannot be excluded. In particular, a recent family-based 
study conducted in Germany implicates the transmission of the R275W mutation as an 
autosomal dominant trait, thereby providing further support for the notion that single 
R275W parkin mutation might be sufficient to cause disease (Krueger R pers. comm.). 
Consistent with the above, our current study demonstrates that the overexpression 
of parkin R275W in Drosophila is toxic to dopaminergic neuronal survival, albeit in 
select clusters. Further, R275W expression in Drosophila flight muscles also promotes 
mitochondrial abnormalities. The dissimilar outcomes mediated by R275W and G328E 
mutants in flies may be related to their different properties, as observed in our previous in 
vitro study (Wang et al. 2005a). Interestingly, our observations corroborate with a very 
recent study conducted by Sang and colleagues who showed that expression of parkin 
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T240R and Q311X mutants in Drosophila causes age-dependent, selective degeneration 
of DA neurons accompanied by progressive motor impairment (Sang et al. 2007). 
 In our current study, we have adopted an unbiased confocal microscopy-based 
quantitative method described recently by Whitworth and colleagues to detect subtle 
neuronal loss in the fly brains (Whitworth et al. 2005). Similar to the observation made by 
Whitworth and colleagues with parkin null mutants, we detected comparable loss in the 
number of dopaminergic neurons within the PPL1 cluster in our parkin null flies at 20-
day post-eclosion. Further, we also observe an obvious loss of dopaminergic neurons in 
the PAM cluster of these flies. Importantly, R275W parkin-overexpressing flies show the 
same degeneration pattern as parkin null flies and both these mutant fly species present 
marked mitochondrial pathology, suggesting that heterozygous parkin mutations could 
result in similar outcomes to that arising from the overt loss of parkin function. Flies 
expressing the R275W mutant also appear to be more susceptible to rotenone-induced 
neurotoxicity. Whilst accelerated neuronal loss is observed in all the dopaminergic 
clusters in the various fly strains following rotenone treatment, the PPL1 neurons in 
R275W are significantly more affected. Interestingly, the selective impact on neuronal 
integrity exerted by the expression of R275W in flies correlates well with their impaired 
climbing ability compared to age-matched control flies. Although previous studies have 
attributed compromised locomotory activity observed in parkin null flies largely to 
defects in their masculature (Greene et al. 2003; Pesah et al. 2004), our results with Ddc-
driven parkin R275W flies show that dopaminergic neurodegeneration in select clusters 
alone is sufficient to trigger climbing defects. Further, the protection of similar clusters of 
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neurons by the Ddc-driven expression of wild-type human parkin translates to better 
climbing scores. It is thus tempting to suggest a direct association between dopaminergic 
neurodegeneration and locomotory dysfunction in flies, a phenomenon that is seen in PD 
patients.  
How the expression of R275W mutant influences the function of endogenous parkin 
remains to be elucidated, but its expression does not appear to aggravate the 
dopaminergic neurodegeneration process when expressed in parkin null flies. Although 
the latter is consistent with the R275W mutant parkin acting as a dominant negative 
protein, we remain intrigued by the poorer climbing scores of R275W/- flies compared to 
R275W and parkin null flies. As with all experiments involving the expression of 
transgenes in a heterologous system, we cannot completely exclude the possibility that 
the phenotypic characteristics exhibited by R275W mutant flies arise from neomorphic 
manifestations associated with the expression of a foreign gene. However, several 
observations made in this study would argue against R275W mutant acting as a 
neomorph. Firstly, Ddc-driven expression of R275W mutant in flies affects the same 
clusters of dopaminergic neurons as those in parkin null flies. Secondly, although the 
effects mediated by R275W and parkin null mutant on Drosophila flight muscle are not 
exactly identical, they nonetheless promote a similar outcome, i.e. mitochondrial 
dysfunction. Thirdly, compared to the R275W mutant, the better-expressed parkin G328E 
mutant behaves as a relatively benign foreign protein in Drosophila. Importantly, when 
we crossed wild type parkin expressing flies with R275W mutant flies, we found that 
their co-expression significantly mitigates the loss of PPL-1 dopaminergic neurons 
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observed in R275W flies (Fig. 5.9). Taken together, our results suggest that the 
overexpression of R275W either results in loss of Drosophila parkin function via a 
dominant negative mechanism or phenocopies Drosophila parkin null mutant through a 
common pathway. Although the exact mechanism of R275W mutant-mediated toxicity 
remains to be clarified, it is apparent that the R275W fly model recapitulates the essential 
symptomatic features of PD and thus represents an ideal in vivo model of parkin 
dysfunction. Given the demonstrated pathogenicity of R275W mutant parkin expression 
in flies, our results also help explain the increased susceptibility of some heterozygous 
parkin carriers to develop PD. 
 
Figure 5.9 Co-expression of wild-type parkin and R275W mutant mitigates the loss of PPL1 
neurons (A) Representative confocal microscopy images showing TH-positive (red) 
dopaminergic neurons in the PPL1 cluster of 20 day-old transgenic flies expressing wild-type 
(WT) or R275W parkin alone (Genotype: Ddc-Gal4/+; UAS-hParkin/+)or in combination 
(Genotype: WT, Ddc-Gal4/ R275W, Ddc-Gal4), as indicated (B) Bar-graph showing the number of 
dopaminergic (DA) neurons in different clusters of the various fly species described above, as 
indicated (**P < 0.01, Student’s t-test, n=10). 
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In summary, our study here provided in vivo evidence demonstrating that selected 
parkin mutations could generate marked neurotoxicity in vivo. Whether the neurotoxic 
effects mediated by these mutants could indeed account for a proportion of single parkin 
mutation-linked PD cases remains to be established. Further study should help elucidate 







Results presented in this chapter have been published in the Journal of Neuroscience 
(Wang et al., 2007) 
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CHAPTER 6 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
As stated earlier, the overall objective of my thesis project is to understand how 
parkin function becomes altered in familial PD as well as possibly in sporadic PD. At the 
end of my project, I have made several discoveries that are pertinent to our understanding 
of parkin dysfunction that are relevant not only to familial PD linked to parkin mutations 
but also to sporadic PD. Indeed, there appears to be a common thread underlying parkin 
dysfunction in both forms of PD. Further, my in vivo studies of select parkin mutants in 
the Drosophila system suggest that we should perhaps revisit our notion that parkin 
mutations manifest in an exclusively autosomal recessive manner. Although not entirely 
phenocopying the phenotype of parkin null mutant flies, parkin R275W flies surprisingly 
recapitulate salient features exhibited by the former, including neuronal degeneration in 
selected dopaminergic clusters and associated locomotion deficits as well as 
mitochondrial abnormalities. Taken together, the findings presented in this thesis have 
considerably updated previously-held paradigms of parkin dysfunction, and at the same 
time help suggest therapeutic strategies that might mitigate PD pathogenesis due to parkin 
dysfunction. Indeed, we now understand more about how parkin function could become 
altered in both familial and sporadic PD, and why heterozygous parkin carriers have 
increased risk in developing PD. I shall now discuss all these results in perspective. 
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6.1 Contributors to parkin dysfunction 
It was originally thought that parkin dysfunction is limited to familial PD cases 
harboring parkin mutations. Further, parkin mutations were thought to result in the 
impairments of parkin’s catalytic function. The studies conducted here suggest otherwise. 
Indeed, environmental stress factors and normal aging could mimic parkin mutations in 
promoting the loss of functional parkin in the brain.  
 
6.1.1 Parkin dysfunction in parkin-related familial PD cases 
Parkin was originally thought to function as a degradation-associated ubiquitin ligase 
whose catalytic activity is compromised by its mutations thereby leading to its 
dysfunction. By conducting a systematic and comprehensive analysis of parkin mutations, 
we showed that the majority of mutations in parkin alter the protein’s solubility (group II 
& III in Fig 3.8) and concomitantly promote its intracellular aggregation (group III in Fig 
3.8). The depletion of soluble pool of functional parkin as such may reduce the cell’s 
ability to handle protein load efficiently thereby increasing its susceptibility to stress-
induced toxicity. For the group of parkin mutants with comparable solubility as the wild 
type protein (group I in Fig 3.8), particularly for those mutants that retain substantial 
catalytic activity (i.e. A82E), their presumably higher propensity to stress-induced 
solubility alterations, as shown in Chapter 4, may explain why neurons harboring these 
apparently normal parkin species are also vulnerable to degeneration. Thus, the 
predisposition of parkin mutations to solubility alterations, either inherently or due to 
exogenous stress, is an important contributor to parkin dysfunction. 
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Whether select parkin mutations may produce a dominant negative mutant remains a 
hotly debated topic, although a dominant negative mechanism could potentially explain 
the apparently increased risk for PD associated with heterozygous parkin carriers. 
Supporting the latter, we demonstrate that overexpression of select parkin mutations (i.e. 
R275W) in Drosophila cause DA neuron degeneration against a background of 
endogenous parkin expression. This finding contradicts the widely presumed recessive 
transmission of parkin mutations, but supports emerging evidence suggesting that 
heterozygous parkin mutations may be pathogenic. Conceivably, multiple mechanisms 
involving solubility changes, catalytic impairment, protein aggregation and plausible 
dominant negative effects may affect the normal function of parkin. Our findings thus re-
defined current thoughts about how parkin mutations affect the protein function, which 
certainly go beyond pure catalytic impairments. 
 
6.1.2 Parkin dysfunction in parkin-related sporadic PD cases 
Interestingly, age-dependent changes could trigger parkin insolubility in a manner 
brought about by a large number of clinically relevant mutations (Pawlyk et al. 2003). 
This shared mechanism of parkin dysfunction is further supported by our subsequent 
finding presented in Chapter 4 that a wide variety of PD-linked stressors, including 
dopamine (DA), induce parkin solubility alterations and promote its aggregation within 
the cell, a phenomenon that again mimic the biochemical alterations of parkin brought 
about by a large number of familial PD-linked parkin mutations thereby suggesting a 
mechanism for parkin dysfunction in the pathogenesis of idiopathic PD. Loss of soluble, 
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functional parkin resulting from age- or stress-induced modifications may therefore be as 
relevant to sporadic PD as parkin dysfunction triggered by disease-associated mutations is 
to parkin-related familial PD. Thus, aberrant parkin function is not limited to familial 
forms of PD where overt mutations occur. Our results thus positioned parkin prominently 
in the large majority of PD cases where no mutations of PD-linked genes have been 
found. 
 
6.2 How does Parkin dysfunction lead to DA neurodegeneration? 
The simple hypothesis on how parkin dysfunction elicits DA neuronal death is that in 
parkin-linked PD, the accumulation of certain parkin substrates could interfere with 
cellular functions and induce neurotoxicity. A strong evidence for this came recently from 
the Dawson’s lab, who observed accumulation of the parkin substrate, p38/JTV-1 
(AIMP2), in the brains of parkin null mice as well as ARJP individuals. Overexpression 
of p38 leads to neurotoxicity in vitro and in vivo, suggesting that p38 accumulation in the 
absence of functional parkin could trigger neurodegeneration. While wild type parkin 
mitigates the pro-cell death effects of p38, mutant parkin (R42P) fails to do so. Similarly, 
the accumulation of Pael-R in the absence of function parkin is also toxic to neuronal 
survival both in vitro and in vivo. One could therefore envisage that age or stress-induced 
modifications of parkin could promote similar pathogenic outcomes. Supporting this, the 
Dawson’s group also observed p38 accumulation in sporadic PD brains, where parkin has 
been found to be significantly S-nitrosylated. S-nitrosylation of parkin has been shown to 
inactivate the enzyme and could conceivably deplete the pool of functional parkin in the 
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brain. This is related to our earlier description that a wide variety of PD-linked stressors 
induce parkin solubility alterations and promote its aggregation within the cell.  A model 










Figure 6.1. A cartoon depicting how various endogenous and exogenous factors could 
promote parkin dysfunction and thereby substrate accumulation and neuronal death. 
 
However, loss of parkin function might also impact on pathogenic pathways 
described in Chapter 1 other than the UPS, including those related to oxidative stress and 
mitochondrial dysfunction, which collectively render dopaminergic neurons sensitive to 
neurotoxicity and death. Current studies certainly suggest this interplay between UPS, 
oxidative stress and mitochondrial function (Fig. 6.2). Notably, parkin threads through all 
of these. Parkin might be a crucial bridging protein between UPS and mitochondrial 
pathway, which are important for ubiquitinating and degrading oxidized mitochondrial 
proteins, thereby ameliorating oxidative stress. Parkin is itself sensitive to oxidative 
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stress, and is inactivated by nitric oxide-mediated nitrosylation, which could lead to a 
simultaneous increase in UPS and mitochondrial dysfunction (Chung, et al., 2004; Yao, et 














Figure 6.2. A cartoon depicting the interplay between various pathogenic factors involved in 
PD. 
 
Indeed, mitochondrial impairments in the absence of functional parkin likely 
synergise with aberrant protein homeostasis to bring about neuronal demise. Drosophila 
parkin null model has revealed a role for parkin in maintaining mitochondrial function 
and preventing oxidative stress - pathways heavily implicated in sporadic PD. Parkin null 
mutants had severe mitochondrial pathology associated with reduced lifespan, apoptosis, 
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flight muscle degeneration and male sterility (Greene, et al. 2003). Microarray analysis in 
these flies revealed upregulation of genes involved in oxidative stress and electron 
transport. A genomic screen for modifiers of lifespan in the parkin null flies found the 
strongest modifier to be loss-of-function mutations of glutathione S-transferase (GSTS1), 
a factor that has been implicated in the cellular response to oxidative stress (Greene, et al. 
2005; Singh, et al. 2001). Re-analysis of the same flies revealed progressive degeneration 
of a select cluster of dopaminergic neurons and evidence of increased oxidative damage 
with increased protein carbonyls compared with controls. Furthermore, 
neurodegeneration was enhanced in GSTS1 null mutants, whereas GSTS1 overexpression 
significantly rescued the parkin phenotype (Greene, et al. 2005). In our R275W parkin 
mutant fly model, we also observed abnormal flight muscle mitochondrial morphology, 
which provides further support that loss of parkin function may cause mitochondrial 
dysfunction (Chapter 5).  
 Consistent with the findings from fly models, mammalian models of parkin 
dysfunction also suggest a role for parkin in maintaining mitochondrial function. Deletion 
of exon 3 of parkin in mice results in nigrostriatal dysfunction and reduced expression of 
several proteins involved in mitochondrial function and oxidative stress, including 
subunits of complexes I and IV. The mice also had decreased mitochondrial respiratory 
capacity and showed evidence of increased oxidative damage (Palacino, et al. 2004). 
Thus, both Drosophila and mice model support a role of parkin in maintaining 
mitochondria function, although it is uncertain exactly how parkin regulates 
mitochondrial function. Parkin might be directly involved in maintaining mitochondrial 
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integrity as suggested previously by others (Darios, et al. 2003). It is equally possible that 
parkin could indirectly maintain mitochondrial function. As free radical-induced 
oxidative damage is a normal consequence of the electron transport chain, parkin might 
have a role in clearing oxidatively damaged proteins and mutant parkin might fail to do 
that and then lead to the accumulation of such proteins, which might cause further 
oxidative stress and apoptosis. This mechanism would be most compatible with the 
known function of E3 ligases in the UPS. Interestingly, Parkin expression is upregulated 
after exposure to the complex I inhibitor MPP+ in neuronal cells (Hyun, et al. 2005), as 
well as rotenone (Chapter 4).  
Although UPS dysfunction, oxidative stress and mitochondrial aberrations are 
thought to be the major pathogenetic pathways involved in PD pathogenesis, the 
discovery of a wide range of parkin substrates involved in disparate cellular processes 
implicates additional pathways. Future studies should illuminate these pathways, and it 
will be of significant interest to see whether and how these additional pathways impact 
and/or converge on the currently accepted pathways of PD pathogenesis. 
 
6.3 Implications for PD therapy 
Since the loss of soluble, functional parkin resulting from age- or stress-induced 
modifications appears to be as relevant to sporadic PD as parkin dysfunction triggered by 
disease-associated mutations is to parkin-related familial PD, it is thus conceivable that 
parkin gene delivery could offer a novel avenue of PD therapy. Indeed, virus-mediated 
delivery of parkin prevents dopaminergic neurodegeneration in rats either overexpressing 
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α-synuclein (Lo Bianco, et al. 2004; Yamada, et al. 2005) or treated with 6-OHDA 
(Vercammen, et al. 2005), as well as in mice treated with MPTP (Paterna, et al. 2007). 
Similarly, enhanced expression of parkin in Drosophila counteracts PD-like symptoms 
promoted by the overexpression of alpha-synuclein (Haywood, et al. 2004) or Pael-R 
(Yang, et al. 2003). As mentioned above, a recent screen for modifiers of parkin 
dysfunction in flies identified glutathione S-transferase S1 (GstS1) (Whitworth, et al. 
2005). Overexpression of GstS1 prevents dopaminergic neurodegeneration in parkin 
mutants flies (Whitworth, et al. 2005), suggesting that the induction of GstS1 expression 
might be useful in the treatment of PD. However, whether parkin gene therapy can correct 
motor abnormalities in animal models of PD remains to be established. Undeniably, this 
would be an important prerequisite to human trials. 
 
6.4 Conclusions 
In essence, my project seeks to understand how mutations and stress factors 
contribute to parkin dysfunction, information of which will improve our understanding of 
the role of parkin in familial PD as well as sporadic PD. I have made the following 
findings, which I believe are significant to the field and have contributed to the 
refinement of the paradigms of parkin function.  
 
I. Mutations in parkin could impair the protein function in more than one way, 
including frank catalytic impairment, direct alteration of the protein solubility 
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and localization, or simply a predisposition to such alterations. Our results 
explain why seemingly catalytic-viable parkin mutants could be dysfunctional. 
 
II. Several PD-linked stressors, including neurotoxins (MPP+, rotenone, 6-
hydroxydopamine), paraquat, NO, dopamine and iron, induce alterations in 
parkin solubility and result in its intracellular aggregation. Furthermore, the 
depletion of soluble, functional forms of parkin is associated with reduced 
proteasomal activities and increased cell death. Mechanistically, our results 
provide a link between the influence of environmental and intrinsic factors and 
genetic susceptibilities in PD pathogenesis. Our results also suggest a 
mechanism for parkin dysfunction in the pathogenesis of idiopathic PD. 
 
III. The expression of human R275W in Drosophila promotes dopaminergic 
neurodegeneration and mitochondrial dysfunction and suggests the interesting 
possibility that select parkin mutations may potentially exert dominant negative 
effects in vivo. Our results provide an explanation to why heterozygous parkin 
carriers have increased risk for PD and challenge the widely presumed recessive 
transmission of parkin mutations. 
 
Taken together, it is apparent that we are moving towards a new paradigm of parkin 
function. Whether the new knowledge of parkin function would eventually be cast in 
stone remains an uncertainty. Paradoxically, therein lays the excitement of change.  
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APPENDIX A 
 
IMPORTANCE OF PARKIN’S CYSTEINE RESIDUES IN 
MAINTAINING THE PROTEIN SOLUBILITY 
 
This short chapter provided as an appendix is a result of a close collaboration between 
myself and Dr. Esther Wong, a postdoctoral fellow in the Neurodegeneration Research 
Labortory. Our findings have been published recently in the Journal of Biological 
Chemistry (Wong et al., 2007). Shown here are results that I have help contributed that 
are relevant to the work discussed in previous chapters of this thesis. 
 
A.1 Overview 
In chapter 4, we have speculated that enzymes whose structure and function are 
dependent on catalytic Cys are more susceptible to the consequence of oxidative 
modification. While the active-site Cys-dependent tyrosine phosphatase family of 
enzymes provides one example (Tonks, et al., 2005), the RING-finger containing 
ubiquitin ligases, all of which characterized by their Cys-rich catalytic moieties, 
potentially represent another example. In particular, the abundance of Cys residues 
residing on RING-IBR-RING-containing proteins, such as parkin, conceivably could 
present a ready source of targets for oxidative modification. As the majority of these 
highly conserved RING-finger Cys residues are thought to fulfil important structural roles 
(Capili, et al., 2004; Zheng, et al., 2000), it is conceivable that their modification by 
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oxidation could disrupt the overall structural integrity of the protein, leading to alterations 
in their biochemical properties. Here, we demonstrate that conserved Cys residues 
residing both within and outside of the RING-IBR-RING motif of parkin are important 
for maintaining its solubility, although modification of Cys residues within parkin RING-
IBR-RING motif also resulted in a significantly higher tendency for the protein to form 




A.2.1. Conservation and structural implication of parkin’s cysteine residues  
Inspection of the amino acid sequence of human parkin reveals a total of 35 Cys 
residues, the majority of which (23 out of 35) resides within the RING-IBR-RING motif 
of the protein (Fig. A.1 & A.2A). Further, comparison of human parkin protein sequence 
with orthologous sequences from rodent, fish, insect and worm reveals that almost all of 
parkin’s Cys residues are absolutely conserved in these species, a feature that suggest 
their importance to the protein’s structure and/or function (Fig. A.1). Although the 
invariant Cys residues in parkin across different species are largely found within the 
catalytically important RING-IBR-RING motif, a number of such highly conserved Cys, 
like C150, C166, C212 and C457 are notably also found along the length of the protein 
outside of this motif (Fig. A.1).  
 
 














































Figure A.1. Conservation of cysteines in parkin across different vertebrate and invertebrate 
species. (A) Schematic depiction of the human parkin protein. The positions of invariant (bold 
text, asterisk) and non-invariant (regular text) cysteine residues of parkin across different species 
examined are indicated along the length of the protein. The number of cysteines each domain 
contains is reflected within parenthesis above the respective domains. (B) Multiple sequence 
alignment of orthologous parkin protein sequences from human, rat, mouse, Fugu, zebrafish, 
Drosophila, Anopheles and C. elegans. Invariant and non-invariant cysteine residues across these 
species are highlighted in dark gray and black respectively. All other invariant residues are 
highlighted in light gray. The UBL (double-lined) and RING1-IBR-RING2 domains (solid lines), 
as well as the position of cysteines, are indicated. 
 
To gain insights into the importance of individual Cys residue on parkin to its overall 
tertiary architecture, it is essential to elucidate the 3-dimensional structure of the protein, 
information of which is currently lacking. However, the structure of both RING1 and 2 in 
related proteins, c-Cbl and HHARI respectively, have previously been reported (Capili, et 
al., 2004; Zheng, et al., 2000). Accordingly, we used the structure of c-Cbl RING1 and 
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HHARI RING2 as templates to model parkin RING1 and 2 domains respectively. 
Homology models of parkin RING1 and 2 so obtained reveal the co-ordination of C238, 
C241, C260 and C263 to a zinc atom in RING1 and the co-ordination of C418, C421, 
C436 and C441 to another zinc atom in RING2 (Fig. A.2B). Although our program failed 
to model C289 and C293 accurately, these residues, together with C253 and H257, should 
co-ordinate a second zinc atom in RING1 in view of their high sequence homology to c-
Cbl RING1 (Zheng, et al., 2000) (Fig. A.2B). Not surprisingly, all of these structurally 
important Cys residues are absolutely conserved in parkin across different species (Fig. 
A.1). On the other hand, C268, which does not appear to have a critical structural role in 
RING1 (Fig. A.2B), is replaced by a leucine (Leu) in C. elegans parkin (Fig. A.1), and by 
other amino acid residue in related proteins such as RBCK1 (Threonine) and Ariadne-2 
(Phenylalanine) (Morett, et al., 1999). Similarly, the non-structural C451 residue 
proximal to RING 2 (Fig. A.2B) is poorly conserved among parkin from different species 
(Fig. A.1). Since the structure of parkin’s UBL domain is known (Sakata, et al., 2003), we 
also inspected the structural position of C59 and found that this Cys residue is located at a 
solvent-exposed loop on the surface of the UBL domain and not within its core (Fig. 
A.2C), thereby offering some structural flexibility. Notably, in C. elegans parkin, C59 is 
substituted with a Leu (Fig. A.1). Taken together, the degree of Cys conservation in 
parkin across different species appears to correlate with their structural importance. 
Conceivably, modification of any of the numerous highly conserved Cys residues on 
parkin is likely to influence its structural topology and thereby its biochemical properties. 
 




















Fig A.2. Conservation of cysteines in parkin and their predicted structural roles. (A) 
Schematic depiction of the parkin protein. The positions of invariant (bold text, asterisk) and non-
invariant (regular text) cysteine residues of parkin across different species examined are indicated 
along the length of the protein. The number of cysteines each domain contains is reflected within 
parenthesis above the respective domains. (B) Predicted tertiary structure of RING1 (left panel) 
and RING2 (right panel) domain of parkin showing Zn2+ co-ordinating cysteine and histidine 
residues in c-Cbl and HHARI (blue) and parkin (yellow). Substituted cysteine residues that 
resulted in protein aggregation are labelled in yellow whereas those that remained soluble in cyan. 
(C) C59 is located at the solvent exposed loop region in parkin UBL domain (1 IYF), highlighted 
in cyan on the molecular surface of UBL in I. Substitution of C59 with A59 does not cause 
observable perturbation at this site as shown in II. 
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A.2.2 Conserved cysteine residues on parkin residing both within and outside the 
RING-IBR-RING motif are important in maintaining its solubility. 
To examine whether the modification of parkin’s Cys residues would influence its 
solubility, we generated a large series of parkin Cys-Ala (C-A) point mutants that cover 
the length of the protein via site-directed mutagenesis and expressed each of these 
mutants in SH-SY5Y neuroblastoma cells (Fig. A.3A). When cells transfected with these 
mutants were subjected to sequential detergent extraction, we found that all the C-A 
mutations occuring on Cys residues that are invariant in parkin across different species, 
except C431A, show preferential localization to the detergent-insoluble (P) fraction 
relative to control, wild-type parkin (Fig. A..3A). Conversely, Cys residues on parkin 
such as C59, C95, C268, C323, C431 and C451 that are either not absolutely conserved 
among different species or are otherwise structurally unimportant, or both, do not 
significantly alter parkin solubility when mutated (Fig. A.3A). Consistent with our in 
silico sequence and structural prediction, our results suggest the importance of conserved 
parkin’s Cys residues in maintaining the structure and hence solubility of the protein, and 
that alteration of parkin solubility via the modification of its Cys residues are not limited 
to those residing within the RING-IBR-RING motif. As dicusssed in chapters 3 and 4, we 
have previously demonstrated an association between altered parkin solubility and its 
propensity to form intracellular aggregates. Since mutations of conserved and non-
conserved Cys residues on parkin produce different effects on the protein’s solubility, we 
were interested to know their respective influence in promoting parkin aggregation within 
the cell. For this purpose, representative pairs of mutants containing C-A substitutions of 
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either an invariant or non-invariant Cys at different regions of parkin were examined (Fig. 
A.3B). Between the paired mutants, we found that aggresome-like structures occur more 
frequently in cells expressing the one substituting for the absolutely conserved Cys and 

















Figure A.3 Modification of parkin’s cysteine residues affects its solubility and intracellular 
localization. (A) Representative anti-FLAG immunoblots of cell extracts sequentially prepared 
with Triton-X 100 (S) and SDS (P)- containing buffer from SH-SY5Y cells transfected either with 
FLAG-tagged wild-type parkin or parkin C-A mutants, as indicated. The blots were stripped and 
reprobed with anti-actin antibody to reflect loading variations. The experiment was repeated 3 
times with similar results. (B) Representative anti-FLAG immunostaining of SH-SY5Y cells 
transfected with select parkin C-A mutants showing the tendency of some mutants to form 
perinuclear inclusions (arrows). (C) Bar-graph showing the percentage of cells containing anti-
FLAG-positive inclusions. Bars represent means from at least 3 independent experiments, and 
error bars indicate the mean±SEM. Statistical variance, whenever significant, are indicated (*P < 
0.05, **P < 0.001 vs wild-type control, Student’s t-test) 
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This is consistent with their respective solubility profile as described above (Fig. 
A.3B). Quantitatively, C-A mutations occuring on invariant Cys residues located on 
RING1 and 2 domains or the C-terminal tail of the protein show the highest propensity to 
generate intracellular inclusions, compared to wild-type parkin as well as mutants bearing 
similar mutations on the IBR domain or at the N-terminal region of parkin (Fig. A.3C). It 
thus appears that Cys modification occuring on the RING domains or C-terminal end of 
parkin result in more significant alterations of the protein (i.e. solubility changes and 
higher tendency to aggregate) compared to analogous modification occuring at other 
regions of the protein. 
 
A.3 Discussion  
Of the twenty naturally occuring amino acids found in proteins, cysteines are 
recognized to be exceptionally susceptible to oxidative modification due to the presence 
of sulfhydryl groups. Sulfhydryl groups are the strongest nucleophile in the cell at 
physiological pH and thus represent ideal targets for nucleophilic attack by oxidants or 
nitrosative agents. Accordingly, the abundance of Cys residues on a protein should, in 
part, contribute to the tendency for the protein to be modified by cellular oxidants. We 
found that this appears to be the case when we subjected parkin, an enzyme with high 
cysteine content to the effects of oxidative/nitrosative stress agents (discussed in chapter 
4).  
The extent of a protein’s alteration via its Cys modification is obviously also related 
to the importance of the targeted Cys residue to the overall tertiary structure of the 
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protein. We have demonstrated that the large majority of Cys residues residing on parkin 
(23 out of 28 examined), both within and outside the RING-IBR-RING domain, are 
important in maintaining its solubility. With the notable exception of C431, all the Cys 
residues of parkin found to be invariant across diverse species resulted in parkin 
insolubility when they are mutated to alanine, suggesting their importance in fulfilling 
critical structural roles. While the Zn2+ co-ordinating Cys residues in RING1 and 2 are 
obviously structurally important, it is interesting that almost all the Cys located at the 
IBR, a domain whose function remains unclear, appears to be critically important for the 
native folding of parkin. 
Our results here thus offer significant insights into the components important for 
parkin solubility, and at the same time provide some structural basis for the solubility 
alterations of the protein produced by cellular stress.  
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APPENDIX B 
 
Table A1. Summary of genetic data of 22 parkin mutations studied  
 
Mutation Type References 
R42P* 
HMZ; 
COM/HTZ with deletion (n = 2) 
HTZ 
Terreni, et al., 2001; 
Hedrich, et al., 2002; Bertoli-Avella, et al., 2005 




HMZ with HMZ deletion (n = 1) 
West, 2002a; Oliveira, et al., 2003; Lincoln, et al., 2003 
Schlitter, et al., 2006 
Hedrich, et al., 2001 
K161N* COM/HTZ with deletion (n = 1)  HTZ 
Abbas., et al., 1999; Periquet, et al., 2001;  
Lucking, et al., 2000 
M192L* HTZ Clark et al., 2006 
K211N 
COM/ HTZ with exon 3 deletion (n 
= 3); duplication (n = 1) 
HTZ 
Van, et al., 2001; Periquet, et al., 2001; Kann, et al., 2002 
Nichols, et al., 2002 
Lucking, et al., 2000; Foroud, et al., 2003 
C212Y HTZ Hoenicka, et al., 2002 
T240R HMZ Hattori, et al., 1998; Abbas, et al., 1999 
R256C* HTZ COM/ HTZ 
Abbas, et al., 1999; Lucking, et al., 2000; West, 2002a; 
Hedrich, et al., 2002; Periquet, et al., 2003; Oliveira, et 
al., 2003; Lincoln, et al., 2003; Khan, et al., 2005; Shyu, 
et al., 2005; Schlitter, et al., 2006 
C268Stop COM/ HTZ with exon 4 deletion Khan et al., 2003 
R275W* 
Compound HTZ with Deletion (n = 
8); Point mutation (n=2); 
Duplication (n = 1)  
HTZ  
HMZ with HTZ point mutation 
Abbas et al., 1999; Lucking et al., 2000; Periquet et al., 
2001; Hedrich et al., 2002; Nichols et al., 2002; West et 
al., 2002; Foroud et al., 2003; Khan et al., 2003; Lincoln 
et al., 2003; Oliveira et al., 2003; Periquet et al., 2003; 
Wiley et al., 2004; Hedrich et al., 2004; Sinha et al., 2005 
Clark et al., 2006 
D280N HTZ Oliveira, et al., 2003 
C289G* HMZ HTZ 
Thobois, et al., 2003 
Lucking, et al., 2000 
Q311stop HMZ Hattori, et al., 1998; Abbas, et al., 1999 
G328E* HTZ Lucking, et al., 2000; West, 2002a; Thobois, et al., 2003 
R334C COM/ HTZ with D230N Khan et al., 2003 
E409Stop   
T415N HMZ Abbas et al., 1999 
G430D COM/HTZ Oliveira, et al., 2003 
C431F COM/HTZ HMZ Maruyama, et al., 2000; West, 2002a 
P437L HTZ; COM/HTZ with R275W Oliveira, et al., 2003 
C441R* COM/HTZ with deletion (n = 1)  HTZ 
West, 2002a; Thobois, et al., 2003;  
Shyu, et al., 2005 
W453Stop HMZ Abbas, et al., 1999 
 
HMZ, homozygous; *HTZ, heterozygous; COM/HTZ, Compound heterozygous 
Mutations highlighted in bold are examined in Chapter 5 
dA recent PET study reported a significant reduction in 18F-dopa uptake in the caudate and putamen of an 
asymptomatic R256C heterozygous carrier, suggesting that this mutation represents a genetic risk factor for 
nigrostriatal dysfunction (88). 
eIdentical among vertebrates from fish to humans. 
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APPENDIX C 
 
Table A2. Hparkin point mutation primers (22 pairs) 
 
forward 5’ GCT GAC CAG TTG CCT GTG ATT TTC GCA 3’ R42P reverse 5’ TGC GAA AAT CAC AGG CAA CTG GTC AGC 3’ 
forward 5’ CAA GAA ATG AAT GAA ACT GGA GGC GAC 3’ A82E reverse 5’ GTC GCC TCC AGT TTC ATT CAT TTC TTG 3’ 
forward 5’ GTG CAG CCG GGA AAC CTC AGG GTA CAG 3’  K161N reverse 5’ CTG TAC CCT GAG GTT TCC CGG CTG CAC 3’  
forward 5’ ATT CCA AAC CGG CTG AGT GGT GAA TGC 3’  M192L reverse 5’ GCA TTC ACC ACT CAG CCG GTT TGG AAT 3’ 
forward 5’ GAA TTT TTC TTT AAT TGT GGA GCA CAC 3’  K211N reverse 5’ GTG TGC TCC ACA ATT AAA GAA AAA TTC 3’ 
forward 5’ TTT TTC TTT AAA TAT GGA GCA CAC CCC 3’ C212Y reverse 5’ GGG GTG TGC TCC ATA TTT AAA AAG AAA 3’ 
forward 5’ ATC ACT TGC ATT AGG TGC ACA GAC GTC 3’ T240R reverse 5’ GAC GTC TGT GCA CCT AAT GCA AGT GAT 3’ 
forward 5’ CAG TGC AAC TCC TGC CAC GTG ATT TGC 3’ R256C reverse 5’ GCA AAT CAC GTG GCA GGA GTT GCA CTG 3’ 
forward 5’ TTC CAC TTA TAC TGA GTG ACA AGA CTC 3’  C268stop reverse 5’ GAG TCT TGT CAC TCA GTA TAA GTG GAA 3’ 
forward 5’ AGA CTC AAT GAT TGG CAG TTT GTT CAC 3’ R275W reverse 5’ GTG AAC AAA CTG CCA ATC ATT GAG TCT 3’ 
forward 5’ CAG TTT GTT CAC AAC CCT CAA CTT GGC 3’  D280N reverse 5’ GCC AAG TTG AGG GTT GTG AAC AAA CTG 3’ 
forward 5’ TAC TCC CTG CCT GGT GTG GCT GGC TGT 3’ C289G reverse 5’ ACA GCC AGC CAC ACC AGG CAG GGA GTA 3’ 
forward 5’ CTG GGA GAA GAG TAG TAC AAC CGG TAC 3’ Q311stop reverse 5’ GTA CCG GTT GTA CTA CTC TTC TCC CAG 3’ 
forward 5’ GTC CTG CAG ATG GAG GGC GTG TTA TGC 3’ G328E reverse 5’ GCA TAA CAC GCC CTC CAT CTG CAG GAC 3’ 
forward 5’GTG TTA TGC CCC TGC CCT GGC TGT GGA 3’ R334C reverse 5’ TCC ACA GCC AGG GCA GGG GCA TAA CAC 3’ 
forward 5’ GCA GCC TCC AAA TAA ACC ATC AAG AAA 3’ E409stop reverse 5’ TTT CTT GAT GGT TTA TTT GGA GGC TGC 3’ 
forward 5’ ATC AAG AAA ACC AAC AAG CCC TGT CCC 3’ T415N reverse 5’ GGG ACA GGG CTT GTT GGT TTT CTT GAT 3’ 
forward 5’ GAA AAA AAT GGA GAC TGC ATG CAC ATG 3’ G430D reverse 5’ CAT GTG CAT GCA GTC TCC ATT TTT TTC 3’ 
forward 5’ AAA AAT GGA GGC TTC ATG CAC ATG AAG 3’ C431F reverse 5’ CTT CAT GTG CAT GAA GCC TCC ATT TTT 3’ 
forward 5’ CAC ATG AAG TGT CTG CAG CCC CAG TGC 3’ P437L reverse 5’ GCA CTG GGG CTG CAG ACA CTT CAT GTG 3’ 
forward 5’ CCG CAG CCC CAG CGC AGG CTC GAG TGG 3’ C441R reverse 5’ CCA CTC GAG CCT GCG CTG GGG CTG CGG 3’  
forward 5’ TGT GGC TGC GAG TGA AAC CGC GTC TGC 3’ W453stop reverse 5’ GCA GAC GCG GTT TCA CTC GCA GCC ACA 3’ 
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Table A3. Cysteine mutant primers 
 
RING1 
forward CGG AAC ATC ACT GCC ATT ACG TGC ACAG C238A reverse CTGT GCA CGT AAT GGC AGT GAT GTT CCG 
forward CACT TGC ATT ACG GCC ACA GAC GTC AGG C241A reverse CCT GAC GTC TGT GGC CGT AAT GCA AGTG 
forward CTG GTT TTC CAG GCC AAC TCC CGC CAC C253A reverse GTG GCG GGA GTT GGC CTG GAA AAC CAG 
forward CGC CAC GTG ATT GCC TTA GAC TGT TTC C260A reverse GAA ACA GTC TAA GGC AAT CAC GTG GCG 
forward GATT TGC TTA GAC GCC TTC CAC TTA TAC C263A reverse GTA TAA GTG GAA GGC GTC TAA GCA AATC 
forward GTTTC CAC TTA TAC GCC GTG ACA AGA CTC C268A reverse GAG TCT TGT CAC GGC GTA TAA GTG GAAAC 
forward CTAC TCC CTG CCT GCC GTG GCT GGC TGT C289A reverse ACA GCC AGC CAC GGC AGG CAG GGA GTAG 
forward GT GTG GCT GGC GCC CCC AAC TCC TTG C293A reverse CAA GGA GTT GGG GGC GCC AGC CAC AC 
IBR 
forward GGT GCA GAG GAG GCC GTC CTG CAG ATG C323A reverse CAT CTG CAG GAC GGC CTC CTC TGC ACC 
forward GGG GGC GTG TTA GCC CCC CGC CCT GGC C332A reverse GCC AGG GCG GGG GGC TAA CAC GCC CCC 
forward CCC CGC CCT GGC GCC GGA GCG GGG CTG C337A reverse CAG CCC CGC TCC GGC GCC AGG GCG GGG 
forward GG AAA GTC ACC GCC GAA GGG GGC AAT C352A reverse ATT GCC CCC TTC GGC GGT GAC TTT CC 
forward CAAT GGC CTG GGC GCC GGG TTT GCC TTC C360A reverse GAA GGC AAA CCC GGC GCC CAG GCC ATTG 
forward GGG TTT GCC TTC GCC CGG GAA TGT AAA C365A reverse TTT ACA TTC CCG GGC GAA GGC AAA CCC 
forward CTTC TGC CGG GAA GCC AAA GAA GCG TAC C368A reverse GTA CGC TTC TTT GGC TTC CCG GCA GAAG 
forward CAT GAA GGG GAG GCC AGT GCC GTA TTT C377A reverse AAA TAC GGC ACT GGC CTC CCC TTC ATG 
RING2 
forward 5’ACC ACC AAG CCC GCT CCC CGC TGC CAT3’ C418A reverse 5’ATG GCA GCG GGG AGC GGG CTT GGT GGT3’ 
forward 5’CCC TGT CCC CGC GCT CAT GTA CCA GTG3’ C421A reverse 5’CAC TGG TAC ATG AGC GCG GGG ACA GGG3’ 
forward 5’AAA AAT GGA GGC GCT ATG CAC ATG AAG3’ C431A reverse 5’CTT CAT GTG CAT AGC GCC TCC ATT TTT3’ 
forward 5’ATG CAC ATG AAG GCT CCG CAG CCC CAG3’ C437A reverse 5’CTG GGG CTG CGG AGC CTT CAT GTG CAT3’ 
forward 5’CCG CAG CCC CAG GCT AGG CTC GAG TGG3’ C441A reverse 5’CCA CTC GAG CCT AGC CTG GGG CTG CGG3’ 
forward 5’AGG CTC GAG TGG GCT TGG AAC TGT GGC3’ C446A reverse 5’GCC ACA GTT CCA AGC CCA CTC GAG CCT3’ 
forward 5’TGG TGC TGG AAC GCT GGC TGC GAG TGG3’ C449A reverse 5’CCA CTC GCA GCC AGC GTT CCA GCA CCA3’ 
C-terminal 
forward 5’TGG AAC TGT GGC GCT GAG TGG AAC CGC3’ C451A reverse 5’GCG GTT CCA CTC AGC GCC ACA GTT CCA3’ 
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forward 5’TGG AAC CGC GTC GCT ATG GGG GAC CAC3’ C457A 
reverse 5’GTG GTC CCC CAT AGC GAC GCG GTT CCA3’ 
 
Table A4. pUAST-hparkin cloning primer 
 
forward 5’ TCT AGC GGC CGC AAC ATG GAC TAAC AAG GAC GAC 3’ 
reverse 5’ ATA TCT AGA CTA CAC GTC GAA CCA GTG 3’ 
 
Table A5. Single fly PCR primer 
 
forward 5’-CAA CTG GGA GTG TCG CTA CTC TCC C-3’ Gal4 
reverse 5’-GAG AAC CGT CGC CAA AGA ACC CAT T-3’ 
forward 5’-GAG CAT GTC TCC GGC GGG GAG AAG-3’ Park1 reverse 5’-CGC CCG TCC CCT CGG GCA GAC ACT C-3’ 
hParkin-C365 forward 5’-TGC CGG GAA TGT AAA GAA GCG TAC C-3’ 
UAS-3’ reverse 5’-GGC ATT CCA CCA CTG CTC CCA TTC A-3’ 
 
        
 
Fig A.4 Schematic figure showing *dparkin null mutant. (Pk-/- present no band since the P 
element, several kb, can not be amplified at the PCR condition. Tm 60ºC. eg. park1, Ddc-
Gal4/Tm3sb we select homozygote fly to do the PCR. And the positive clone should have no band 
when PCR dparkin and present band when PCR Gal4.) 
 
*dParkin null mutant (Cha et al.PNAS 2005, 102 (29) 
 
Table A6. Sequencing primer 
 
Parkin Y147 5’ T TAT GTG TAT TGC AAA GGC C 3’  






park1 forword primer (700) 
park1 reverse primer (1200) 










APPENDIX D: Schematic figure showing the crosses performed to obtain flies overexpressing 
hParkin (WT &R275W) in DA neuron over dparkin null background. 
 
2.    Ddc-Gal4/Ddc-Gal4♂ × pk1/Tm6tb ♀ 
                       ♀ Ddc-Gal4/pk1  ×  Tm3sb/Tm6tb ♂ 
Single fly PCR to check the positive recombination 
  
           Ddc-gal4-pk1/Tm3sb 
 Ddc-Gal4…pk1/Tm3sb♂× Tm3sb/Tm6tb ♀ 
    Ddc-Gal4…pk1/Tm3sb 
1.    hPK/Tm3sb ♂ × pk1/Tm6tb ♀
    hPK…pk1/Tm3sb
                 ♀ hPK/pk1  ×  Tm3sb/Tm6tb ♂
     hPK…pk1/Tm3sb♂× Tm3sb/Tm6tb ♀
(Sibling cross) 
Single fly PCR to check the positive recombination 
  




 hPK-pk1/Tm3sb  ×  Ddc-gal4-pk1/Tm3sb 
Uas-Parkin-pk1/ Ddc-Gal4-pk1 
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